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Abstract
Infection with hepatitis B virus (HBV) has been detected in most populations
throughout the world, as well as in a number of non-human primate species. In
humans HBV infection represents a major global health problem, with an estimated 1
million deaths per year due to hepatocellular carcinoma and chronic hepatitis. HBV
variants infecting humans can be classified into at least 7 different genotypes
differing from each other by 11-13% in nucleotide sequences. A range of distinct
genotypes also infect African apes, Asian apes and possibly New World monkeys.
Studies of HBV epidemiology and the geographical species associations of different
HBV genotypes have led to a number of hypotheses for the origin ofHBV in humans
and primates. These are the "Out of Africa" hypothesis, the hypothesis that HBV
originated in South America and spread in Africa and Western countries in the last
200-300 years, and more recently, proposed origins from cross-species transmission
and/or co-evolution of HBV in their current host. The main aim of this thesis is to
investigate the molecular evolution of human and non-human primate HBV to gain
further insights into the origin ofHBV in these species. This investigation was carried
out in three main sections.
The first comprised an extensive and detailed genetic analysis of the distribution of
human HBV genotypes in HBV endemic areas in sub-Saharan Africa and South East
Asia. In the second section complete genome sequences of HBV variants were
analysed for recombination between different HBV genotypes. This analysis included
the use of a novel method based on the calculation of association scores for
phylogenetic groups, an approach that helps resolve many of the uncertainties and
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difficulties of interpretation of results arising from conventional methods, such as
SimPlot.
The third section investigated the frequencies of HBV infection in non-human
primates, and the relationship between HBV genotype, primate species and
geographical range. In my survey, HBV infection was confined to African and Asian
apes, and uniformly absent from a wide range of African monkey species.
Phylogenetic analysis of chimpanzee-, gibbon- and orangutan-derived HBV variants
indicated that a geographical rather than a species correlation with genotypes,
implying the co-circulation and cross-species transmission of HBV between species
of overlapping habitats. However, in no cases were primate-associated HBV variants
found in humans, nor human genotypes in non-human primates. These findings and
the interspersed nature of human and non-human primate HBV genotypes deepens
the mystery ofHBV origins and evolution in humans. The findings, however, provide
a context for ongoing studies of HBV biological variability and genotype-associated
differences in pathogenicity and outcomes of infection.
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1.1 History and discovery of hepatitis B virus
Hepatitis as a disease has been known for a very long time, possibly even since the
time of the Babylonians (Hollinger, 1996). Hepatitis transmitted by blood, however,
was not described or established until the 1930's. This thesis will investigate one of
the viruses that have since been identified as a causative agent of hepatitis in humans,
hepatitis B virus (HBV).
HBV represents a major global health problem, with an estimated 1 million deaths
from hepatocellular carcinoma and chronic liver disease each year (Thomas and
Jacyna, 1993). HBV was the first virus from a family of viruses to be discovered.
These are the hepadnaviruses, and the other members of this family will be discussed
in more details in later sections. In the 1960's B.S. Blumberg was involved in some
research into the antibody responses mounted by people who had received blood
transfusions, and through this he stumbled upon an antigen which was given the
name Australia antigen, as it had been isolated from sera from Aborigines
(Blumberg, 2003). It was not known at the time, but what had in fact been found was
the surface antigen of HBV. Studies into the distribution of this antigen identified
patients suffering from hepatitis as the major carrier group. This in turn led to the
idea that part of a hepatitis virus had been discovered, and the term hepatitis B virus
was coined, before the existence of such a virus was known. The name assignation
was alphabetical; hepatitis A was used to describe the infectious form of hepatitis
and hepatitis B described the transfusion-related form of hepatitis. Any virus
associated with this type of hepatitis would therefore be the hepatitis B virus. We
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now know that transfusion-related hepatitis, or type B hepatitis, is in fact caused by
one of two viruses, HBV or hepatitis C virus (HCV).
A major breakthrough came with the discovery of the Dane particle in 1970 (Dane et
al., 1970), as the agent responsible for causing type B hepatitis revealed itself. The
Dane particle turned out to be the virus particle that they had been looking for, and
the Australia antigen was renamed hepatitis B surface antigen (HBsAg). Once the
virus responsible for causing hepatitis had been identified it became possible to try to
prevent the spread of hepatitis through transfusions. The introduction of screening
tests for HBsAg in the late 1960's led to a dramatic drop in the incidence of
transfusion-associated hepatitis, but it was not until the 1980's and the discovery of
hepatitis C virus (HCV) that this type of hepatitis virtually disappeared (Blumberg,
2003). The rapid development of molecular biology techniques in the last 10-20
years has led to a huge increase in what we now know about HBV, the infection it
causes, and its epidemiology throughout the world. HBV-like viruses have been
identified in species other than humans, and multiple genotypes exist within the
human HBV group. These aspects of HBV infection will be covered in following
sections and chapters.
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1.2 The HBV genome
In this section the genetic structure, organisation, and replication of the HBV genome
is going to be discussed.
1.2.1 Genetic structure and organisation
The genome ofHBV is around 3200 nucleotides in size, consists of circular partially
double-stranded DNA (Tillolais et al., 1985), and is found inside a virion which is 42
nm in diameter and has an envelope. The inner core contains the core antigen and the
envelope contains the HBsAg. The HBV genome consists of four open reading
frames (ORFs) which overlap (Fig. 1-1.). These have been given the names S
(surface), C (core), P (polymerase) and X (X protein) (Tillolais et al., 1985).
The S region is where the viral envelope is encoded, and this is in turn divided into
three regions. These are the S gene, PreSl region and PreS2 region and are initiated
by three separate start codons and share a common stop codon. The PreSl region
may vary in length between genotypes, human genotype D and the non-human
primate genotypes have a deletion in this region that distinguishes them from the
other genotypes. The PreSl and PreS2 regions are also more variable in sequence
compared to the S gene, implying a more important role for this region that requires
sequence conservation. This may also be due to less immune pressure being placed
on the S region than the rest of the genome. Three envelope proteins are produced by
this open reading frame, S (S gene), M (PreS2), and L (PreSl). Antibodies against S
are able to prevent HBV infection (Seeger and Mason, 2000), suggesting an
important role for this protein in the attachment and entry of HBV into cells. The S
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gene has also been found to be useful for the genotyping of HBV (Norder et al.,
1993).
Fig. 1-1. The circular genome of hepatitis B virus consists of four open reading
frames (ORFs) which overlap, meaning most of the genome codes for more than
ORF. The S ORF (pre SI, pre S2, and S) is completely contained within the P ORF,
which also overlaps with ORF X and ORF C (pre-C and C).
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The C region encodes the viral core protein which is the major component of the
nucleocapsid (Tillolais et al., 1985). The C region contains two start codons.
Translation starting at the first of these leads to the production of e antigen and
translation starting at the second results in core antigen production. The e antigen is
thought to play a role in the attachment of the core to the envelope. Hepatitis e
antigen is a secretory core gene product. E antigen attached to cells may serve as a
potential target for antibodies involved in eliminating HBV (Schlicht and Schaller,
1989). Mutations in the PreC promoter appear to have a major impact on viral DNA
replication and may result in a lower level or stop of e antigen production (Parekh et
al., 2003), the significance of which will be discussed in section 1.3. Mutagenesis
studies of the core gene have shown that deletions or insertions in the central fold of
the protein destabilizes the protein (Koschel et al., 1999), and this indicates that this
region of the genome has constraints when it comes to the amount of variation that is
possible without impairing replication of the virus. This in turn will place
evolutionary constraints on HBV.
The P region encodes the viral polymerase protein, which also has a reverse
transcriptase function. It has no proof-reading activity and errors may therefore be
introduced when the genome is replicated (Seeger and Mason, 2000). The mutation
rate of this gene has been found to be higher than that of the rest of the genome,
possibly due to the large extent of overlap with other genes (see Fig. 1-1). This may
be important in the development of drug-resistant HBV variants (Park et al., 2003).
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The X region is the least characterised of the HBV coding regions. The X gene
overlaps both the pol gene and the precore region. It appears to be well conserved
between genotypes and species (Kidd-Ljunggren et ah, 1995). The X protein may be
involved in the attachment of HBV to cells (Paran et al., 2003), as well as having
transactivating activities. It appears to be essential for viral replication, but the
mechanisms involved are unknown. It is not clear what role it plays during HBV
infection (Seeger and Mason, 2000). The X protein has been implicated in the
development of hepatocellular carcinoma. It has been proposed that X mutants may
be selectively replicated in tumour tissues and thereby modifying X protein activity
and aiding carcinogenesis (Iavarone et al., 2003; Tu et al., 2001). Other studies have
shown that X protein induces the expression of interleukin-18, a pro-inflammatory
cytokine, in the liver and this may be associated with liver injury during the course of
HBV infection (Lee et al., 2002).
1.2.2 Replication of the viral genome
When HBV has entered a new host it needs to replicate to establish an infection and
produce progeny viruses to enable its eventual spread to new susceptible hosts.
Attachment to the cell surface of hepatocytes is followed by entry into the cell and
uncoating of the viral genome prior to replication (Cooper et al., 2003).
The first step in HBV replication is the conversion of the relaxed circular viral
genome into a covalently closed circular genome (cccDNA). The mechanisms
involved in this are unknown. cccDNA then accumulates in the in the nucleus and is
used as the transcription template for the viral messenger RNAs (mRNAs). Four viral
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mRNAs are produced. The largest of these is the pre-genomic RNA which will be
reverse transcribed to produce new viral genomes. This is also the C mRNA and P
mRNA. Separate mRNAs are then produced for translation into the viral envelope
proteins and the X protein. HBV transcription is thought to be dependent on
transcription factors found in the hepatocytes. Transcription is followed by assembly.
Following translation of the viral polymerase the pre-genomic RNA is reverse
transcribed to form a new viral genome which is then packaged into the virion. The
reverse transcriptase is involved in the packaging together with host factors (Cooper
et al., 2003; Seeger and Mason, 2000). New virus particles can now be transported to
the cell surface and released, and may then go on to infect new cells, and possibly
new hosts.
1.2,3 Classification ofHBV
HBV genomes have been classified into 9 serotypes and 8 genotypes. The serotypes
are based on the amino acid sequences of the surface antigen. The genotype
distribution follows a geographical pattern and will be described in more detail in
chapter 3. The serotypes also have geographical distributions, and show different
associations with particular genotypes. For example, serotypes aywl and adw2 are
associated with genotype A, aywl with genotype B, ayr, adr and adrq- with genotype
C, ayw2 and ayw3 with genotype D, ayw4 with genotype E and adw4p- with
genotype F (Norder et al., 1992b). The genotypes were identified using phylogenetic
analysis of large numbers of HBV isolates (Kidd-Ljunggren et al., 1994; Norder et
al., 1992b; Norder et al., 1992a; Norder et al., 1993; Norder et al., 1994; Okamoto et
al., 1988). The genotyping of HBV may be important when diagnosing patients, and
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deciding which course of treatment to choose, as genotypes are associated with
different prognoses (see section 1.3). HBV can be genotyped either by polymerase
chain reaction (PCR) followed by sequencing and phylogenetic analysis, but a
number of alternative strategies have been developed for use in diagnostic
laboratories around the world. Restriction fragment length polymorphism (RFLP)
analysis following PCR amplification of viral DNA has proven a useful tool in the
relatively rapid determination of genotypes (Lindh et ah, 1997; Lindh et ah, 1998;
Mizokami et ah, 1999). This type of method is very useful when it is necessary to
determine which genotype an individual is infected with so that the most effective
treatment can be chosen. Type-specific PCR amplification is another rapid
genotyping method (Kato et ah, 2001; Naito et ah, 2001).
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1.3 Disease association and epidemiology
As mentioned earlier HBV is a major public health problem, causing high levels of
morbidity and mortality throughout the world. Certain areas of the world are endemic
for HBV infection, such as Southeast Asia, sub-Saharan Africa, and South and
Central America, and here prevalence rates of active infection of 8-15% can be seen.
Even larger proportions of the populations of these countries show evidence of past
infection with HBV (Andre, 2000; Ding et al., 2001; Ding et al., 2003a; Liu et al.,
2002; Murhekar et al., 2002; Nakai et al., 2001; Quintero et al., 2002; Sirisena et al.,
2002; Sugauchi et al., 2002a; Tanaka, 2000). High rates of infection have also been
identified in Russia (Flodgren et al., 2000) and among the Inuits in Greenland
(Langer et al., 1997). In traditionally low prevalence countries like England and Italy
high infection rates can be detected in immigrant populations from high endemicity
areas (Chironna et al., 2000; Kawsar and Goh, 2002). This is leading to a change in
the HBV epidemiology of the UK, with high prevalence rates seen in certain
population groups. This is also leading to the introduction of HBV genotypes not
traditionally found in Europe.
The modes of transmission of HBV include parenteral, sexual, and perinatal routes
(Hollinger, 1996), but mosquitoes have also been suggested as a possible vector for
transmission (Blow et al., 2002). Unsafe injections have been identified as a major
factor for new HBV infections in the developing world, and it has been estimated
that 8-16 million new infections could occur each year by this transmission route
(Kane et al., 1999). Hepatitis B can cause acute infection which is then cleared
(transient) or chronic infections (Blumberg et al., 1975a).
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The majority of cases are transient when infection occurs in adults, whereas infection
in children tends to lead to chronic infection (Hollinger, 1996; Seeger and Mason,
2000). It is this that makes it a difficult infection to eradicate, as there is a huge
reservoir of potential infection spreaders. One possible explanation for the
difference seen in the type of infection that results depending on the age of the
individual is that the immune system needs to be fully developed in order to mount a
successful response to HBV and eliminate it. In Asia perinatal infection is
predominant, whereas in Africa horizontal spread between young children is the
main mechanism for maintaining HBV infection within the population.
Even though most infections are transient they still have a major effect, as these
infections usually last for 1-6 months. The first few weeks after infection are
asymptomatic, which again has an impact when it comes to spreading infection
(Seeger and Mason, 2000). After this initial asymptomatic period a highly viraemic
stage follows, and virus is then gradually eliminated until it becomes undetectable
after 4 to 6 months. HBsAg can be detected in the blood from a month post infection
until 5 months post infection (see Fig. 1-2 below). Once acute disease is seen
antibodies against the core antigen start to appear, and these remain detectable for
years after infection has disappeared. Antibodies against the surface antigen become






Figure 1-2. Schematic diagram showing the serological marker profile of HBV
infection . The diagram was taken from a PHLS communicable diseases report (Teo,
1992).
These serological markers are important in the diagnosis and prognosis ofHBV, but
they leave a window of around one month after infection where there are no
detectable signs of infection. This is where the development of molecular detection
techniques has made a dramatic impact. The routine use of PCR screening identifies
individuals who are in the very early stages of HBV infection. Hepatitis e antigen
positivity can be used as an indicator of how infectious a carrier is. Patients positive
for HBeAg have been shown to have high levels of infectious virions and HBV DNA
(Hollinger, 1996). As described earlier core promoter mutations may lead to reduced
e antigen production, and this would influence this type of test. A patient may appear
to be less infectious than he/she really is.
Chronic infection with hepatitis B virus follows the same initial disease course as
that described for acute and transient infection above (Hollinger, 1996). Patients who
develop chronic infection in adulthood tend to have a poorer prognosis than those
who get infected as children, as there may be outbreaks of acute liver disease,
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cirrhosis of the liver may occur and hepatocellular carcinoma may develop
(Blumberg et al., 1975b; Seeger and Mason, 2000). HBV DNA can be found
integrated in the cancerous cells in the liver of an infected patient although this is a
rare event and the role in carcinogenesis is unknown (Hino et al., 1984).
The risk of developing liver cancer is 10-15% for chronically infected patients.
Certain mutations in the core promoter have been identified that increase this risk
(Kao et al., 2003). Mutations within the PreS2 region are also found at a high
frequency (50%) in cancer patients (Blackberg and Kidd-Ljunggren, 2003).
Mutations associated with carcinoma have also been identified as coinciding with a T
cell epitope of the surface antigen (Tai et al., 1997). Certain genotypes seem to be
more closely associated with the development of hepatocellular carcinoma than
others, for example genotype C (Ding et al., 2001; Ding et al., 2003b; Nakayoshi et
al., 2003; Sugauchi et al., 2002a). This association is made more complex due to the
fact that genotype C causes more severe disease in Japan than it does in China
(Sugauchi et al., 2002b). It has also been shown that immune-mediated cell injury
can trigger tumour development even in the absence of viral factors, and this
suggests that a combination of host and viral factors are involved in the
carcinogenesis due to HBV infection (Koike et al., 2002; Nakamoto et al., 1998).
There are no treatments that are able to clear HBV infection once the chronic state
has been established. The aim for treatment is therefore damage limitation. Alpha
interferon and lamivudine are the two most common treatments that are used with
HBV today, although tenofovir is also being used (Seeger and Mason, 2000). These
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treatments suppress viral replication and reduce the symptoms of liver disease. The
alternative to these treatments in severe disease is transplantation of the liver.
Recurring infection after transplantation is a problem (Roche et al., 2003) and
mutants able to evade the drugs used to suppress symptoms may be selected for in
these situations (Brind et al., 1997). Treatment of HBV with different drugs, those
mentioned above and new ones under development, can also give rise to the
emergence of resistant mutant viruses. For example, a mutation in the pol gene has
been detected that is associated with the use of adefovir dipivoxil (Angus et al.,
2003), a treatment that has been shown to give good reductions in serum levels of
HBV DNA (Westland et al., 2003). Mutations have also been identified in B and T
cell epitopes of the X protein, and this may also be involved in evasion of the
immune responses (Hwang et al., 2003).
Even though HBV infection cannot be cured, it can be prevented. The development
of HBV vaccines has made liver cancer the first cancer that can be prevented by
vaccination. Vaccination is the process where a vaccine is injected into the body to
induce immunity against the agent in question. This is a form of immunisation.
Immunisation is the exposure of an individual to an antigen in order to raise
antibodies against a particular agent to improve the ability to resist infection. Plasma-
derived vaccines were developed in the 1970's , and were then replaced by
recombinant yeast-derived vaccines in the 1980's (Hollinger, 1996). Vaccination has
been very successful in reducing the numbers of new infections and the development
of chronic infections in countries like The Gambia (Fortuin et al., 1993; Whittle et
al., 1991) where HBV infection is endemic. It has also been successful in Italy
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(Stroffolini et al., 2000) and in the Pacific Islands (Vryheid et al., 2001). As has been
seen before for other infections, the introduction of vaccination has brought with it
the emergence of vaccine-escape mutants. These mainly have mutations within the S
gene that prevent neutralization by antibodies by altering the a determinant of the
surface antigen (Hollinger, 1996). Research into the development of new alternative
vaccines that will prevent the emergence of such mutants is ongoing.
As mentioned above, different genotypes of HBV are associated with different
disease outcomes and serological profiles. A recent study from China found an
association between more severe disease in genotype C than genotype B infected
patients. They also found that genotype B patients sero-converted to HBeAg earlier
than those infected with C, and suggested this might explain the less active infection
seen for this genotype (Chu et al., 2002). These results were seen also in Shanghai
and Harbin provinces, China (Ding et al., 2001; Ding et al., 2003a). Genotype C is
also associated with increased mortality in Japan, where genotypes B and C are the
most commonly isolated genotypes (Orito et al., 2001). In Thailand there also seems
to be a bias for severe disease and development of liver cancer in genotype C patients
when compared to genotype B infected patients (Sugauchi et al., 2002a). Similar
results were reported from Spain, where genotype F was associated with a more
frequently fatal outcome compared to genotypes A and D, and suppression of
symptoms was more successful in genotype A (Sanchez-Tapias et al., 2002).
In contrast to this, researchers found that there was no difference in the severity of
disease caused by genotypes A and D in Uzbekistan (Kato et al., 2002c). In contrast
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to the association between genotype C and severe disease described above for China,
another study also from China found the opposite, genotype B was associated with
higher mortality (Yuen et al., 2003). This clearly shows that host factors as well as
viral factors play a major role in determining the outcome of HBV disease. For
example, mutations in the p53 gene have been suggested as playing a role in the
development of hepatocellular carcinoma (Kirk et al., 2000). Viral factors may be
influencing changes in the host, as well as the host immune response driving changes
in the viral genome.
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1.4 HBV in other animals- primates, rodents, and birds
Apart from the 8 human HBV genotypes, HBV-like viruses have been isolated from
a number of other species of primate, rodent and bird. Primates were early on found
to be positive for HBV during post-capture screening programs, although these
infections were thought to be of human origin, either through vaccinations or other
contacts (Deinhardt, 1976). Primates captured in the wild were routinely vaccinated
with pooled human sera to protect them from human infections, and as this occurred
prior to the identification of the hepatitis B virus this is a possible route of
introduction of HBV into primate populations. Primates may also catch human
infections through biting and scratching accidents.
Species-specific HBV variants were then reported for chimpanzees (Vaudin et al.,
1988; Zuckerman et al., 1978), gibbons (Mimms et al., 1993; Norder et al., 1996),
orang-utans (Warren et al., 1999), and the New World primate woolly monkey
(Lanford et al., 1998). Since these first reports several more isolates from these
species and also a gorilla (Grethe et al., 2000) have been reported (Aiba et al., 2003;
Hu et al., 2000; Hu et al., 2001; Lanford et al., 2000; MacDonald et al., 2000;
Noppornpanth et al., 2003; Starkman et al., 2003; Takahashi et al., 2000; Takahashi
et al., 2001; Vartanian et al., 2002; Verschoor et al., 2001). Primate HBV variants
and their history are described in more detail in Chapter 5.
1,4.1 HBV in rodents
Rodent HBV-like viruses have been isolated from woodchucks (Marmota monax)
(Summer et al., 1978), Beechey ground squirrels (Spermophilus beecheyi) (Marion et
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al., 1980), tree squirrels (Sciurus carolinensis pennsylvanicus) (Feitelson et al.,
1986), and Arctic ground squirrels (Spermophilus parryi kennicotti) (Testut et al.,
1996). Woodchuck hepatitis virus (WHV) may be a cause of hepatic disease in the
host species, as it was identified in animals that had died of hepatocellular carcinoma
or acute hepatitis. Two animals with WHV surface antigen positive sera that died
were found to have malignant liver tumours. The level of inflammation seen in the
livers of these animals was high, whereas a surface antigen positive animal that died
of heart failure was shown to have minimal inflammation. This difference in
inflammation is seen also in humans with HBV infection (Summers et al., 1978).
These woodchucks were all part of a research colony, but wild-caught woodchucks
have also been found to have a high rate of carriage of WHV (Tyler et al., 1981).
Due to the similarities between human HBV and WHV, the woodchuck is a useful
model system for research into viral hepatitis and hepatocellular carcinoma (HCC)
(Summers et al., 1978).
The woodchuck has been extensively used as a research model for HBV infection.
One example of the use of the WHV model is in antiviral therapy development. From
this type of research it has emerged that responses to toxicity of compounds in
woodchucks is similar to human responses, and the woodchuck may therefore be a
useful model to use more widely in drug development (Tennant and Gerin, 2001).
The WHV model has also been applied to DNA vaccine research. DNA vaccines
based on WHV core antigen and surface antigen have been shown to induce an
immune response that inhibited infection with WHV in vaccinated animals (Lu et al.,
1999). Mutagenesis studies into the biological function of the WHV X protein have
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shown that HBx functional domains are biologically important. Mutated viruses are
able to replicate as well as wild-type viruses and appear to induce a strong immune
response, leading to immunity to subsequent challenge with infectious wild-type
WHV. These studies identify the X protein as a potential target for future research
into novel treatments and vaccines (Zhang et ah, 2001).
In a recent study it was shown in the WHV model that an antibody to the hepatic
asialoglycoprotein receptor, frequently found in patients with hepatic damage, could
affect the severity ofWHV infection (Diao et ah, 2003). Antibody present prior to
infection appeared to be indicative of a chronic infection outcome, and induction of
antibody production during the course of infection increased the severity of the
existing disease. Work on the WHV model has revealed the presence of genomes in
serum with deletions and rearrangements like those found in integrated genomes in
HCC. This suggests these mutation events may take place prior to the integration and
these genomes maybe involved in HCC pathology once integrated. The study
implicated topoisomerase I in the production of the mutants (Kew et ah, 1993). Virus
escape mutants normally have alterations in MHC Class I restricted T cell epitopes of
the S gene (Tai et ah, 1997). This has been shown to occur also in WHV infection
(Botta et ah, 2000).
Although WHV infection is similar to human HBV infection in certain aspects, there
are also differences between the two. Human core deletion mutants have been shown
to act like defective interfering particles, meaning they replicate preferentially to
wild-type virus although they require the presence of the wild-type virus to replicate
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(Sahu et al., 2002). Defective mutants exist also in WHV infection, but here there
appears to be no defective interference activity of these mutant viruses (Sahu et al.,
2002). Mutagenesis was used to create in WHV the most common precore mutation
ofHBV to produce a stop codon. In contrast to HBV the precore gene was found not
to be essential for viral replication, though it may be important in chronic infection
(Chen et al., 1992), as precore mutations are frequently found in chronically infected
woodchucks (Botta et al., 2000), a further parallel between WHV and HBV. There
may be other such differences between other similar mutant strains, and further
research will be needed to evaluate the use of woodchucks as a model for human
disease. The genomes ofWHV and HBV are related, but aligning their sequences for
phylogenetic analysis is difficult. The most conserved area of the genome that allows
alignment is found in the S gene region, where it is possible to design primers for
PCR conserved enough to allow detection and amplification of all known primate
and rodent hepadnavirus variants (Starkman et al., 2003).
Beechey ground squirrel hepatitis virus (GSHV) was the second HBV-like virus to
be identified in rodents. The virion is similar to HBV. The animals it was isolated
from showed no signs of disease, although it was impossible to follow up whether
disease developed at a later stage in infection, as the animals were released after
sampling. GSHV appears to be enzootic, with 44-55% of animals in different
locations being infected with the virus. The serology results also suggest a persistent
infection in these animals, so it is possible that there may be an association with liver
pathology similar to WHV even though this was not observed in the study (Marion et
al., 1980).
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Tree squirrel hepatitis virus (THBV) also appears to be associated with hepatitis in
its host through the establishment of a chronic infection. A carrier rate of around
50% was reported, again suggesting it is enzootic within the host species (Feitelson
et ah, 1986).
Arctic squirrel hepatitis virus (ASHV) is also enzootic in wild populations (carriage
rate of 14%), and again appears to be associated with hepatic disease in the host
(Testut et al., 1996). There is around 16% nucleotide difference between the rodent
hepadnaviruses, and ASHV is most closely related to GSHV. The rodent viruses
have been shown to be around 37% different from the human hepatitis B viruses at
the nucleotide level. Phylogenetic analysis has also revealed the presence of
geographically defined clusters ofWHV which had not been reported before (Testut
et al., 1996).
1.4,2 HBV in birds
Hepadnaviruses have also been isolated from large number of species of bird, for
example ducks (Anas domesticus), herons (Ardea cinerea), snow geese (Anser
caerulescens), storks (Ciconia ciconia), and cranes (Anthropoides virgo, Balearica
regulorum) (Chang et al., 1999b; Mason et al., 1980; Prassolov et al., 2003; Pult et
al., 2001b; Sprengel et al., 1988). Duck hepatitis B virus (DHBV) was the first avian
hepadnavirus to be discovered and is also the most widely studied, partly due to
availability of animals for study. As for WHV, DHBV was first isolated from captive
populations, in this case commercially bred ducks in the USA (Mason et al., 1980).
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Subsequent studies have also identified DHBV in wild bird populations in France
with a relatively high rate of carriage (3-12%) (Cova et ah, 1986). It is not known
whether liver disease is associated with DHBV infection, as commercial flocks are
usually killed before they reach the age of 2 years (Mason et ah, 1980), and more
recent studies have failed to find any evidence of significant liver damage in
naturally infected ducks (Jilbert and Kotlarski, 2000).
Again like the WHV, DHBV has been used as a model for HBV infection, including
investigations into the immune responses to hepadnaviral infection. Inoculation
experiments suggest that both viral factors and host factors play a role in determining
disease outcome. Viral factors may be the infective dose, the viral replication
kinetics and tropism, and host factors being of the immune response. Low virus dose
appeared to induce a protective immune response, whereas a high dose induced a
non-protective response (Jilbert and Kotlarski, 2000). The duck humoral immune
response to DHBV infection is similar to that in humans with anti-HBc being
detected in chronic carriers, but dissimilar in the fact that anti-HBs does not appear to
be formed (Jilbert and Kotlarski, 2000).
Mutagenesis studies of DHBV envelope protein have identified a stmctural
determinant that plays an important role in the translocation of virus particles during
assembly, and that may be common to all hepadnaviruses (Grgacic, 2002). The
DHBV genome has mostly been reported as lacking the X open reading frame found
in all mammalian hepadnaviruses, but traces of an X-like protein coding sequence
have now been reported that corresponds in position to the mammalian X gene (Lin
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and Anderson, 2000). An X-like protein has now also been found to be expressed in
vivo in DHBV infection, encoded by a hidden open reading frame. There are
functional similarities between this protein and the mammalian X proteins,
suggesting a common ancestry for these genes with the divergence in sequence being
mediated by host adaptation (Chang et al., 2001).
The availability of ducks makes them an attractive model for research. DHBV has
also been used to estimate the natural mutation rate of hepadnaviruses, something
there is little information about. Mutagenesis/reversion studies found the mutation
rate of DHBV to be 1 x 10"5 to 1 x 10"6 (Pult et al., 2001a), which is lower than the
previous estimate of 2.1 x 10~5, which was based on the HBV evolution within a
chronically infected carrier (Hannoun et al., 2000a).
The DHBV model has proved a useful one for investigating the mechanisms of
human HBV entry. The narrow host ranges and also the tissue specificity have been
major obstacles. DHBV work has shown that uptake into cells is a process with at
least two steps. First- binding to a primary receptor that appears to be common to all
avian hepadnaviruses, and then as a receptor-virus complex binding to a secondary
species-specific receptor. A PreS domain was identified as the binding site for the
primary receptor. Mutational studies revealed that it was not the sequence that
determined the receptor interaction directly, but the tertiary structure of the domain
and hence a common cell interaction with related receptors for avian viruses. As the
authors of this study suggested the conservation of a structural element within the
surface antigen, rather than a specific sequence brings the advantage for
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hepadnaviruses of allowing a high level of diversity to escape host immune
responses (Urban et al., 1998).
The primary receptor has now been identified as gpl80, or carboxypeptidase D. The
proposed mechanism of cell entry is that gpl80 binds the virus at the cell surface and
following binding of a secondary or co-receptor internalizes the bound particles
(Breiner et al., 1998). An analogous protein to gpl80 has now been identified in
humans- p80. The PreS 1 region contains the binding site for p80, indicating again
that the S gene may be involved in the species specificity of the hepadnaviruses (Ryu
et al., 2000). Phylogenetic analysis has now revealed the presence of DHBV
subgroups defined by the geographical origin of the species of duck from which the
virus was isolated (Pult et al., 2001b).
Heron HBV (HHBV) appears to be enzootic in grey herons, and also very host-
specific, as it is not possible to infect ducks with this virus. As for DHBV infection it
does not appear that HHBV is associated with hepatocellular carcinoma in its host. It
is 21.6% different from DHBV at the nucleotide level over the entire genome, and
again it appears to lack the X ORF found in the mammal hepadnaviruses (or
orthohepadnaviruses). The highest level of divergence between DHBV and HHBV is
found in the PreS region of the viral genome (50.3%) and this is suggested as the
likely reason HHBV will not infect ducks and may be an important host
species/range determinant (Sprengel et al., 1988).
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Snow goose HBV (SGHBV) infection also appears to have a high prevalence,
although it is not known whether this occurs in nature, as the geese from which it
was isolated were captive. It has a genome identical in length to DHBV, and it does
appear to have an X gene. The putative protein encoded by this X gene does not
show any significant similarity to those produced by the orthohepadnaviral X genes.
Phylogenetic analysis of the avian hepadnaviruses has revealed that they stem from a
common ancestor. SGHBV differs from DHBV by 11-13% and HHBV by 27%
respectively at the nucleotide level (Chang et ah, 1999b).
Storks have a close evolutionary relationship with herons, and mirroring this
relationship the white stork HBV (STHBV) is more closely related to HHBV than
any of the other avian hepadnaviruses (14.2-14.5% difference in nucleotide sequence
compared to 22.2-23.6% difference between STHBV and DHBV). It also appears to
be enzootic, at least in captive stork populations. The most variable region of the
genome was again found to be the PreS region, and there again appears to be an X
gene present encoding a short X protein(Pult et al., 2001b).
Crane HBV (CHBV) is most closely related to a hepadnavirus isolated from a Ross's
goose (RGHBV), even though evolutionarily cranes are closely related to herons and
storks. CHBV was able to infect duck hepatocytes, which STHBV and HHBV are
not able to do. The PreS region, thought to be involved in host species determination,
of CHBV differed from those of all other avian hepadnaviruses with the highest level
of divergence seen throughout the genome. An X gene which is also divergent from
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all other avian hepadnavirus X genes is present (Prassolov et al., 2003). This
suggests that the PreS and X regions of hepadnaviruses are species specific.
Due to the severity of HBV disease in humans it is highly desirable to carry out
research into disease course and mechanisms, treatments, and prevention using
animal models. The presence of HBV-like viruses in several other species of animal
makes this possible. Some of these are more attractive as potential models than
others. Ducks and squirrels are attractive due to their availability, but there are also
limits to their usefulness. For example, there is still a lot that is unknown about the
duck immune system (Jilbert and Kotlarski, 2000), and it may be that these
differences make the model unsuitable for human research. Primates are attractive
due to their close relationship to humans in evolutionary terms, and although some
vaccine studies have been carried out using chimpanzees (Prince et al., 1997) and
orang-utans (Davis et al., 2000) it has to be remembered that these species are on the
endangered list, and using them in primary research is not feasible. The morality of
using our closest relatives for experimentation also has to be considered. The WHV
model may be more useful for this type of research (Lu et al., 1999).
The hepadnaviruses discovered to date all show species-specificity when it comes to
which host they are able to infect. Infectivity studies using HHBV and DHBV have
shown that the host range is determined at the virus entry level, either at the binding
step or the internalization step, as determined by the pre-S region variability of the
large surface protein (Ishikawa and Ganem, 1995). Both similarities and differences
between the different hepadnaviruses give us important insights into the evolution of
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these viruses. Studies on the X protein of human, rodent, and avian hepatitis B
viruses have shown that their transactivating and pro-apoptotic functions are
conserved (Schuster et al., 2002). Experimental infection of non-hepatoma cell lines
with HBV, DHBV, and WHV indicates that there are differences in transcription
factor usage between these mammalian and avian hepadnaviruses during viral
replication. This may reflect the adaptation of the viruses to their host organisms
(Tang and McLachlan, 2002).
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1.5 Evolution of viruses and theories ofHBV origins
The viral genome evolves just like the genomes of bacteria and eukaryotes through
the fixation of naturally occurring mutations, or nucleotide changes. As is the case
for HBV, fixation of these mutations may be subject to constraints imposed by
fitness selection. In the case ofHBV, the existence of four overlapping open reading
frames, and 67% of the Pol gene also coding for other proteins severely limits the
number of neutral sites, and therefore limits the amount of variation possible
(Mizokami et al., 1997). Mechanisms involved in the evolutionary genetic change
are numerous and varied. These mechanisms are discussed in more detail in
Simmonds 2001 (a and b). Pressure from the immune system of the host may be
responsible for driving genetic change in B or T cell epitopes, in order to continue
infecting the host and be spread to other new hosts, rather than being neutralised and
eliminated. Sequence change may also be driven by the widespread use of HBV
vaccines that may lead to changes in the a determinant in HBsAg. Antiviral treatment
frequently leads to changes in the Pol gene that confer antiviral resistance (Angus et
al., 2003). Rapid sequence change under these selection pressures is favoured by
large population sizes in HBV-infected individuals, and by the nature of the
replication mechanisms of HBV, in which transcription of the genome is carried out
by enzymes without proof-reading activity, and consequently high nucleotide mis-
incorporation rates (see section 1.2).
For viruses like HBV where multiple genotypes or subtypes exist, the possibility of
one host being infected with more than one of these types at one time introduces
another mechanism to drive the evolution of the viral genome- recombination.
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Recombination can also occur with parts of the host genome in viruses such as HBV
that can integrate into the host genome (see section 1.2). Recombination with
genomes from other related or unrelated viruses infecting the same host is also a
possibility. The crossing of the species barrier by a virus can drive its evolution by
all the above mentioned mechanisms, but especially immune pressure and
recombination. The use ofmolecular biology to investigate the genomic nucleic acid
composition of viruses is an important tool in virology today, especially when
coupled with statistical analysis and phylogenetics. By obtaining the genetic
sequences of viruses one can attempt to discover their origin and evolutionary
history.
Three main hypotheses regarding the evolutionary origin of HBV have been
proposed. These will be discussed separately below. Alternative hypotheses will also
be discussed.
1.5.1 Out of Africa
This hypothesis proposes that HBV originated in Africa and was then spread to the
rest of the World as man moved out of Africa 100 000 to 150 000 years ago
(Magnius and Norder, 1995; Norder et al., 1994). This hypothesis was mainly based
on the observed distribution of serotypes of HBV, which appeared to be determined
by geographical origin of the host population. The distribution of the genotypes of
HBV, however, do not show the same distribution pattern, and each of the serotypes
may be found in more than one genotype, including the primate genotypes. The
phylogenetic outlier position of human genotype F and H can also not be explained.
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South America was the last main landmass to be populated, yet the viruses here are
the most divergent. Apart from these two genotypes there is no association between
the HBV genotypes and population groups, even though the genotypes do exhibit
differences in geographical distributions (see chapter 3 for more details about
genotypes and their distributions).
The fact that HBV from other primates exists and are phylogenetically interspersed
with the human genotypes (see chapter 5) also does not agree with this hypothesis, as
they would be expected to be much more distantly related to human viruses and to
each other, indeed, to include the different primate genotypes in this hypothesis one
needs to propose a process of co-evolution element in which the origin of would date
back to the time of ape speciation around 18 million years ago (Stewart and Disotell,
1998). In summary, the poor match between human HBV genotypes and the
population groups they infect, and the "wrong" position for the non-human primate
genotypes, indicates major flaws with this as an explanation for HBV diversity.
Even though to date this hypothesis does not seem to fit the available data on HBV
molecular evolution this type of scenario has been proposed for other viruses such as
hepatitis G virus/GBV-C (HGV/GBV-C) (Charrel et al., 1999). The distribution of
HGV/GBV-C genotypes matches the population groups that emerged following the
spread out of Africa. Furthermore, there are also genotypes found in chimpanzees
and New World monkeys, and these do group separately from the human genotypes
as expected(Simmonds, 2001b; Simmonds, 2001a). The polyoma virus JC virus
(JVC) is a virus that follows the out ofAfrica model also very well.
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This virus can be found as several genotypes with distinct geographical distributions
as well as distinct ethnic host populations (Chang et ah, 1999a; Guo et ah, 1996;
Hattwell and Sharp, 2000; Sugimoto et ah, 1997). JCV has in fact become so adapted
to its host populations that there does not appear to be any transmission across ethnic
groups (Kato et ah, 1997). This was demonstrated by the absence of Japanese
derived isolates in American soldiers based in Japan, and vice versa, though it might
have been expected to be some transmission between the two ethnic groups when in
such close contact. This has enabled researchers to determine that the distribution of
genotypes does mirror the spread of modern humans. Another polyoma virus, BK
virus (BKV) may also have evolved following this model (Laura Jackson,
unpublished data). The fact that this hypothesis can be applied to other virus
infections means that it will have to be reconsidered and re-evaluated as more HBV
sequence data becomes available.
1.5.2 New World Origin
This was the second hypothesis to be proposed. It stipulates that the hepatitis B virus
originated in South America, and subsequently spread to Europe and the rest of the
World through contact with returning Spanish colonisers around 400 years ago
(Bollyky et al., 1997). The outlying position of genotypes F and H, which are found
mainly in aboriginal populations of South America, and the high prevalence ofHBV
genotype F within native populations in South America has also been put forward in
support of this hypothesis (Bollyky and Holmes, 1999). Other evidence proposed to
support this hypothesis includes the existence of woolly monkey HBV, and rodent
HBV. All the rodent species from which HBV variants have been isolated are
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indigenous to the Americas, indicating that cross-species transmission from these to
other primates may represent the origin of HBV in the New World (Bollyky and
Holmes, 1999).
However, this theory was proposed at a time when most researchers still assumed
that any HBV infections seen in primates were of human origin (Bollyky and
Holmes, 1999; Lanford et ah, 1998; Norder et al., 1996; Zuckerman et ah, 1978). In
this thesis, and in other published studies, the overwhelming evidence for natural
infections with species-specific primate HBV genotypes in the Old World makes this
type of scenario unlikely. To include the primate HBV genotypes in this hypothesis
one would have to consider multiple cross-species transmission from humans to
primate populations in the wild in Africa and Asia over the last 400 years. This is the
length of time that populations from Europe and South America have been in
contact.
The amount of variation seen within each of the genotypes is also inconsistent with
such a recent origin. The rate of mutation (evolution) of HBV has been estimated as
2.1 x 10~5 substitutions/site/year (Hannoun et al., 2000a). This rate was based on the
rate of change seen for a HBeAg carrier. The rate of change in such carriers is slower
than that seen in individuals who are able to mount an effective immune response to
the infection. This places the origin of human HBV at 2300-3100 years ago. This rate
of mutation is slow to generate the levels of diversity seen in only 400 years as
suggested by this hypothesis. To generate such a large amount of diversity the rate of
change would have to be much faster. Therefore, the geographical distribution of the
genotypes is poorly explained by this hypothesis. If the genotypes existed before
HBV spread to the rest of the World, then why are genotypes F and H the only ones
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represented in the New World, and consequently, why are they not found
elsewhere(Simmonds, 2001b)?
1.5.3 Cross-species transmission and co-evolution
This was the last of the three hypotheses to be proposed (MacDonald et al., 2000).
This hypothesises that the human genotypes seen today originate from multiple
cross-species transmission events from primate carriers following co-evolution of
HBV and these primate hosts over 10-35 million years. The existence of more
divergent HBV variants in mammals and birds opens up the possibility that the co-
evolution may stretch even further back, as primates and rodents diverged around
110 million years ago (Simmonds, 2001b). Human endemic areas show specific
genotypes, for example F and H in South America, E is sub-Saharan western Africa,
and B and C in Southeast Asia. These areas are also where the primates species that
to date have been found to carry HBV are found, i.e. woolly monkeys in South
America, chimpanzees and gorillas in Africa and gibbons and orang-utans in
Southeastern Asia. One possibility is that the genotypes in these areas arose through
cross-species transmission, and the human genotypes are the result of recent endemic
spread (Simmonds, 2001a) as is suggested for human immunodeficiency virus (HIV)
(see below).
Zoonosis as a factor in the evolution ofHBV has been suggested by other groups (Hu
et al., 2000). Hu (2000) argued that the relationship between the phylogenetic and
geographical separation of human genotype F and the woolly monkey isolate from
all other primate HBV variants indicated a possible zoonosis event. The discovery of
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orang-utan HBV and subsequently genomic variants in geographically separated
populations (Verschoor et al., 2001; Warren et al., 1999) also suggest co-evolution
from a common ancestor for ape and human genotypes A-E with possible multiple
cross-species transmissions responsible for creating the different genotypes. An
ancient origin for HBV is implied by the existence of interspecies variants of HBV
determined by species/geography. Genotype F and the woolly monkey virus may
represent even older viruses (Verschoor et al., 2001). This is also suggested by
gibbon studies (Grethe et al., 2000) where five genomic groups were described based
on the geographical origin of the animal from which virus was isolated.
Arguments against this scenario for HBV evolution have also been proposed (Hu et
al., 2000). Gibbon HBV and chimpanzee HBV are in fact more closely related to
each other than to the human genotypes in Africa and Asia respectively, and this is
considered indicative of an absence of co-evolution and cross-species transmission.
This means that the HBV genotype phylogeny does not reflect the host phylogeny, as
would be expected if co-evolution had taken place. Also, any species involved in
these events remain unidentified. And finally; to date no genotypes have been found
to be shared between humans and primates. One chimpanzee was detected that
carried a human genotype E isolate, but this may be due to transmission in captivity
(Takahashi et al., 2000). For more detail about this isolate see section 1.5.4.
Despite the currently conflicting data surrounding the cross-species transmission
hypothesis for the origin ofHBV infection in humans, such a process is now believed
to explain the presence of human immunodeficiency virus type 1 (HIV-1) and type 2
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(HIV-2) in human populations. HIV-2 origins were reported first, and were described
as a minimum of 6 separate transmission events from sooty mangabeys (Cercocebus
atys) to humans in West Africa (Feng et ah, 1992). HIV-1 is believed to have crossed
from troglodytes chimpanzees (see chapter 5 for further information about
chimpanzee subspecies and geographical distribution) of Central African origin to
humans at least 3 times (Gao et ah, 1999), and the HIV-1 genotypes seen distributed
widely across the World are due to the recent epidemic spread of the infection within
its new host populations. The common ancestor for HIV-1 type M and SIVcpz has
been proposed to date back to 1675, with zoonotic transmission of SIVcpz
introducing HIV-1 to human populations occurring sometime before the 1920's, as
the subtypes of HIV-1 had already begun to diverge by then. The major social
changes in Africa in the last century then contributed to the epidemic spread of
infection (Salemi et ah, 2001).
Co-evolution of SIV and its various host primates over thousands of years, with
recombination and cross-species transmission events have also been described by
researchers (Georges-Courbot et ah, 1998; Souquiere et ah, 2001). The finding of
sub-species specific HBV variants within chimpanzee HBV, as can also be seen in
SIV, taken together with the fact that the modes of transmission of HBV and HIV
area similar suggest that cross-species transmission of HBV is a distinct possibility
(Hu et ah, 2001).
Co-evolution between an infectious agent such as a virus and its host is not uni¬
directional. Changes will occur in the host to counteract changes in the virus.
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Consequently, further changes will occur in the virus to counteract these new host
changes. The host and virus drive the evolution of the other forwards.
1.5.4 Alternative hypotheses for HBV origins
In stark contrast to the "Out ofAfrica" hypothesis and cross-species transmission/co-
evolution hypothesis discussed above, it has also been proposed that the evolution of
HBV is independent of the evolution of the host species (Orito et al., 1989).
Calculated divergence times for HBV are much more recent than the host divergence
times. For example, DHBV was calculated as diverging 30 000 years ago, whereas
birds diverged 300 million years ago. With the more recent dates of divergence this
hypothesis does, however, not rule out the possibility of cross-species transmission
as described above. Most alternative hypotheses that have been proposed do suggest
cross-species transmission events have occurred in one direction or the other.
The discovery of genotype E in a chimpanzee (Takahashi et al., 2000) gave rise to a
number of speculations as to the origin of this virus isolate. The first was that it was
human in origin, and was transmitted to the animal either in the wild or in captivity.
The second was it came from another infected chimpanzee in the wild, assuming that
genotype E is shared between humans and chimpanzees. This last suggestion led to
the hypothesis that genotype E was once a chimpanzee strain that was transmitted to
humans and subsequently evolved into the genotype E seen today. The lack of
genotype E sequences available on GenBank makes this hypothesis difficult to
investigate, but as to date there is only one confirmed report of a chimpanzee
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genotype E carrier, and as there have been no reports of human carrying chimpanzee¬
like viruses, there is currently no further evidence to support this hypothesis.
Lanford (2000) suggested three alternative explanations for the close relationship
between gibbon HBV, chimpanzee HBV and human HBV that became apparent
from his phylogenetic studies of several new isolates from gibbons in captivity. The
first of these is that there was a common ancestor for these viruses, but they diverged
too recently for there to be much distinction between them to show this ancestry. As
Lanford himself points out, the outlying position of genotype F within phylogenetic
trees makes this unlikely. His second explanation suggests a human origin for the
other primate HBV infections. Humans infected gibbons and this new infection was
then established in the wild, and started to diverge into a new genotype. The third
explanation is that there are no primate genotypes, but that these infections represent
current cross-species transmissions from humans to gibbons in endemic areas. If this
was the case, where is the evidence for these genotypes in human populations?
A more recent origin for HBV, with frequent cross-species transmission, has also
been proposed (Fares and Holmes, 2002). This places the origin for hominid HBV no
earlier than 6000 years ago and the origin for woolly monkey HBV at 9000 years
ago. Cross-species transmission is supported by the close relationship between
gibbon and orang-utan HBV isolates and the fact that their habitats overlap (see
chapter 5 for more information). A similar relationship is seen between chimpanzee
and gorilla HBV. The interspersed positions of human and primate genotypes in
phylogenetic trees also suggests this type of transmission. Humans are put forward as
46
the vector most important in spreading HBV across the vast geographical distances
necessary to seed HBV infection in human populations throughout the world, and to
other primate species in these same areas.
Fares (Fares and Holmes, 2002) suggest that Old World and New World viruses
must have diverged either more than 15 000 years ago or less than 500 years ago for
humans to have been able to spread the viruses. Two alternative explanations are
subsequently offered as to the origin of human genotype F and woolly monkey HBV.
His first suggestion gives genotype F an Old World origin with entry into the New
World recently, and the woolly monkey isolate dates back to when modem humans
first migrated to the New World. The second supports the New World origin
hypothesis described earlier. This suggests that genotype F has a New World origin
and in fact represents the first vims to diverge from a New World monkey ancestral
vims. HBV then spread out of South America post-Columbus, and seeded all
subsequent outbreaks of HBV, both human and primate. As for the New World
origin hypothesis described earlier, the level of diversity within the genotypes, and
the absence of genotypes other than F and H in South America, and conversely F and
H in the rest of the world, makes this unlikely. There is now a large amount ofHBV
genotype data available on GenBank, and to date there have been very few reports of
these two genotypes outside of South America.
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1.6 Aims and implications for the future
The main aim of this thesis is to investigate the molecular evolution of human and
non-human primate HBV to gain further insights into the origin of HBV in these
species. This type of extensive study has not been carried out before, as most studies
concentrate on either human or non-human HBV. The working hypothesis that the
research design is based on is the cross-species transmission and co-evolution
hypothesis described earlier. Each component of this project is centred around its
own set of aims.
The survey of HBV genotype distribution and variation in humans is designed
around three aims;
1- to investigate further the genotype distributions in endemic areas,
2- to investigate further the diversity within the genotypes, including investigating
the existence of geographically defined clusters within the genotypes,
3- to search for evidence of primate-like sequences in humans that would imply
cross-species transmission or a common origin.
The analysis of recombination between HBV genotypes is carried out to assess the
extent of recombination within HBV, and the likely impact of this on the evolution of
HBV.
The survey of HBV genotype prevalence in non-human primates is also based on
three aims.
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1- to assess the overall frequency of infection in different species of primate, to allow
for closer comparison with human HBV infection,
2- to assess the existence of subtypes within each of the primate genotypes,
3- to look for evidence of recombination within the primate HBV genotypes in the
search for evidence of cross-species transmission.
It is important to understand the origin and evolutionary mechanisms employed by a
virus such as HBV. The data collected from this project will greatly increase the
amount of sequence data available to researchers in the field of HBV biology. This
has implications for both epidemiology and other research into for example novel
treatment strategies and prevention. Knowledge ofwhich regions of the genome that
are most likely to change can target investigations towards more stable regions that
may be more suitable and susceptible to intervention. To epidemiologists it may
provide clues as to why the huge differences in incidence and severity of disease
seen in different populations and parts of the world exist. This may in turn be useful
when trying to devise new prevention strategies for countries where HBV is still of
high endemicity and a major public health problem, such as sub-Saharan Africa and
Southeastern Asia.
By understanding the mechanisms involved in the evolution of HBV more effective
treatments and vaccines may be designed to target potentially critical structures
within the viral genome. Through molecular studies regions of the viral genome can
be identified that undergo little or much change, and these can then be investigated as
potential new targets for antiviral drugs, or for use in vaccine development where a
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strong immune response to the vaccine is critical for its success. This assumes that
any such regions will continue to change at the rate currently seen, so mutation rates
will need to be monitored over time to ensure any new strategies devised do not drive






2.1 Extraction ofDNA from serum and plasma samples
Nucleic acid was extracted from serum or plasma samples using a standard phenol/chloroform
extraction protocol. lOOpl volumes of serum were incubated at 37°C for 2 hours in 400pl
lysis buffer (made with 1M Tris-HCl pH8.4, 0.5M EDTA, 5M NaCl, 10% SDS and protein
kinase) in 1.5 ml Eppendorf tubes. Following incubation tubes were centrifuged briefly to
remove condensation from the lids. 45pi phenol (water saturated, Rathburn) were added to the
samples and tubes were placed in a shaker for 20 minutes. Tubes were then centrifuged for 5
minutes at 15000 rpm at room temperature in a refrigerated Hereaus bench top centrifuge to
separate the layers. The aqueous layer was transferred to a new tube containing 450pl
chloroform/isoamyl alcohol (50:1 mix, BDH) and placed on the shaker for 15 minutes. Tubes
were centrifuged for another 5 minutes to separate the layers. Nucleic acid was then
precipitated by adding the aqueous layer to 800pl 100% ethanol containing 40pl 3mM sodium
acetate and lpl glycogen and stored at -20°C overnight. To collect the nucleic acid samples
were centrifuged for 20 minutes at 15000 rpm at 0°C. Pellets were then washed by adding
600pl 80% ethanol and centrifuging for another 15 minutes at 0°C. All traces of ethanol were
then removed by careful pipetting and the pellets dried for 10 minutes at 42°C in a hotblock.
Pellets were then resuspended in 30pl nuclease free water (Promega) and heated to 65°C for
10 minutes to ensure that nucleic acid was completely dissolved prior to polymerase chain
reaction (PCR) set up. Tubes were centrifuged briefly to remove condensation from the lids.
One positive serum control and one negative serum control were extracted alongside the
samples to check for success of extraction and possible contamination during the process. The
sample used as a positive control was also sequenced to ensure there was no contamination.
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2.2 Amplification ofHBV DNA sequences bv polymerase chain reaction
Samples were subjected to two separate nested (two rounds of amplification) polymerase
chain reactions (PCR reactions) in the screening process. Nested PCR increases the specificity
and sensitivity of PCR in comparison with single round amplification reactions. PCR 1
amplifies a segment of the PreS2/S region, and PCR 2 amplifies a segment covering the
overlap region between ORF P and the PreSl region (see Fig. 2-1 below).
prfi-c ill c n :: PreSl
: 1; P ' -'I T.vTT ; :i P !0
X
PCRi pel? 2;
Fig 2-1. Simplified genome map of the hepatitis B virus genome. The 4 ORF's and their
relative positions along the 3200 bp long genome are shown. The segments amplified by PCR
1 and PCR 2 are shown in the grey boxes.
First round PCR reactions were set up using 2pi of extracted DNA in a total reaction volume
of 50pl. The PCR buffer was made up containing lOpl lOx PCR buffer without magnesium,
lOpl MgCl2, lOpl 3mM dNTP's (Promega), 1.5pl of each primer (Oswel and Life
Technologies) at 100 pM concentration and 0.5 U of Taq polymerase (Promega) per sample.
Prior to cycling the reactions were overlaid with liquid paraffin. PCR 1 primary reaction was
carried out using primers SI (5'-CATCAGGAYTCCTAGGACCCCT-3 , position 171-192)
and S5 (5'-GAGGCATAGCAGCAGGATGMAGAGG-3', position 406-430). PCR 2 primary
reaction was carried out using primers 41 (5'-CGTCGCMGAAGATCCAATCT-3 , position
2423-2443) and 19 (5'-CKGAACTGGAGCCACCARCAG-3', position 69-89). First round
amplification was carried out under the following conditions, 30 cycles of 94 C for 18
seconds, 55°C for 21 seconds and 68°C for 90 seconds, followed by a final extension at 68°C
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for 7 minutes and a holding step at 20°C for 10 minutes. Second round PCR reactions were
set up using 1.5pl of first round product in a total reaction volume of 26.5pl. PCR buffer was
made up as described above and reactions were overlaid with liquid paraffin before cycling.
PCR 1 second round was carried out using primers S3 (5'-
CGTGTTACAGGCGGKGTKTTTCTTGT-3', position 196-221) and S6 (5'-
ATGATAAAACGCCGCAGACACATC-3', position 379-402). PCR 2 second round was
carried out using primers 42 (5'-GTATYCCTTGGACTCATAAGG-3', position 2461-2481)
and 43 (5'-CCACTGCATGGCCTGAGGATG-3\ position 3181-3201). Second round
amplification conditions were as follows; 25 cycles of 94°C for 18 seconds, 50°C for 21
seconds and 72°C for 90 seconds, followed by a final extension at 72°C for 6 minutes and a
holding step at 20°C for 10 minutes. PCR amplifications were carried out in a Techne Genius
thermal cycler (Techne, Cambridge UK).
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2.3 PCR product analysis
A 2% agarose gel was made by dissolving 6g agarose (SeaKemLE agarose, FMC
Bioproducts) in 300ml lxTBE (diluted from lOx TBE made with 108g Tris base (BDH), 55g
Boric acid (BDH), 40ml 0.5M EDTA pH8 in 11 distilled water) by heating in a microwave at
high level for 5 minutes. The agarose solution was then cooled by stirring on a magnetic
stirrer for approximately 15 minutes. The gellified top layer containing any bubbles was then
removed and Ethidium bromide (final concentration 6.67x104 mg/ml) was added. The agarose
solution was then poured into a gel tray and combs were inserted to create wells in the gel.
The gel was left to set for a minimum of 30 minutes at room temperature. 15pl of second
round PCR product were then loaded into the wells and run for 20-40 minutes at 150V in a
gel tank containing lxTBE. Size markers of lkb or 100 bp (Promega) were run alongside the
PCR products to check the amplified fragment sizes to verify that PCR reactions had worked.
PCR products amplified for the purpose of sequencing were always electrophoresed for 40
minutes to ensure accurate sizing. The gel was then illuminated under UV light and a
photograph was taken to record the results.
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2,4 Sequencing
Sequencing of samples was done using radiolabeled dNTP's in the first instance, and when
facilities became available, using an automated fluorescent label protocol.
2.4.1 Primers used for HBV amplification and sequencing
For sequencing of primate samples overlapping primers were designed to cover the entire
genome of HBV (MacDonald et al., 2000). Primers 44, 45, 46, and 47 were designed
specifically for this study (for all primer positions and sequences see Fig. 2-3 and Table 2-1
below). Primers 44 and 45 were used to investigate size differences of PreS fragments (see
Fig.3-x), and primers 46 and 47 were used to amplify a fragment of the HBV genome isolated
from chimpanzee Osang (see Fig.2-2 below). Primers were synthesized by Oswel and Life
Technologies. All fragments for sequencing were amplified using a nested PCR protocol with
buffers and PCR conditions as described above for the screening of samples.
Figure 2-2. Gel image showing the fragment amplified by primers 46 & 47, 400bp in size
(F2). Fragment 1 is 450 bp long, fragment 3 is 520 bp long, and fragment 4 is 300 bp long.
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PRIMER NO. POSITION SEQUENCE DIRECTION
1 2301-2320 GATAGGGGCATTTGGTGGTC R
2 1862-1881 ACTGTTCAAGCCTCCAAGCT F
3 2271-2287 AGTGCGAATCCACACTC R
*4 1932-1953 GAGCTWCTGTGGAGTTACTCTC F
*11 592-615 AAWTGCACWTGTATTCCCATCCC F
*12 800-822 AGACAMAAGAAAATTGGTAAYAG R
13 2892-2913 CAAYCCNYTGGGATTCTTYCCC F
14 2953-2975 AATCCMGATTGGGACTTCAAYMC F
15 245-267 GTCCACCACGAGTCTAGAYTCTK R
16 265-587 CCCCTRGAAAAYTGAGAGAAGTC R
17 300-322 GTCYTGGCCAAAATTCGCAGTCC F
18 3181-3201 CATCCTCAGGCCATGMAGTGG F
19 69-89 CKGAACTGGAGCCACCARCAG R
21 265-287 GACTTCTCTCARTTTTCYAGGGG F
*22 379-402 GATGTRTCTGCGGCGTTTTATCAT F
23 641-664 ACGGRCTRAGGCCCACTCCCATAG R
24 661-684 AGTAAAYTGAGCCARGAGAAACGG R
25 752-772 TGGTATTGGGGGCCAARTCTG F
*26 1171-1191 AGCAAACACTTGGCACAGVCC R
27 1192-1212 CCARCCAGTGGGDGTTGCRTC R
28 1102-1122 TCGCCAACTTAYAAGGCC I I I F
29 1153-1173 CCTTTACCCCGTTGCYCGGCA F
*30 1583-1603 CACGGWCCGGCAGATGAGAAG R
31 1583-1603 GCAGAGGTGAAGCGAAGTGCA R
32 1522-1541 ACGGGGCGCACCTCTC I I IA F
*33 1542-1561 CGCGGWCTCCCCGTCTGTGC F
34 2027-2046 CAATGYTCNGGAGACTCTAA R
35 2055-2075 ACCATACNGCACTCAGGCAAG F
39 2700-2718 CTGGATAATAAGGTTTAAT R
40 2726-2746 GTTTGGAARTAATGATTAAC R
41 2423-2443 CGTCGCMGAAGATCCAATCT F
*42 2461-2481 GTATYCCTTGGACTCATAAGG F
*43 3181-3201 CCACTGCATGGCCTGAGGATG R
*44 2959-2985 GTCCTTGWTGGGRTTGAAGTCCCAATC R
*45 2824-2848 GGTCACMWTAYTCYTGGGAACAAGA F
*46 1778-1801 ACCAWTTTATGCYRCAGCCTCCTA R
47 1415-1442 GGACGTCCTTTGTKTACGTCCC F
S1 171-192 CATCAGGAYTCCTAGGACCCCT F
*S3 196-221 CGTGTTACAGGCGGKGTKTTTCTTGT F
*S5 406-430 GAGGCATAGCAGCAGGATGMAGAGG R
S6 379-402 /VTGATAAAACGCCGCAGACACATC R
Table 2-1. Primers used for PCR amplification and sequencing of hepatitis B virus DNA
positive samples. Primers marked with a * were used in the sequencing reactions. The
directions of the primers have been abbreviated to F for forward and R for reverse. The
positions of the primers are also shown in Fig. 2-1. Positions are described with reference to
HBV isolate accession number V00866 (HBVADW).
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Fig. 2-3. Simplified genome map of the hepatitis B virus genome. The 4 ORF's and their
relative positions along the 3200 bp long genome are shown. The positions and direction of
the primers used are shown. Forward primers are shown in pink boxes and reverse primers in
grey boxes.
58
2.4.2 Sequencing ofHBV using radiolabelled dNTP's
Manual sequencing using radiolabelled dNTP's was carried out using the Sanger method with
the Thermo Sequenase Radiolabeled Terminator Sequencing Kit (USB). 5pi of second round
PCR product were aliquoted into 0.5ml Eppendorf tubes, lpl each of exonuclease 1 and
shrimp alkaline phosphatase was added and mixed well. This was then incubated for 15
minutes at 37°C, and then quickly transferred to a hotblock at 80°C and left for another 15
minutes to inactivate the enzymes. Four 0.5ml tubes for each sample and primer that was
being used were labelled G (guanine), A (adenine), T (thymine), and C (cytosine) respectively
to represent each of the four radiolabelled bases. Termination mixes were made up for the G,
A, T, and C dNTP's by mixing 2pl T mastermix (7.5pM dGTP, dATP, dTTP, and dCTP) and
0.25pl 0.3pM [33P] labelled dNTP (Amersham Pharmacia Biotech) per sample. Then reaction
mixes were made up for each of the primers to be used, containing per sample 2pl
concentrated reaction buffer (260mM Tris-HCl pH9.5, 65mM MgCb), 0.5pl primer (at
lOOpM concentration), 13.5pl distilled water and 2pl thermo sequenase DNA polymerase.
The thermo sequenase was kept in the freezer and added just before the buffer was to be used.
After 15 minutes on the hotblock the tubes were removed and centrifuged to collect the DNA
at the bottom of the tubes. 3.5pi of the treated DNA were then added to the G tube of each
PCR strip. 18pl of reaction mix were then added to this tube and mixed by careful pipetting.
5pl of this were then aliquoted into the G, A, T, and C tubes of the PCR strip. 2.5pl of the
appropriate dNTP termination mix were then added to each tube in the PCR strips and the
reactions were then overlaid with liquid paraffin. The reactions were then thermocycled on a
Techne Genius for 30 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 60
seconds. To stop the reactions after cycling has finished 8pi of the sequencing reaction were
added to a well in a 96 well microtitre plate containing 5pi stop solution (95% formamide,
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20mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF). This was the either
directly loaded onto a polyacrylamide gel or stored at -20°C until needed. If stored at -20°C,
reactions were defrosted on a hotblock at 100°C for 1-3 minutes before being loaded onto the
gel.
A 6% polyacrylamide gel was made to visualise sequencing products. 21 g Urea (BDH) and
0.05g APS were mixed with 6ml Sequagel concentrate and 5ml lOxSanger TBE and made up
to a volume of 50ml with distilled water and dissolved under gentle heating in a conical flask.
The solution was then left to cool to room temperature and 21 pi of TEMED were added. The
gel was then poured between clean glass plates, a comb to make the main well inserted, and
left to set for approximately 2 hours. The gel was fastened into the sequencing rig and
lxSanger TBE (diluted from lOx TBE with distilled water) added to the top to cover the edge
of the inner plate and the bottom to cover the foot of the gel. A comb was inserted to make the
individual wells, and then 6pl of sequencing reaction was added to the wells. The gel was
then run for approximately 1.5 hours at 75W. The sequencing rig was then drained of buffer
and the gel removed and left to cool until hand temperature. The plates were then separated
and the gel transferred to Whatman paper. The gel was then covered with Saran wrap and
dried at 80°C under a vacuum. When dry the gel was placed in a cassette with X-ray film
(Biomax MR, Kodak) and left for a minimum of 24 hours. The film was then developed in an
automated developer. Sequence data was manually entered into the SIMMONIC sequence
analysis program for editing and alignment.
60
2.4.3 Sequencing ofHBV using an automated protocol
Automated sequencing was carried out using either the dRhodamine or BigDye sequencing
kits (Applied Biosystems). For the dRhodamine protocol PCR product was used to give a
concentration of between 30-90ng of DNA in each reaction, whereas for the BigDye protocol
the size of fragment to be sequenced determined the amount of PCR product to add to each
reaction (as described in manufacturer's manual). The required amount of PCR product was
aliquoted into PCR strips into which 2pl of the appropriate primer (3.2mM) had already been
aliquoted. 4pl dRhodamine/BigDye ready reaction mix was then added and the volume made
up to 20pl with milliQ water (prepared on site at the Royal (Dick) Veterinary School,
Edinburgh). The reactions were then overlaid with a drop of liquid paraffin and cycled in a
Techne Genius thermocycler for 25 cycles; rapid thermal ramp to 96°C, 96°C for 30 seconds,
rapid thermal ramp to 50°C, 50°C for 15 seconds, rapid thermal ramp to 60°C, 60°C for 4
minutes, followed by a rapid thermal ramp to 4°C and held there until ready to perform
purification reaction. DNA was purified by removing all the reaction with a pipette and
adding to 0.5ml Eppendorf tubes containing lpl 3M NaAc (pH5.2) and 25pl 100% ethanol.
Tubes were then left at room temperature for 15 minutes to precipitate the DNA, followed by
centrifugation at 13000 rpm at room temperature in a Hereaus bench centrifuge for 30
minutes. The ethanol was then removed using a pipette and the pellet was washed by
centrifugation for 5 minutes with 125pl 70% ethanol. The ethanol was then removed by
pipetting and any residual ethanol removed by pulse-spinning and a final pipetting. The pellet
was dried for 2 minutes at 90°C. (In September 2002 a robotic system for the clean up of
sequencing reactions was introduced at King's Buildings, and manual precipitation and
cleaning was no longer necessary.) Samples were then sent for analysis on an ABI 3100
genetic analyser (Applied Biosystems) at the automated sequencing service at King's
buildings, The University of Edinburgh. Results were returned via email and then viewed
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using Chromas. Sequences were directly imported from Chromas into SIMMONIC for editing
and alignment.
2.5 Alignment and analysis of data
The SIMMONIC software was originally developed to investigate the structural constraints
on the evolution of hepatitis G virus/GBV-C (Simmonds & Smith, 1999).This software allows
the alignment and analysis of multiple sequences. Data generated using SIMMONIC can be
exported in several different formats, such as PHYLIP, MEGA and FASTA, for use in further
downstream applications.
Once imported into the SIMMONIC sequence analysis program sequences were aligned to 61
sequences from GenBank (see Table 2-2) representing the human genotypes, and 26
previously published primate isolates representing chimpanzee HBV, gorilla HBV, gibbon
HBV, orangutan HBV, and woolly monkey HBV. For primate samples, aligned fragments
representing the entire HBV genome were merged using a function of the SIMMONIC
program to create complete genomes. Manually obtained sequences were entered into the
SIMMONIC program from two separate readings and then compared and ambiguities
checked. All Chromas sequence traces were viewed during alignment of sequences and
ambiguities were checked. Following alignment sequences were analysed phylogenetically.
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ACCESSION ACCESSION









E00010 A AB056516 G
AF090639 A AF405706 G
D00331 B AB056515 G
AY033073 B AB056514 G
D23679 B AF160501 G
D50522 B AB056513 G
D00329 B AY090454 H
AJ131133 B AY090457 H
AF282918 B AY090460 H
AF121249 B AF305327 CHIMPANZEE
D00330 B AJ131575 CHIMPANZEE
AF121243 B AF242585 CHIMPANZEE
AF411508 C AF242586 CHIMPANZEE
AF241359 C AB032433 CHIMPANZEE
AF411412 c AB032432 CHIMPANZEE
AF363961 c AB032431 CHIMPANZEE
D00630 c AF222323 CHIMPANZEE
AF330110 c AF222322 CHIMPANZEE
M12906 c AB046525 CHIMPANZEE
AB049610 c D00220 CHIMPANZEE
X75665 c AY077735 GIBBON
AY057948 c AY077736 GIBBON
AF297619 D AB037928 GIBBON
X68292 D AB037927 GIBBON
U95551 D U46935 GIBBON
X65257 D AJ131568 GIBBON
X80925 D AJ131569 GIBBON
X72702 D AJ131571 GIBBON
Z35716 D AJ 131572 GIBBON
Y07587 D AJ131573 GIBBON
AJ344116 D AJ131574 GIBBON
AF121240 D AJ131267 GORILLA
X75664 E NC_002168 ORANGUTAN
X75667 E AF193864 ORANGUTAN
X69798 F AF046996 WOOLLY MONKEY
AF223965 F




Phylogenetic analysis of aligned sequences was carried out using the MEGA2 program
(Kumar et al., 2001). Phylogenetic trees were constructed using the Jukes-Cantor model and
neighbour-joining analysis with 100 bootstrap replications. For analysis of primate samples
the complete genomes were compared to the previously published sequences described for the
amplification and sequencing of the samples. A larger data set of S gene sequences was
created by searching GenBank and downloading further sequence data (see Appendix A).
This data set was then split into genotype-specific sequence alignments and sample sequence
data was re-analysed. Primate samples were also analysed in the S gene region of the HBV
genome, as a number of further isolates from chimpanzees, orangutans and gibbons are
available with sequences from this region. S gene sequences used in this analysis include
those used for aligning and genotyping the data and these further partial sequences (see Table
2-3).
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ACCESSION GENOTYPE ACCESSION GENOTYPE
NUMBER NUMBER
AF222312 CHIMPANZEE AF477482 GIBBON
AF222313 CHIMPANZEE AF477483 GIBBON
AF222314 CHIMPANZEE AF477484 GIBBON
AF222316 CHIMPANZEE AF477485 GIBBON
AF222317 CHIMPANZEE AF477486 GIBBON
AF222318 CHIMPANZEE AF477487 GIBBON
AF222319 CHIMPANZEE AF477488 GIBBON
AF222320 CHIMPANZEE AF477489 GIBBON
AF222321 CHIMPANZEE AF477490 GIBBON
AF305326 CHIMPANZEE AF477491 GIBBON
AF305328 CHIMPANZEE AF477492 GIBBON
AF305329 CHIMPANZEE AF477493 GIBBON
AF305330 CHIMPANZEE AF477494 GIBBON
AF213010 GIBBON Y17559 ORANGUTAN
AF213009 GIBBON Y17561 ORANGUTAN
AF213008 GIBBON Y17562 ORANGUTAN
AF274495 GIBBON Y17564 ORANGUTAN
AF274496 GIBBON Y17565 ORANGUTAN
AF274499 GIBBON
Table 2-3. Additional accession numbers of further partial primate sequences obtained from
GenBank. These sequences were used in the phyolgenetic analysis of the S gene region of
primate HBV isolates.
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2.7 Assessment ofHBV groupings using association indices
Intragenotype groupings visible after phylogenetic analysis (see chapter 3) were investigated
using Association Index (AI) analysis. This is a novel phylogenetic analytical method, which
was initially developed to investigate the segregation of populations of HIV-1 isolates from
different body tissues from the same patient (Wang et ah, 2001), and it couples the
SEMMONIC package to the PHYLIP program package (Felsenstein, 1993). The degree of
genetic segregation between variants from different locations is scored based on phylogenetic
analysis. An association value id) is calculated using the formula d = (n - f)/2" ~ \ where /is
the frequency of the most common sample type within each cluster within the tree, and n is
the total number of sequences within each cluster. Values for d are calculated for each node
within the tree and added together to give a total d for the tree. Random re-sampling of
sequences into groups is carried out 10 times to provide a control value based on the null
hypothesis of no segregation. 100 bootstrap replications are carried out as part of the control
analysis, thus yielding 1000 control values. The control d of the tree is the mean of these 1000
values. The Association Index value is obtained by the ratio of d total for the tree divided by
the mean d for the control analysis. The maximum score possible is 1, and this would indicate
no segregation of variants, whereas a score of 0 would indicate complete segregation. A score
of 0-0.5 indicates a significant degree of segregation, 0.5-0.7 indicates a lower degree of
segregation, and 0.7-1 indicates no significant segregation of groups. The segregation ofHBV










































Total d for tree = 1.49 x 10°
Mean control d = 22.24
Association Index for tree = 6.68 x 10'5
Fig. 2-4. Example AI calculation for the complete genome phylogenetic tree of HBV
genotypes. The human genotypes and the primate genotypes are marked. There are 19 main
nodes within this tree, and these are marked with the numbers 1-19. The calculation to obtain
the d value is shown for the root node (node 1). For all remaining nodes only the d values are
shown. The control value was calculated using the SIMMONIC program.
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AI analysis can be carried out for whole tree analysis as shown above in Fig. 2-4, but can also
be used in other applications. Associations between groups can be investigated, for example
how well HBV genotype D isolates from Europe and Africa segregate. The segregation of a
single defined group from all other sequences within a tree can be investigated, for example
isolates of genotype C from hepatocellular carcinoma patients versus all other genotype C
isolates. AI can also be used as an alternative genotyping method by investigating the
associations of a single query sequence to the different genotypes. This last application can
also be applied in the investigation of recombination (see section 2.8.1 below). All these four
applications of the AI method can be carried out on the complete sequences or as bootscans as
described below (see section 2.8).
2,8 Detection ofHBV recombination
Complete full length HBV genomes were investigated for evidence of inter-genotype
recombination events using two different bootscanning methods, SimPlot and AI.
Bootscanning is a phylogenetic method which investigates the phylogenetic relationships of a
query DNA sequence by dividing the sequence into segments that overlap, these are called
windows. The level of overlap between the windows is also defined. Phylogenetic analysis is
then carried out for each window along the genome, scanning the genome. Bootstrap analysis
is carried out for each tree that is generated. In traditional bootscanning analysis, such as
SimPlot bootscanning analysis which will be described below (see section 2.8.2), the result is
shown as a graph of the bootstrap values generated for each window analysed. Bootscanning
will show recombination events as a switch in which sequence/sequence group the query
sequence is most closely related to. Association Index analysis can be used as a novel
bootscanning method.
68
2.8.1 Association Index bootscanning
Association Index bootscanning follows the same principles as described in general for
bootscanning above. The difference between this method and other methods is that the result
is not a set of bootstrap values, but a set of AI values for the query DNA sequence against
predefined sequence groups. The query DNA sequence is divided in windows with a defined
overlap and AI analysis with bootstrap replications is carried out for each window. The results
are again plotted on a graph, and recombination events will be shown as a switch in the
sequence group that the query sequence is closest associated to. In this analysis the scale is 0-
1 as described earlier, but now 1 can be taken as meaning strongest association and 0 as no
association.
2.8.2 SimPlot
The SimPlot program was initially developed to investigate HIV-1 intersubtype
recombination. This program is also coupled to the PHYLIP program package. SimPlot can
be used in two different ways; to generate similarity plots (which initially was the only
function and gave the method its name), or to do bootscanning. Similarity plots investigate the
degree of similarity of a query sequence with predefined groups of sequences such as
genotypes. Recombination is shown by the query sequence switching which sequence group it
is most similar to. This method was used for recombination analysis prior to the advent of
bootscanning methods (Salminen et al., 1995). Bootscanning was added to the SimPlot
program in 1999. As the results are bootstrap values, a graph is generated with a scale of 0-
100%. For each window of the query sequence that is investigated a bootstrap percentage




Genotypic Variation Within the
Human Hepatitis B Virus Genotypes
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3.1 Introduction
Hepatitis B virus (HBV) infection has been detected in most populations throughout the
world, as well as in a number of primate species (this will be discussed in more detail in
chapter 5). HBV infection is a global health problem, with approximately 1 million deaths
from hepatocellular carcinoma and chronic hepatitis estimated to be caused by HBV infection
each year (Thomas and Jacyna, 1993). High rates of active infection ranging from 8-15 % are
found in South and East Asia, sub-Saharan Africa and amongst indigenous peoples in Central
and South America (Andre, 2000). Human HBV can be divided into 8 genotypes based on
genetic diversity, differing from each other by 10-13% at the nucleotide level (Figure 3-1).
The human genotypes also show a geographically defined distribution pattern (Figure 3-2).
As well as variation between the genotypes, there is also variation within the genotypes.
Isolates from the same genotype can show very different virological and clinical
characteristics, and the classification of possible subtypes may be important in trying to
understand these differences (Miyakawa and Mizokami, 2003). Several reports have
described the existence of distinct subgroups within certain genotypes.
One such example is the A' subtype which has been described in HBV isolates from South
Africa and Malawi (Bowyer et al., 1997; Kramvis et al., 2002; Owiredu et al., 2001a;
Sugauchi et al., 2003c). This subtype does not appear to be associated with a specific disease







Fig. 3-1. Phylogenetic analysis of complete HBV genomes representing human genotypes A-
H. Phylogenetic analysis was carried out using the neighbour-joining method (as described in
chapter 2) and using the woolly monkey HBV isolate as an outgroup. This analysis was based
on full length genome sequences of HBV isolates from various countries (for accession
numbers see Table2-2).
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the dominant type of genotype A circulating in the southern regions of Africa or whether it is
specific to a particular population group or transmission route, although it has now been
suggested that this particular subtype, showing a high level of genetic heterogeneity, may be
characteristic of the indigenous populations of some of the African countries (Sugauchi et al.,
2003c). Genotype A isolates from Europe cluster distinctly from those from southern Africa
and those from elsewhere suggesting the existence of other geographically defined HBV
variants (Hannoun et al., 2002).
Another genotype that has been reported as existing in different forms is genotype B, one of
the predominant Asian genotypes. The different forms in this case are defined as either
recombinant or non-recombinant within the core region, with the recombinant form having a
core region derived from genotype C variants (Bowyer and Sim, 2000; Sugauchi et al.,
2002b). These two variants appear to have distinct geographical distributions, with the non-
recombinant strains circulating in Japan, and recombinant strains in Southeast Asia. These
subtypes are associated with differences in clinical outcome, with the recombinant genotype B
form associated with a more severe disease than the non-recombinant form in Japan. In Japan
the most severe liver disease is caused by genotype C (Sugauchi et al., 2002b). The difference
in pathogenicity between genotypes B and C has been well documented in many studies
(Ding et al., 2002; Kao et al., 2000; Kao et al., 2002; Lindh et al., 1999; Sugauchi et al.,
2003a; Sumi et al., 2003). Associations between genotypes and disease is
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Fig. 3-2. Map of the World showing the distributions of the human HBV genotypes A-H.
Genotype A is found predominantly in Europe, the US and Africa, genotypes B and C in East
and Southeast Asia, genotype E specifically in Western Africa, genotypes F and H in various
population groups in Central and South America. Genotype D is found worldwide, and is also
the predominant genotype in the Mediterranean region. Genotype G may have a similar
distribution as genotype A or D, having been isolated only from patients in Europe and the US
to date.
described in more detail in chapter 1 section 3. Recombination (such as that described for B
and C above) between different HBV genotypes will be discussed in more detail in chapter 4.
Apart from existing alongside of genotype B in Asia, genotype C has also been described as
existing with at least three subgroups (Alestig et ah, 2001a; Alestig et al., 2001b; Huy et ah,
2004; Sugauchi et ah, 2001), with isolates from Australian aborigines being highly divergent
from isolates from other geographical areas (Alestig et ah, 2001a; Sugauchi et ah, 2001), and
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another subgroup being formed by isolates from SE Asia (Alestig et al., 2001b). A recent
study revealed the presence of two separate subgroups in Asia, one representing Southeast
Asia and the other the Far East and Northern Asia (Huy et al., 2004).
No such groups have been suggested for genotype D, E, and G. Genotype D isolates from
isolated tribes of the Nicobar and Andaman Islands have been reported as grouping separately
from isolates from mainland India, but were not described as a distinct subgroup or subclade
(Arankalle et al., 2003). Genotype E has been described as being very homogeneous (Suzuki
et al., 2003) as has genotype G.
Genotype G has so far been reported as consisting of isolates with a high level of
homogeneity despite the large distances that separate the two areas where it has so far been
identified- France and North America (Kato et al., 2002b; Stuyver et al., 2000; Vieth et al.,
2002). It actually appears to be restricted geographically to these two areas, as studies have
failed to detect the presence of genotype G in other countries (Kato et al., 2002a; Kato et al.,
2002b).
Genotype F has also been reported as existing as a group of geographically defined subsets of
strains (Arauz-Ruiz et al., 1997; Arauz-Ruiz et al., 2002; Devesa et al., 2004; Mbayed et al.,
1998; Mbayed et al., 2001; Pineiro y Leone et al., 2003; Sanchez et al., 2002). Within these
subsets there appear to be high levels of homogeneity within some populations (Nakano et al.,
2001) and high levels of heterogeneity in others (Blitz et al., 1998). One genotype F clade
representing Central America has now been reported as being defined by a precore mutation
associated with the presence of another precore stop codon mutation, although it is not known
whether this is a genotype characteristic (Norder et al., 2003). Future research within the field
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may reveal similar genetic definitions for other genotype subgroups that may also be related
to disease outcome.
Another of the described subgroups was initially tentatively described as a possible new
genotype (Arauz-Ruiz et al., 1997; Sanchez et al., 2002), and it has now been identified as
such, genotype H (Arauz-Ruiz et al., 2002). As more data becomes available on the
prevalence and diversity of genotype H it may turn out that geographically defined subgroups
exist within this genotype as well.
The current study aimed to look further at the genotype distributions ofHBV within countries
in endemic areas, and to investigate further the existence of geographically defined virus
variants within the human HBV genotypes. The novel Association Index method will be used
to analyse intra-genotypic variation.
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3.2 Materials and Methods
3.2.1 Human serum samples for HBV study
A total of 477 human serum samples were available for screening. 332 of these samples were
from indigenous and predominantly rural African communities; 12 from Zaire (now the
Democratic Republic of Congo), 51 from Nigeria, 62 from South Africa, 93 from Gambia, 46
from Zimbabwe and 68 from Sudan. The samples were archive samples from previous studies
carried out by the Scottish National Blood Transfusion Service (SNBTS). The samples were
included in the study as they were from populations in areas where HBV is highly endemic
and the contact between humans and other primate species is more likely. The remaining 145
samples were from Papua New Guinea and represented samples taken at time intervals from
38 study subjects. These samples were also representative of indigenous rural populations.
Between 1 and 4 samples were available for each study subject. Samples were screened for
the presence of HBV DNA as described earlier (chapter 2). Selection criteria for the original
samples were indigenous population, further data is not available (Prescott et al., 1999).
3.2.2 PreS PCR to investigate primate-like sequences present in human samples
In order to identify any samples that may contain a primate-like virus variant, a short
fragment nested PCR was carried out in the PreS region of the HBV genome. This region is
phylogenetically informative and polymorphic. Primate HBV and human HBV of genotype D
contain a 50bp deletion in this region, so PCR amplification of this region followed by an
extended gel electrophoresis can distinguish these types of HBV from all other human
genotypes. The first round products from screening PCR 2 (as described in chapter 2) were
used to set up an alternative second round PCR with primers 44 and 45. A human control (not
genotype D) and a chimpanzee HBV control sample were included. PCR conditions were as
described earlier. PCR products were then electrophoresed for 40 minutes at 150 V on a 2%
77
agarose gel (Ethidium Bromide stained) with a 100 base pair DNA size marker (Promega) and
visualised under UV light. A selection of DNA positive samples from Africa was made and
sequenced using primers 42 and 43 directly from screening PCR 2 second round amplification
products to obtain the PreS region sequence. Phylogenetic trees were then constructed and the
genotypes of the samples were determined. DNA positive samples from Papua New Guinea
that showed the shorter fragment size were chosen in the first instance for sequencing and
were sequenced in the S gene region after this region was determined to be a good region for
genotyping (as described in section 3.2.3). Accession numbers for sequences used in the
genotyping phylogenetic analyses (PreS and S) can be found in chapter 2.
3.2.3 S gene PCR for genotvping
African samples that were sequenced in the PreS region were also sequenced in the S gene
region of the genome for genotyping. It was then decided to sequence all human positive
samples in the S gene region to get a better idea of the genotype distributions within the
countries in this study. Samples were amplified in the S gene region using primers 18 and 31
for first round PCR, and S3 and 26 for second round PCR, with cycling conditions as
described earlier. Primer S3 was used for sequencing according to the automated sequencing
protocol described earlier (chapter 2). Phylogenetic analysis was then carried out to determine
the genotypes of the samples.
3.2.4 Genotype-specific phylogenetic analysis of S gene sequences
To investigate any variation within the genotypes, samples were also analysed
phylogenetically using larger genotype-specific data sets retrieved from GenBank. Accession
numbers for these sequences can be found in appendix A. Mean pairwise distances were also
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calculated to enable comparisons of the degree of diversity within the genotypes. This was
done using a function of the SIMMONIC sequence analysis package.
3.2.5 Association Index analysis
Phylogenetic analysis of S gene sequences using the genotype specific data sets described
above appeared to show geographically defined clusters within the trees (see section 3.3.4).
To investigate this finding Association Index (AI) analysis was employed. This novel
phylogenetic analytical method was initially developed to investigate the segregation of
populations of HTV-1 isolates from different body tissues from the same patient (Wang et al.,
2001) and is described in more detail in chapter 2. Briefly, the degree of genetic segregation
between variants from different locations is scored based on phylogenetic analysis. An
association value (d) is calculated according to the formula d = (n-f)/2"~\ In this formula/is
the frequency of the most common sample type in each cluster within the tree, and n is the
number of sequences within the cluster. Random re-sampling of sequences into groups was
carried out to provide a control value based on the null hypothesis of no genetic segregation.
The Association Index value represents the mean ratio of 100 bootstrap replications of the d
of the test sequences to the controls.
This method is implemented in the SIMMONIC sequence analysis package (see chapter 2).
Groups of sequences were labelled according to their geographical origin prior to
phylogenetic analysis and calculation of the AI score. The resulting AI values indicate the
extent to which these geographically pre-defined groups cluster separately within the
phylogenetic tree. The maximum score possible is 1, and this would indicate no segregation
according to the pre-defined groupings. A score lower than 0.5, on the other hand, indicates a
significant degree of segregation.
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3.3. Results
3.3.1 Frequency ofHBV viraemia
The levels of viraemia detected in the samples for each country were calculated (Table 3-1)
based on PCR positive results in both PreS and S gene PCR as described in chapter 2. S gene
PCR fragments were 1000 basepairs in length (Figure 3-3) and were used directly for





Figure 3-3. Gel image showing an example of S gene PCR products. Lanes 1 to 11 represent
samples from Papua New Guinea, lane N is a negative control, lane P is a positive control
(size of fragment 1000 bp), and lane L is a molecular size marker. The brightest band seen is
500 bp in length.
3.3.2 PreS PCR to detect possible primate-derived virus variants
African samples were found to contain amplicons of the expected length for human genotypes
other than D (Figure 3-4). Some samples from Papua New Guinea were found to be of the
shorter length (n = 16). These 16 samples were chosen for S gene amplification and
sequencing for genotyping in the first instance, to investigate whether the deletion was due to
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genotype D being present or another possibly primate-derived genotype being present. Of the
16 samples that were sequenced 11 were shown to contain genotype D, and the remaining 5
genotype C. No samples from Papua New Guinea were found to contain a genotype other
than human genotypes C and D. This suggests that PreS deletions may be more common in
genotypes other than genotype D than previously reported, and not exclusively in genotype D
and the primate genotypes.
Figure 3-4. Gel image showing an example of the PreS PCR showing size differences. The
positive control used in this PCR is chimpanzee derived, and shows the 50 bp deletion (lane
C, 150 bp in length). All samples in this PCR are of African origin (lanes 1 to 9, 200 bp in
length) and are of the normal length expected for human genotypes other than genotype D.
Lane L is a molecular size marker, with the brightest band being 500 bp in length.
3.3.3 Genotype distribution
Of the 121 DNA positive samples, a total of 118 positive samples were genotyped. Three
samples were only sequenced in the PreS region due to lack of sample material, yielding 115
new S gene region fragments for analysis (Figures 3-5a and 3-5b). Insufficient material was
available to allow genotyping of three positive samples.
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new S gene region fragments for analysis (Figures 3-5a and 3-5b). Insufficient material was
available to allow genotyping of three positive samples.
The majority of samples fall into genotypes A, C, D, and E, as would be expected for samples
from these regions. No samples were found to contain human genotypes F, G, and H or any of
the primate HBV genotypes. Two samples from South Africa were found to contain genotype
B, and when going back to patient information these two patients both had an Asian
background (see also Table 3-2 and Figure 3-6).
Samples from Sudan were all found to be negative, which was an unexpected finding. The
HBsAg status and e antigen status for these samples were unknown, as the samples had not










































Figure 3-5a. S gene phylogenetic analysis of positive samples for genotyping.
Sequences obtained from study subjects are identified with filled in circles.
Genotype C and D sequences from this study are all from Papua New Guinea,
whereas the A, B and E sequences are of African origin. Primate HBV isolates
are indicated with red boxes. The outgroup for the tree is the woolly monkey
HBV sequence.
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Figure 3-5b. PreS phylogenetic tree for genotype determination of tree DNA
positive samples where there was insufficient material to allow S gene
sequencing. Sequences from study subjects are identified with filled in circles, all



























































Table3-2.Genotypdistributionfthe118sequencesobtai edfr mt t yampl s.Za r ,Nig r adThGamh vg notyp Eastheprevalentgenotype,whichou dbexpectfromth rW sAfricanlocati n.SouthndZimbabwehavgenotyp
astheprevalentgenotype,whichcor pondsithth rmors u rlylocati nwit itcon inefAfri a.
86
SOUTHAFRICA GAMBIA ZIMBABWE PAPUA NEW
N = 3 N = 15 N = 5 N = 49 N = 17
Figure 3-6. Percentage distribution of genotypes in the countries studied.
Genotypes A and E are most prevalent in the African countries, whereas genotypes C
and D are found in Papua New Guinea.
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3.3.4 Genotype-specific S gene phylogenetic analysis and Association Index analysis
A total of 423 S gene region sequences were downloaded from GenBank and
aligned, and where necessary genotyped by phylogenetic analysis. All sequences did
not provide genotype information within the GenBank data and therefore needed to
be genotyped. Data sets were compiled to represent each of the human genotypes
separately. Phylogenetic analysis of the S gene sequences was then carried out to
investigate the levels of variation within the genotypes. The woolly monkey
sequence was used as an outgroup in all cases. Sequences were selected from
GenBank so as to represent as large a number of studies as possible, and as wide a
selection of different countries as possible. Even though no samples were detected in
this study, genotypes F, G, and H were also analysed in this way, to enable
comparisons of the levels of variation seen within all the human genotypes (Figures
3-7 to 3-13). Genotypes F and H are analysed in the same tree due to the lack of
available sequences for genotype H, they do however represent separate genotypes
and will be discussed as such.
The woolly monkey isolate is the outgroup for all analyses.
The mean pairwise distances were also calculated for each genotype (Table 3-3).
Pairwise distances show the level of dissimilarity between sequences, and the higher
the distance value, the less related the sequences being compared are. Pairwise
distances can be used to estimate the level of diversity seen within a genotype, and
therefore as an estimation of the evolutionary history of a particular genotype.
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After being labelled both the samples from this study, and the sequences obtained
from GenBank, according to the country/region of origin manually, following the
data provided either from GenBank or the publication where the sequences were
reported, the phylogenetic trees obtained were visually inspected for any clustering
of sequences by me. Sequences were then also labelled according to these groupings
in the SIMMONIC alignment, and the Association Index analysis was run (Table 3-
4). Phylogenetic analysis showing the geographical labelling of HBV sequences for
the AI analysis of each genotype were included to allow interpretation of AI values
(Figures 3-7 to 3-13).
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Genotype A appears to have quite a high level of diversity within the genotype, and
this is confirmed by the pairwise distance figure of 0.0309 (Figure 3-7). Samples
from this study mainly group together, which may reflect the source population and
the transmission networks seen there. The high level of diversity seen among the
samples from this study would suggest that the viral evolution is being driven at a
fast rate by either host factors or treatment and prevention regimes. The study
populations are from endemic areas, and this level of diversity suggests a large pool
of circulating HBV variants. S gene analysis distinguishes the A' subgroup, though
not so clearly, from European isolates as is shown also by the AI result (see below),
as has been suggested before (Sugauchi et al., 2003c). These A' sequences group
together to root the main European isolate branch, suggesting a close link between
South African and European genotype A variants.
From these data it can be clearly seen that genotype A is mostly found in Europe and
southern parts of Africa. There appears to be some degree of segregation between
isolates from the different regions. When performing AI analysis on the tree labelled
as described the score is 0.2157, indicating a significant degree of segregation
according to geographical area of origin. There does not appear to be any separation
ofHBV strains due to the specific country of origin, with strains from Nigeria, South


































Northern Asia is represented by pale grey,
South East Asia by pale pink, Europe by pale
yellow and Africa by pale purple.
AN 0.2157
Fig. 3-7. Geographically labelled S gene phylogenetic analysis ofHBV genotype A.
The samples from this study are highlighted in the white boxes (n = 25). AI analysis
suggests segregation of isolates according to geographical origin.
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Genotype B appears to have a high level of diversity, but the pairwise distance is
only 0.0159 suggesting a lower level than expected (Figure 3-8). The limited number
of isolates included in the analysis may be the reason for this. The isolates from this
study do not appear significantly different from other isolates within this genotype.
This would suggest that either the patients were infected in Asia prior to arrival in
South Africa, or they were infected by a strain circulating within a transmission
network involving the Asian community in South Africa.
There does in fact not appear to be any separation between genotype B virus isolates
from different geographical origins, with strains from the northern parts of Asia
being interspersed with strains from southern Asia and Europe. One cluster with
sequences from Japan does appear to exist (see sequences marked in Fig. 3-8 above).
The AI score for this tree is 0.5205, indicating no significant segregation of isolates
according to geographical origin for genotype B.
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Northern Asia is represented by pale grey, South
East Asia by pale pink, Europe by pale yellow
and Africa by pale purple,
Al= 0.5205
Fig. 3-8. Geographically labelled S gene phylogenetic analysis ofHBV genotype B.
Samples from this study are highlighted in white boxes (n = 2). Japanese isolates are
marked with black filled in circles. AI analysis suggests a lack of segregation
according to geographical origin.
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Genotype C appears to have a large amount of diversity within some subgroups, and
the overall level within the genotype is high, with a pairwise distance of 0.0316
(Figure 3-9). Isolates from Papua New Guinea which appeared quite divergent in the
genotyping phylogenetic analysis (Figure 3-5a) no longer appear so divergent when
the larger genotype-specific data set is used and group most closely to two isolates
from Polynesia. The two most divergent groups are made up of isolates from
Australian aborigines and isolates of a Southeast Asian or Pacific origin. This
Australian clade has been described before (Alestig et al., 2001a; Sugauchi et al.,
2001). The Southeast Asian subgroup (Alestig et ah, 2001b) is not as apparent in this
analysis. Southeast Asian and European isolates are distributed between the clades.
Al analysis of genotype C gives a score of 0.1848, which indicates a strong





Northern Asia is represented by pale grey, Southern
Asia by pale pink, Papua New Guinea by magenta,
Fiji by brown, Tonga by orange, Kiribati by green,
Vanuatu by blue and Australia by yellow.
Al= 0.1848
Fig. 3-9. Geographically labelled S gene phylogenetic analysis ofHBV genotype C.
Samples from this study are highlighted in the white boxes (n = 18). AI analysis
suggests segregation of isolates according to geographical origin.
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Genotype D also appears to contain a fairly high level of diversity within it, although
the pairwise distance of 0.0226 indicates a more moderate level of diversity (Figure
3-10). As for genotype C, isolates from Papua New Guinea that appeared highly
divergent in the genotyping analysis appear less so in this genotype-specific analysis
and cluster closely with isolates from Pacific Islands. A close association between
Papua New Guinean isolates and Australian isolates has been reported previously,
but is not so apparent in this analysis (Sugauchi et al., 2001). Australian isolates are
interspersed with isolates from the Pacific region, and Papua New Guinea isolates
can be seen to form two distinct clusters.
Phylogenetic analysis of genotype D sequences results in a similar formation of
geographical clades and branching pattern as genotype C. Isolates from Europe and
Northern Asia appear fairly mixed. The AI score for this tree is 0.4789. This does
indicate a degree of geographical segregation, though not as strong as for genotype


















Northern Asia is represented by pale
grey, Europe by paie yellow, Africa by
pale purple, India by red, Papua New
Guinea by bright pink, Australia by
bright yellow, Kiribati by green, Fiji by
brown and Tonga by orange.
Al= 0.4789
Fig. 3-10. Geographically labelled S gene phylogenetic analysis ofHBV genotype D.
Samples from this study are highlighted in the white boxes (n = 11). AI analysis
suggests segregation according to geographical origin.
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On first glance genotype E appears to have less diversity than the other genotypes,
but a pairwise distance of 0.0184 suggests a level of diversity similar to that seen for
genotypes B, D, F and H (Figure 3-11). This genotype has previously been described
as having limited diversity (Suzuki et al., 2003), but this appears not to be the case
and may simply be an artefact due to lack of available sequence data until now. From
the data set generated for this study it is clear that genotype E is specific to western
African countries.
In contrast to the results seen for genotypes C and D, there does not appear to be any
segregation of isolates according to the country of origin in genotype E, which is
supported by the AI score of 0.6246.
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Al= 0.6246
Fig. 3-11. Geographically labelled S gene phylogenetic analysis ofHBV genotype E.
Gambia is represented by red, Nigeria by
blue, Ivory Coast by green, Europe by pale
yellow and other West African origin by
yellow,
Samples from this study are highlighted with the white boxes (n = 61). AI analysis
suggests there is no segregation according to geographical origin.
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Genotypes F and H were analysed phylogenetically together due to the lack of data
available for genotype H (Figure 3-12). Prior to its identification as a novel genotype,
genotype FI was in fact thought to be a subtype of genotype F (Arauz-Ruiz et al.,
1997; Arauz-Ruiz et ah, 2002; Mbayed et ah, 1998; Mbayed et ah, 2001; Torbenson
and Thomas, 2002), and this is reflected in their close relationship phylogenetically.
Both these genotypes are found in Central and Southern America. When carrying out
complete genome phylogenetic analysis genotypes F and H are always outliers,
whereas as can be seen in the genotyping tree (Fig. 3-5a), when S gene sequences are
used they group together with the other human genotypes. The changing relationship
between F and FI and the other human genotypes depending on the part of the
genome used for phylogenetic analysis has been described previously (Naumann et
al., 1993). There is limited diversity within both genotypes F and H. The pairwise
distance value for F alone is marginally lower than that of Ft, 0.0132 compared to
0.0021. As more data becomes available for genotype H this analysis should be
repeated.
Genotype F has been isolated from both Central and Southern America, and there
appears to be some segregation of isolates according to area of origin. When
genotype F is analysed, with two groups defined as Central and Southern America,
an Al value of 0.4811 is obtained. This suggests that there is some segregation,
though not highly significant. The lack of diversity seen between isolates may
explain this result, as visually the groupings seem segregated. As more data becomes
available for genotype H, this analysis should be carried out to investigate whether







South American genotype F is represented by blue. Central
American genotype F by red and genotype H by yellow. Two
isolates identified in Europe are represented by palae yellow.
"AF046996
Al= 0,4811
Fig. 3-12. Geographically labelled S gene phylogenetic analysis ofHBV genotypes F
and H. AI analysis suggests segregation according to geographical origin.
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A very limited amount of sequence data is available also for genotype G, so as is the
case for genotype H, it is difficult to speculate about the true amount of diversity
within this genotype within human populations. The diversity seen within the isolates
published to date compares to that of genotype H only. As for genotype H, genotype
G was also recently discovered (Stuyver et al., 2000), and a very limited set of
sequences are available for analysis making it difficult to analyse the geographical
distribution patterns.
These sequences all originate in Europe and the US, and there appears to be no
segregation between these two areas even though the geographical distance between
them is substantial. The AI value for the genotype G tree is 0.4804 (Figure 3-13).
This value is very similar to that seen within genotypes D, and F. When looking at
the genotype G tree, two possible groups are seen; one containing all isolates from
North America and one European isolate, and the other consisting of one outlying
European isolate. The bootstrap values for this genotype G tree are all below 70%,
making the tree less significant. The data set for this genotype is limited by the
number of isolates, but if this is extrapolated one may argue that the outlying
sequence represents European strains and the other European isolate represents an
infection with a North American strain. If this is the case, as more genotype G data
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The United States are represented by blue and Europe by red.
AN 0.4804
Fig. 3-13. Geographically labelled S gene phylogenetic analysis ofHBV genotype G.











































































Table 3-4. Association Index analysis results for each of the HBV genotypes.
AI values above 0.5 indicate no significant separation according to the predefined groupings,
whereas values below 0.5 do indicate a separation of groupings. Genotype H has not been




In this study high rates ofHBV DNA positivity were found in all study populations.
These high levels may not accurately portray the real level ofHBV prevalence within
the countries represented in the study, due to for example low numbers of samples
available for analysis and the selective nature of the specimens used in the study. The
backgrounds of the study groups are unknown, and the possibility therefore arises
that they may represent groups of individuals within the general population that are
already at a high risk for HBV infection. This would result in an artificially high
level of detectable viraemia. The countries represented in this study are however
known to be endemic for HBV, so high levels ofHBV infection would be expected.
Detection ofHBV DNA indicates an active infection, but patients who have lost their
HBsAg are also HBV DNA positive. Patients with HBsAg expression do not show
HBV DNA positivity. This means that the presence of HBV DNA does not identify
all carriers of infection.
The distribution of genotypes within the countries was mostly as expected. Genotype
A is the most prevalent in the more southerly African nations of Zimbabwe and
South Africa and genotype E in the Western African countries of Nigeria and
Gambia. Two of the isolates from South Africa were of genotype B, which was not
expected. These two samples came from individuals of Asian origin/background,
making the result more easily explained. The genotyping results for Papua New
Guinea were somewhat unexpected. The presence of genotype C in this population
was as expected, whereas the high number of genotype D isolates and absence of
genotype B were unexpected. The close proximity of Papua New Guinea to
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Southeast Asia suggests a genotype distribution similar to this region would be
found.
The finding of genotype D in Papua New Guinea further strengthens the evidence
that this is a globally prevalent genotype. No isolates of genotypes F, G, or H were
found in any of the study populations. This was as expected, as F and H are found in
South and Central America, and G has only been isolated in a small number of
European and North American patients to date.
Genotype A shows geographical separation between Europe and Africa (Fig. 3-7) as
has been described (Hannoun et al., 2002), but not between different countries in
these areas. There is a close relationship between the European isolates and isolates
from South Africa (A'), and considering the fact that South Africa was under
European rule and domination for a long period of time this is not entirely
unexpected.
The separation of European and African isolates is indicative of the HBV
transmission networks involved, for example a founder effect. Different geographical
regions have circulating virus strains from a common ancestor. Infections appear to
be picked up within the region of residence, where FLBV is then maintained within
the population through for example horizontal and/or vertical transmission within the
family setting. This also indicates that the different pools ofHBV variants circulating
within the two regions share a common evolutionary origin, but are different, having
diverged at some point in the past as the carrier populations became more separated.
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This type of scenario would be consistent with an HBV origin around the time of the
Out of Africa migration around 100 000 years ago. The genotype A ancestor was
present in African populations, as they moved into Europe and formed new
settlements the virus started to change. A founder effect would mean that there is less
variability between the strains circulating within these new population settlements,
and slowly over time these geographically separated virus populations become more
divergent from each other and the ancestral strain. Considering the long history of
European colonization ofAfrican nations, it is slightly puzzling that the HBV strains
are so separated. Colonization would have provided an opportunity for new virus
strains to enter new population groups, and this would be expected to lead to a
homogenisation of the viruses found in the native and the colonising populations.
Although genotype A appears to exist in geographically defined subtypes when
analysed in the S gene, the previously described A' subtype is not apparent. This
subtype has been described following phylogenetic analysis of complete genomes, S
gene and Pol gene (Bowyer et al., 1997; Kramvis et ah, 2002; Owiredu et ah, 2001b),
but one previous study also found that small S gene phylogenetic analysis failed to
distinguish the group (Sugauchi et ah, 2003c). The phylogenetic analysis in the
current study was carried out on the small S gene region of the S open reading frame,
confirming this previous report (Sugauchi et ah, 2003c). As differences can be seen
in the geographic cluster/subgroup formation within genotype A further work will be
necessary to evaluate the groupings within all the 4 open reading frames ofHBV as
well as for complete genomes. This data will then be a useful tool when performing
epidemiological investigations. Differences in host factors as well as the evolutionary
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origin may explain why the level of diversity seen within this genotype is higher than
that of other genotypes such as genotype G.
Genotype B is a contrast to genotype A, showing both a lower level of intra-genotype
diversity and a lack of geographical segregation of groups of isolates (Fig. 3-9).
There is no clear segregation between Southeast Asian and Northern Asian
(Japanese) isolates, as is evident from the AI analysis, although one clade of
Japanese isolates appears to form (see Fig. 3-9). The difference in pathogenicity of
genotype B seen between these two regions is substantial, and the lack of genetic
segregation between isolates from the regions makes this difference even more
puzzling. Had distinct isolates been found in the two regions one could argue that
within the nucleotide changes that separate them lies an important determinant for
pathogenicity. The reported prevalence of recombinants with genotype C may play a
role in determining these differences (this will be discussed further in chapter 4).
Differences in host factors may also be important in determining the differences in
disease outcome in these regions. This type of scenario is more indicative of a more
recent origin of the genotype within the affected population. Pathogens new to a
population, for example, a virus entering a human population through cross-species
transmission, such as Ebola, tends to cause more severe disease in the new host than
pathogens which have been circulating for a long time, for example HGV/GBV-C,
where both the host and the pathogen have had time to adapt.
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Genotype C is another genotype that, like genotype A, shows a high level of
diversity within the genotype with a high pairwise distance value (Table 3-3), and
this is also reflected in the existence of geographically defined clusters of related
isolates which are supported by AI analysis (Fig. 3-10 and Table 3-4). The isolated
position of Papua New Guinea and the tribes who live there make the existence of a
divergent strain there seem quite likely. This is also reflected in the fact that a
similarly divergent subgroup exists in Australian aborigines (Alestig et ah, 2001a;
Sugauchi et ah, 2001). The AI score obtained for the phylogenetic tree (Fig. 3-10)
supports previous claims of sub-groups within Asian genotype C (Huy et ah, 2004).
The high pairwise distance value suggests that this genotype is old, as many
differences between strains have accumulated. The existence of geographical
subgroups within genotype C suggests some co-evolution, with population based
HBV variants being established through a founder effect as described above for
genotype A.
The overall level of diversity within genotype D is not as high as for genotype C with
a pairwise distance value of 0.0226 (Table 3-3), and the segregation of geographical
subgroups not as strong (AI = 0.4789, Table 3-4). The existence of a divergent
subgroup of genotype D, like that for genotype C described above, consisting of
isolates from Papua New Guinea is not unexpected. Further data is needed from
isolated tribes around the world, such as those living in the Nicobar and Andaman
Islands (Arankalle et ah, 2003). If genetic data were published for HBV isolates from
these populations the geographical distribution of genotype D may become clearer.
Genotype D is found throughout the world, so it is surprising that there is not more
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segregation. One could argue that there are ancestral strains of genotype D such as
those from Papua New Guinea, and that the spread of one such strain throughout the
world happened relatively recently. Papua New Guinea was inhabited between
40 000 and 60 000 years ago, and isolated tribes still exist there today (Catriona
MacFarlane, PhD thesis). This would explain the lower level of diversity and lack of
geographical variants.
Genotype E has a low level of diversity compared to the other genotypes, and also
shows a lack of geographical subgroups. The limited diversity of this genotype has
been described before (Suzuki et al., 2003). The association of genotype E infection
with West African countries is clearly demonstrated. There is more diversity within
this genotype than previously suggested, but it still appears that the origin of
genotype E in its host populations is again more recent. The pairwise distance value
for genotype E in 0.0184, suggesting there has been less time available to accumulate
differences between strains. This also indicates a rapid spread of infection within
West Africa. The lack of segregation of isolates according to the geographical origin
(AI = 0.6246) supports this epidemic spread. As more data is made available for this
genotype geographical clusters may become more apparent, or the evidence for a
recent origin of the genotype may be strengthened. For geographically segregated
subgroups of viruses to evolve the populations carrying them need to be isolated.
Genotypes are also maintained by separation. Increased frequencies of superinfection
with multiple virus types will drive the evolution of the virus towards a lack of
genotypes and subtypes through the mechanisms of recombination and mutation.
HBV infection is endemic in West Africa which makes superinfection a real
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possibility, and therefore, this may be responsible for the lack of diversity seen
within genotype E. If this is the case the origin ofHBV in West Africa may be more
ancient than expected.
Genotypes F and H both show very limited sequence variability, although there does
appear to be some geographical segregation of subgroups of isolates. The outlier
position of genotypes F and H, this lack of diversity, and the close relationship
between them suggests a recent origin from a common ancestor. It has been
suggested that South America is the source ofHBV infection in the rest of the World
as a consequence of European colonisation in the last few hundred years (Bollyky et
al., 1997), but the low level of diversity does not agree with this hypothesis (see
section 1.5 for more information on this hypothesis). A study recently published
analysed a larger data set of sequences from genotype F (Devesa et al., 2004). They
showed three distinct geographically defined clades containing isolates from Central
America, northern South America and southern South America respectively, as well
as two clades containing isolates from Central America and southern South America.
This clearly demonstrates that the more data about a genotype becomes available and
are analysed, the clearer the picture of the distribution of that genotype in its host
populations becomes. If this new data was to be analysed using the Association
Index the results may show segregation to a greater extent than that which was
obtained in this study.
Genotype G adds further confusion to the problem. It appears to be an Old World
genotype of HBV with a very low level of diversity, suggesting a recent origin. The
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geographical distance between the only two areas, Europe and The United States of
America, where it has been isolated is substantial, yet the genetic distance is not.
Modem human travelling habits may be involved in the distribution of this new
genotype. As more data becomes available the origin of this genotype may become
clearer.
The continuing evolution of HBV appears to be driven by a combination of host,
viral and possibly also environmental factors, and discovering the differences
between genotypes of different regions will be important for the development of new
treatment and prevention strategies, as well as in furthering the understanding of the
different disease outcomes seen in HBV infection. Epitope specificities of different
genotypes and the same genotype in different regions may differ. This would mean
that a novel drug developed using the prevalent HBV type in a particular
geographical area may not be as efficient in halting viral replication when used to
treat a different genotype or the same genotype in a different part of the world. These
differences in epitopes may also help explain why a particular genotype is more
pathogenic than another, although host factors such as HLA types need to be taken
into consideration here as well.
Within human populations differences can be seen in the severity of disease that can
be correlated to the specific genotypes responsible for infection. Differences can also
be seen in the severity of disease caused by a specific genotype in different countries
(Sugauchi et al., 2002b; Sugauchi et al., 2003b). The geographically defined sub-
groupings within genotypes may play an important role in explaining these
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differences. Molecular characterisation of the complete genomes and amino acid
sequences of these variants, together with investigations into any differences in host
factors will be important for any future research into HBV pathogenesis and
prevention. There is no sequence evidence to date to suggest cross-species
transmission from primates to humans. So far there have been no reports of primate¬
like sequences being isolated from humans, even where they have been in contact
with primates (Noppornpanth et al., 2003). This will be discussed further in chapter
5.
AI analysis was used here to investigate the existence of geographically defined
subgroups within the human HBV genotypes. This method can also be applied to
investigate prevalences of particular variants in certain patient groups, such as those
with hepatocellular carcinoma, or to compare the variants isolated from e antigen
positive versus e antigen negative individuals. Furthering the application of AI
analysis will provide further clues as to the evolutionary pressures put on the HBV
genome by a variety of host factors.
The distribution ofHBV genotypes globally provides clues about the transmission in
the past and origins of this virus in human populations. The understanding of the
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4.1 Introduction
For viruses to evolve, genetic variation needs to be generated. This can occur via a
number of mechanisms; for example the accumulation of point mutations,
reassortment and recombination. All these may accelerate the rate of evolution of a
virus. Mutations of the viral genome may be driven by a positive pressure by the
immune system or a treatment regime. This type of pressure may also lead to the
selection of recombinant genomes over wild-type genomes during viral replication.
Apart from driving evolution, recombination may also influence the interpretation of
phylogenetic data and hence the estimation of evolution of a virus. The presence of
recombination causes the length of terminal branches, as well as the total branch
length, to increase. This will cause the estimation of the time to the closest, most
recent ancestor to be underestimated and lead to false evolutionary histories being
proposed (Schierup & Hein, 2000). It is therefore very important to be aware of
recombination when investigating the evolutionary history of a virus. This section
will concentrate on recombination as a mechanism of evolution.
For recombination to take place a number of requirements need to be fulfilled.
Firstly, the virus must exist as more than one genotype. Secondly, more than one
genotype needs to be present in the population in a specific geographical area.
Thirdly, super-infection of one individual with viruses representing different
genotypes must be biologically possible and occur. And finally, the replication
mechanisms employed by the virus must contain steps at which recombination events
are possible.
Recombination between viruses belonging to different genotypes has been
documented, for example for HIV-1 (Lole et al., 1999), another parallel that can be
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drawn between HIV and HBV infection. A large number of HBV sequences have
been published as being recombinants between HBV variants of different genotypes,
most notably between A and D, and B and C (Bowyer and Sim, 2000; Fares and
Holmes, 2002; Morozov et al., 2000; Sugauchi et ah, 2002b; Tran et ah, 2003; Yuasa
et ah, 2000), but also different combinations in fewer cases (Bollyky et ah, 1996; Cui
et ah, 2002; Hannoun et ah, 2000b). There are even reports that suggest differences
in pathogenicity between HBV variants with or without recombinant elements in
their genomes (Sugauchi et ah, 2002b; Sugauchi et ah, 2003b).
The first here criteria for recombination to take place are fulfilled by HBV; there are
8 different human genotypes, some genotypes can be found in the same areas, for
example B and C in Asia and A and D in Europe. Recombination between the
particular genotypes mentioned above is as expected the most commonly reported.
Mixed genotype infections can be found in certain patient groups, such as
intravenous drug users (Chen et ah, 2004a; Chen et ah, 2004b) and those treated with
interferon (Hannoun et ah, 2002) . The mechanisms involved in HBV recombination
events are unknown, but it is clear that is homologous recombination with a specific
part of the genome being replaced with that from another genotype. One possibility
is that there is a swapping of template during the replication of the viral genome.
This is known to occur during the reverse transcription stage of HIV-1 replication
(Hu et ah, 2003; Negroni & Buc, 2001). HBV also undergoes a reverse transcription
stage to produce mature virions, and if more than one template from different
genotypes is present, template switching could occur. The integration of HBV DNA
fragments into the host genome may also play a role.
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The strategies used for investigating the phenomenon of intergenotype recombination
in HBV have mainly been based on phylogenetics, and more recently bootscanning
methods such as SimPlot (Lole et al., 1999).
Methods such as phylogenetics and bootscanning do have some problems which may
lead to the generation of false positive recombination results. Within a viral genome
phylogenetically uninformative regions may occur. These are regions where positive
selection pressures are affecting the genome. One example of this would be point
mutation in known epitopes leading to immune escape mutants, although this is not
the immune system driving mutation, but the virus mutating to avoid the immune
system. This would lead to the emergence of viruses from different genotypes with
genetically highly conserved regions. When performing phylogenetic analysis on
such strains, they would appear to belong to one genotype in the region affected,
whereas the rest of the genome is phylogenetically most closely related to another
genotype. One region of the HBV genome where this may occur is the PreC/C
region, where stop codon mutations are known to occur leading to a halt in the
production of e antigen.
Another problem that affects bootscanning methods is the existence of sequences that
show no affiliation with a specific genotype when analysed phylogenetically,
appearing as an outgroup to a genotype rather than a member of it. Bootscanning will
include this sequence in the most closely related genotype group, i.e. the one it forms
an outgroup for, and this may result in a false recombination result.
In this study a novel bootscanning method was used to re-analyse the previously
published recombinant HBV sequences. This method is based on the calculation of
association scores for phylogenetic groups, an approach which helps resolve many of
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the uncertainties and difficulties of interpretation of results arising from conventional
methods such as SimPlot (Wang et al., 2001). The recombination analysis carried out
will help to get a better picture of the evolutionary pressure recombination might be
putting on HBV, and what effect this might have on the epidemiology and
pathogenicity ofHBV infection.
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4.2 Materials and Methods
4.2.1 Sequences
The accession numbers of the previously published sequences that were used in this
analysis can be found in table 4-1. A number of control sequences were also analysed
(table 4-2).
ACCESSION RECOMBINATION ACCESSION RECOMBINATION
NUMBER 13ETWEEN NUMBER BETWEEN
HBVDNA AID AB073824 B/C
HBVP4PCXX AID AB073825 B/C
HBVP5PCXX AID AB073826 B/C
HBVP6PCXX AID AB073827 B/C
HBVAYWC1 AID AB073828 B/C
HBVAYWE AID AB073829 B/C
AF297619 AID AB073830 B/C
AF297620 AID AB073831 B/C
AB031265 B/C AB073832 B/C
AF121243 B/C AB073833 B/C
AF121245 B/C AB073834 B/C
AB100695 B/C AB073835 B/C
AF100308 B/C AB073836 B/C
AF100309 B/C AB073837 B/C
HPBADW2 B/C AB073839 B/C
HPBADW3 B/C AB073840 B/C
HPBADWZ B/C AB073841 B/C
HBVP4CSX B/C HPBADW1 A/B
HBVP6CSX B/C AY057948 C/D
HBVCGWITY B/C AF241407 AIC
AB073821 B/C AF241408 AIC
AB073822 B/C AF241409 AIC
AB073823 B/C
Table 4-1. Accession numbers and reported genotype recombinations of sequences
re-analysed for recombination.
ACCESSION ACCESSION
NUMBER GENOTYPE NUMBER GENOTYPE
AY057947 C AF241410 C
AB031262 C AF241411 C
AB031266 B AB073838 B
AB031267 B
Table 4-2. Accession numbers of sequences used as controls for recombination
analysis. Sequences were chosen from studies with reported recombinants.
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4,2.2 Association Index bootscanning
The AI method (described in chapter 2) can also be used to look for recombination in
HBV genomes. This function of the program utilises the PHYLIP program package
(Felsenstein, 1993). Ten representative sequences from each of the HBV genotypes
(except genotypes E and H) reported not to be recombinants were selected and used
in all recombination analyses (table 4-3). Each genotype was given a different tag,
producing the groups required by the software to carry out the analysis. 500bp
windows and lOObp overlapping steps were selected for the analysis with 100
bootstrap replications. The resulting data was then plotted onto a graph using
Microsoft Excel and compared to the data generated by the SimPlot analysis. A
recombination event was determined to have occurred when these two analyses both
produced cross-over points in the graphs. Control sequences reported as non-
recombinants were analysed using this method. The results can be found in appendix
D.
The association index method was also used to scan the HBV genome for the
presence of phylogenetically uninformative regions. This was done by making pair
wise comparisons of the different genotypes along the entire genome. 500 bp
windows were used, with a lOObp overlapping step.
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ACCESSION ACCESSION
NUMBER GENOTYPE NUMBER GENOTYPE
AF090838 A AF223965 F
AF090839 A X69798 F
S50225 A X75663 F
AF297624 A X75658 F
AF297625 A AB056513 G
E00010 A AB056514 G
AJ344115 A AB056515 G
L13994 A AB056516 G
X51970 A AB064310 G
U87742 A AB064311 G
AY206391 B AB064312 G
AF461360 B AB064313 G
D23677 B AF160501 G
D23678 B AF405706 G
AB010292 B AY090454 H
AF282918 B AY090457 H
AY033073 B AY090460 H
D50522 B AB032432 CHIMPANZEE
HBV131133 B AB032433 CHIMPANZEE
D23679 B AF222322 CHIMPANZEE
AB046910 C AF222323 CHIMPANZEE
AF363961 C AF242585 CHIMPANZEE
AF233236 C AF242586 CHIMPANZEE
AF330110 C AJ131567 GORILLA
AF411408 C D00220 CHIMPANZEE
AF411412 C AF498266 CHIMPANZEE
AF461359 C AF305327 CHIMPANZEE
X75665 C AY330912 CHIMPANZEE
M12906 C AY330911 CHIMPANZEE
D00630 C AB037927 GIBBON
AF121240 D AB037928 GIBBON
AB090270 D AY077735 GIBBON
X65257 D AY077736 GIBBON
Z35716 D AJ131568 GIBBON
X72702 D AJ131569 GIBBON
AJ344116 D AJ131571 GIBBON
U95551 D AJ131572 GIBBON
AB033559 D AJ131573 GIBBON
AF280817 D AJ131574 GIBBON
Y07587 D AJ131575 GIBBON
AB032431 E U46935 GIBBON
X75657 E AF193864 ORANGUTAN
X75664 E NC 002168 ORANGUTAN
AB036905 F AY330913 GIBBON
AB036908 F AY330914 GIBBON
AB036910 F AY330916 GIBBON
AB036913 F AY330917 GIBBON
AB036916 F AF046996 WOOLLY MONKEY
AF223962 F
Table 4-3. Accession numbers of non-recombinant sequences used in the
phylogenetic analysis, AI analysis, and SimPlot analysis.
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4.2.3 Bootscanning using SimPlot
The SimPlot program was also developed to investigate HIV-1 intersubtype
recombination (Lole et al., 1999). It uses PHYLIP programs to do its calculations, as
does the AI method described above. SimPlot bootscanning analyses a query
sequence against pre-defined groups of sequences as in AI, and the output is a line
graph comparable to that obtainable from the AI results. Sequences were tagged into
the groups as defined by genotype in SIMMONIC and then exported in FASTA
format. A SimPlot description line was added to the FASTA file as described in the
documentation that comes with the program, and this file was then opened up in
SimPlot. The bootscanning option was then selected, the query sequence selected,
and the parameters selected. To allow comparison between the AI and SimPlot
results 500bp windows with lOObp overlapping steps were selected together with
neighbour-joining and 100 bootstrap replications. The sequences used for the control
groups were those that were used for the AI analysis described above. Control non-
recombinant sequences were analysed with this method. Results can be found in
appendix D.
4.2.4 Phylogenetic analysis
Example isolates where AI and SimPlot produced different results were analysed
phylogenetically as described below.
Sequences that appeared recombinant in the both the AI and SimPlot bootscanning
analyses were also analysed phylogenetically. The fragment of the genome up to the
cross-over point, the fragment containing the cross-over region, and the fragment of
the genome after the cross-over region were selected and phylogenetic analysis
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carried out on these. The MEGA2 program was used for the phylogenetic analysis
with Jukes-Cantor model, neighbour-joining and 100 bootstrap replications. The
sequences used for the phylogenetic analysis of possible recombinants were the same
as were used in the AI and SimPlot analyses (table 4-3). The genotype of the
sequence was recorded for each segment. The recombinant status of each sequence
analysed was then assessed. The suitability of each of the methods used to
investigate recombination was then assessed by comparing the results.
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4.3 Results
4,3.1 Phvlogenetic segregation of genotypes
A pair wise comparison of the HBV genotypes identifies a major phylogenetically
uninformative region (Fig. 4-1). This is found in the region of the HBV genome
containing the Pol/X overlap and PreC/C. Genotypes B and C do not segregate fully
in the region between bases 1101 and 2400, and genotypes D and E do not segregate
fully in the region between bases 1301 and 2600. This implies that these two
genotype pairs are under specific selection pressures in this region. PreC/C mutations
to evade the immune system may be responsible for this. Genotypes D and E
consistently group together in phylogenetic analysis, suggesting a shared
evolutionary history, and the fact that their genomes are highly similar in this
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Figure 4-1. Binary AI scan comparisons of the genetic segregation between the
human and non-human primate HBV genotypes. A simplified map of the HBV
genome is shown below the AI graph to show the segregation across the genome.
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4.3.2 Bootscanning and phvlogenetics results
Association Index bootscanning results and SimPlot results for each sequence
analysed are shown on the same page to allow comparison. A simplified map of the
HBV genome has been inserted between the two graphs to enable references to be
made to the regions involved in recombination. In these analyses many discrepancies
can be seen between the two different methods used. Three control sequences
reported to belong to specific genotypes were also tested (Figures 4-2 to 4-4). Of
these, the reported genotype B isolate AB073838 (Figure 4-3) appears recombinant
using SimPlot, suggesting this method may overestimate recombination. The results








HBVDNA A/D R R Y
HBVP4PCXX A/D N N
HBVP5PCXX A/D N N
HBVP6PCXX A/D N R
HBVAYWC1 A/D R R Y
HBVAYWE A/D R R Y
AF297619 A/D N R
AF297620 A/D R R Y
AB031265 B/C R R Y
AF121243 B/C N R
AF121245 B/C N R
AB100695 B/C N R
AF100308 B/C N R
AF100309 B/C N R
HPBADW2 B/C N R
HPBADW3 B/C N R
HPBADWZ B/C N R
HBVP4CSX B/C N R
HBVP6CSX B/C N R
HBVCGWITY B/C N R
AB073821 B/C N R
AB073822 B/C N R
AB073823 B/C N R
AB073824 B/C N R
AB073825 B/C R R Y
AB073826 B/C N R
AB073827 B/C N R
AB073828 B/C N R
AB073829 B/C N R
AB073830 B/C N R
AB073831 B/C N R
AB073832 B/C N R
AB073833 B/C N R
AB073834 B/C N R
AB073835 B/C N R
AB073836 B/C N R
AB073837 B/C N R
AB073839 B/C N R
AB073840 B/C N R
AB073841 B/C N R
HPBADW1 A/B N R
AY057948 C/D R R Y
AF241407 A/C R R Y
AF241408 A/C R R Y
AF241409 A/C R R Y
TOTAL 45 10R 43R 10
35N 2N
Table 4-4. Results of recombination analysis carried out using AI and SimPlot. N=
non-recombinant, R= recombinant, Y= determined recombinant. Highlighted
sequences (AF241407, AF241408, and AF241409) are determined recombinants,
though not A/C recombinants as reported earlier.
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Association Index
Recombinant (R) Non-recombinant (N)
SimPlot R 10 33
N 0 2
Table 4-5. Summary of recombination analyses highlighting the discrepancies between the
two methods used in this study. SimPlot overestimates the number of recombinant isolates
when compared to Association index analysis.
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Figure 4-2. Recombination analysis ofHBV isolate AB031262 (Yuasa et al., 2000) using the
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Figure 4-3. Recombination analysis ofHBV isolate AB073838 (Sugauchi et al., 2002b) using
the AI (top) and SimPlot (bottom) methods. Isolate was reported to be a genotype B, AI
analysis supports this whereas SimPlot shows the isolate to be recombinant in the core region.
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Figure 4-4. Recombination analysis of HBV isolate AF241410 (Hannoun et al., 2000) using
the AI (top) and SimPlot (bottom) methods. Isolate was reported to be of genotype C, both
analyses support this.
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Reported recombinants fall into two main groups; recombinants and non-recombinants.
Sequences were deemed to be recombinant when both AI scanning and SimPlot bootscanning
showed the sequences to be recombinant. Graphical depictions of the analyses of 3 of the 10
isolates found to be recombinant can be found below (Figures 4-5, 4-7, 4-9), and the
remaining 7 can be found in appendix B. 7 of the 10 recombinant isolates were confirmed to
be recombinants between the genotypes they were initially reported to be recombinants of. 3
isolates showed different results. Isolates AF241407, AF241408, AF241409 (Hannoun et al.,
2000b) were reported to be recombinants between genotypes A and C. The analyses carried
out for this study shows that these isolates are recombinants between genotype C and a
possible new undiscovered genotype ofHBV, showing characteristics both of genotype A and
G. Genotype G had not been discovered when these isolates were published, and they would
have appeared recombinant with genotype A in SimPlot analysis. SimPlot analysis carried out
with genotype G included, as was done in all analyses for this study, shows these isolates to
be closer to genotype G than A. Phylogenetic analysis of recombinant isolates was also
carried out. The analyses of isolates FIBVAYWC1, AB073825, and AF241408 can be seen







0 500 1 000 1 500 2 000 2 500 3 000
Position (bp)












Figure 4-5. Recombination analysis of HBV isolate HBVAYWCl(Bowyer et al.,




































Figure 4-6. Phylogenetic analysis of HBV isolate HBVAYWC1 reported to be an
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Figure 4-7. Recombination analysis of HBV isolate AB073825 (Sugauchi et al.,
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Figure 4-8. Phylogenetic analysis of HBV isolate AB073825, reported to be a B/C
recombinant. Analysis does not fully support recombinant result from AI and
SimPlot analysis. Phylogenetic analysis of the recombinant fragment shows this to
coincide with the uninformative region, and the isolate does not group with either
genotype B or C.
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Figure 4-9. Recombination analysis of HBV isolate AF241408 (Hannoun et al.,







Figure 4-10. Phylogenetic analysis ofHBV isolate AF241408, reported to be an A/C
recombinant. Analysis supports recombinant result from AI and SimPlot analysis,
and shows the isolate does not group with any specific genotype in the recombinant
region.
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Non-recombinant isolates were those that showed no recombination in the AI
analysis and recombination in SimPlot analysis (43 isolates) or no recombination in
SimPlot analysis (2 isolates; HBVP4PCXX, HBVP5PCXX). These two isolates
were identified using an author-written program (Bowyer & Sim, 2000) and
phylogenetic analysis. The problems regarding false positive recombination
identification described earlier explain why these isolates were reported as
recombinant, and have now been found to be non-recombinant.
HBV isolates HBVP4PCXX and HBVP5PCXX were reported to be A/D
recombinants, however, both AI and SimPlot analysis showed this not to be the case.
Phylogenetic analysis supports this result. The region involved in the recombination
event coincides with the uninformative region described earlier, where genotypes B
and C, and D and E fail to segregate. In the tree it can be seen that genotype D is
divided into two branches, separated by the genotype E isolates. Isolate
HBVP4PCXX can be found on the one of these two genotype D branches that
outgroups the other genotype D and E isolates. This could lead to the sequence being
judged to be more closely related to the genotype A isolates.
Apart from the two isolates described above, one of the reported genotype A and D
recombinants (HBVP6PCXX) was found to be non-recombinant. Isolate
HBVP6PCXX has a divergent X region in the AI analysis, and this is consistent with
the phylogenetically uninformative region identified in Fig. 4-1.
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The majority (30/32) reported genotype B and C recombinants were found to be non-
recombinants in the AI analysis. The region seen to be involved in the recombination
event from the SimPlot analysis can be found inside the phylogenetically
uninformative region described in Fig. 4-1, where genotypes B and C fail to
segregate.
The only reported genotype A and B recombinant was found to be a non-
recombinant, and again the proposed region of recombination falls within the
uninformative region described above. Three examples of discrepant results are
shown below (Figures 4-11, 4-13, 4-15). Remaining discrepant results can be found
in Appendix D.
Phylogenetic trees were constructed for selected examples where SimPlot and AI
showed discrepant results. Trees were constructed to show the region of the genome
preceding the reported recombination event, the region containing the recombinant
part of the genome, and the region following the recombination region.
Reported genotype B/genotype C recombinants were found to be non-recombinants
in the majority of cases. Phylogenetic analysis of selected examples of these
recombinants supports these findings (Figures 4-12, 4-14, 4-16). The regions of the
genome reported to be recombinant falls within the phylogenetically uninformative
region described in Fig. 4-1, where genotype B and C fail to segregate. The
phylogenetic trees show this quite clearly. Half of the genotype B isolates included
in this analysis group on a separate branch, whereas the other isolates form a branch
within the genotype C clade.
The only genotype A/B recombinant reported to date (HPBADW1) was also found to
be non-recombinant using the AI analysis. The phylogenetic analysis supports this
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finding. In the tree the isolate groups with the five genotype B isolates that group
separately from the genotype B/C branch in this region. This smaller genotype B
group falls as an outgroup to genotypes A, D and E in this region, and this could
explain why SimPlot shows HPBADW1 as belonging to genotype A in this region.
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Figure 4-11. Recombination analysis of HBV isolate AB073832 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,













































































































































Figure 4-12. Phylogenetic analysis of HBV isolate AB073832, reported to be a B/C
recombinant. Genotype B is highlighted in the grey box, genotype C in the yellow box, and
the isolate in the red box. The lilac box shows the failure of genotypes B and C to segregate in
this region of the genome. Phylogenetic analysis supports the AI non-recombinant result.
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Figure 4-13. Recombination analysis ofHBV isolate HPBADW1 (Bollyky et al., 1996) using
the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a




























































































































Figure 4-14. Phylogenetic analysis of HBV isolate HPBADW1, reported to be an A/B
recombinant. Genotype A is highlighted in the green box, genotype B in the grey box,
genotype C in the yellow box, and the isolate in the red box. The lilac box shows the failure of
genotypes B and C to segregate in this region of the genome. Phylogenetic analysis supports
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Figure 4-15. Recombination analysis ofHBV isolate AF121243 (Hannoun et al., 2000) using
the AI (top) and SimPlot (bottom) methods. Interpretation: AI non-rccombinant, SimPlot -



























































































































































Figure 4-16. Phylogenetic analysis of HBV isolate AF121243, reported to be a B/C
recombinant. Genotype B is highlighted in the grey box, genotype C in the yellow box and the
isolate in the red box. The lilac box shows the failure of genotypes B and C to segregate in
this region of the genome. Phylogenetic analysis supports the AI non-recombinant result.
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4.4 Discussion
Recombination does appear to occur in HBV infection although maybe not as frequently as
previously reported. Using recombination positive results for both the AI and SimPlot
methods (as described in chapter 2) as the criteria for calling an isolate a recombinant, 10
recombinants HBV genomes, out of the 45 reported genomes that were re-analysed, were
identified. A/D recombination seems to be more common than any other (4/10 isolates), but
as more sequence data becomes published from studies throughout the world this will have to
be reviewed.
SimPlot identified a total of 43 recombinants, making the discrepancy between the AI and
SimPlot methods very large. AI scanning of the HBV genotypes in pair wise combinations
identified a phylogenetically uninformative region, where in particular genotypes B and C,
and D and E respectively, fail to segregate. The majority of the isolates identified as
recombinants using SimPlot only (30/33 isolates) were reported to be B/C recombinants. In
each case the region of the genome reported to be involved in recombination corresponds with
this uninformative region. The way SimPlot calculates the relatedness of an isolate to the
genotypes leads to the isolates being deemed to be part of the genotype it groups closest to,
even though the sequence actually falls outside this group in the phylogenetic analysis.
Phylogenetic analysis confirmed the findings of the AI analysis, both in the identification of
recombinants and non-recombinants. Phylogenetic analysis on its own requires interpretation
from the researcher, and a sequence forming an outgroup may be taken as belonging to the
genotype it groups closest to, as is the case for SimPlot analysis as well, although it should be
judged as having no affiliation with any specific genotype.
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A/D recombinants and the C/D recombinant have much larger regions of overlap than the B/C
recombinants. This suggests that the recombination events have taken place over an extended
period of time, as both these genotypes are found widely throughout the world, and a longer
time would be required to accumulate the different recombinations seen (Fares and Holmes,
2002). The B/C breakpoints are also all found in non-overlapping regions of the genome, and
the fragments involved are always smaller, involving around 500 bp long fragments. Fares
(2002) found all B/C recombinants to have originated from one single recent recombination
event, due to the close relatedness between these isolates in phylogenetic analysis. A/D
recombination points can be found in both overlapping and non-overlapping regions of the
genome, and the isolates do not appear to be related, suggesting a longer time-span since the
different recombination events that gave rise to these isolates (Fares and Holmes, 2002).
If A/D recombinants represent older recombination events this could explain why they seem
to be more frequent than recombination events between other genotypes. A longer period of
time will mean that the recombined parts of the genome have had time to become stabilised,
and any recombination events affecting the replicative fitness and infectivity of the virus will
have been removed from circulating virus populations. If recombination occurs in a region of
the genome that has constraints on it, such as the Pol gene (Mizokami et ah, 1997) the new
genome may be unable to replicate and therefore these will not be produced and potentially
spread to new hosts. The genotype B isolates with the reported genotype C recombination,
shown in this study to be a divergent core region, have been described as being more
pathogenic than non-recombinant genotype B in southeast Asia (Sugauchi et ah, 2002b). If
they have a recent origin as Fares suggests (Fares and Holmes, 2002) their genomes may not
be as stable with breakpoints within epitope regions or other regions important for the
replication and infectivity of the virus, and their new genomes may be responsible for this
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difference in disease. Genotype B is most prevalent in Southeast Asia, whereas genotype C is
more frequent in for example Japan. The disease caused by genotype C in Japan is more
severe than genotype C infection in Southeast Asia. Population factors as well as viral factors
must be considered when investigating such differences.
Recombination between HBV isolates from different genotypes does occur. The genotypes
involved in these recombination events reflect the genotypes in circulation in the countries of
origin. A/D recombinants all originate in Europe, where these two are the two most prevalent
genotypes, and B/C recombinants originate in Asia. The fact that C/D recombinants are found
in Tibet confirms the worldwide distribution seen for genotype D. The existence of some
highly divergent HBV strains in Vietnam that do appear recombinant, but do not seem to be
recombinant with any of the known human or non-human primate genotypes, hints at the
existence of further genotypes of HBV. These genotypes may be infecting humans or other
species of primate, in which case cross-species transmission as an evolutionary mechanism
for HBV must be considered. Recombination has to be considered an evolutionary force when
considering HBV infection. It appears to be occurring currently, based on the B/C
recombination events, but has also occurred further back in the evolutionary history of
hepatitis B virus. Recombination may be responsible for the creation of the genotypes seen
today.
Differences in disease severity may be associated with these recombinant genomes, and needs
to be investigated further. Differences in host factors also need to be taken into consideration.
Recombination has to be considered as one of the mechanisms of HBV evolution that may
become more important in the future. If cross-species transmission of HBV is possible, then
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recombination between native and new HBV genomes could create new viruses capable of
causing much more severe disease and making treatment and prevention more difficult.
Recombination appears to be an important factor in the evolution ofHBV, and this means it is
very important that the methods used to investigate the extent of recombination are adequate.
The SimPlot method appears to overestimate the amount of recombination, by forcing
sequences with low affiliation into the closest genotype. Phylogenetics on its own also
appears to be a poor method of choice when looking for recombination, although this may be
due to interpretation. Many genomes have crossover points in regions of the viral genome
that are uninformative, and may therefore give false positive results. Phylogenetics is most
accurate when it is performed over multiple regions, with overlap between them. Otherwise
any uninformative regions may go unnoticed. The AI methods eliminates the two major
problems associated with using SimPlot and/or phylogenetics as recombination detection
methods. Sequences with low affiliations will not be artificially assigned a genotype, but will
be shown as having no strong association with any particular genotype. Phylogenetically
uninformative regions are also identified when using the AI method. All the above points
mean that studies such as that by Fares & Holmes (2000) significantly overestimate the
amount of recombination that occurs for HBV. This also means that any conclusions drawn
regarding the evolutionary history have to be treated with caution. A combination of methods
such as AI and phylogenetics will be more sensitive in detecting recombination than either
method on its own.
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Chapter 5
Survey of HBV Prevalence in Non-
human Primates
The infection frequency and phylogenetic data presented in this chapter were published in
2003 (Starkman et al., 2003). This manuscript can be found in appendix F.
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5.1 Introduction
Since the discovery of HBV, primates have been involved in research into the infectivity,
pathogenicity, and disease association of the virus, and also in vaccine trials. In the early days
of HBV research chimpanzees were widely used, but even as early as 1969 there were
concerns about the use of chimpanzees in research, due to the threat of extinction facing this
species (Deinhardt, 1976). Morality issues of using our closest genetic cousin for
experimentation also have to be taken into consideration.
5.1.1 History ofHBV infection in primates
Primates have been screened for HBV before entering research centres, and so far only the
great and lesser apes (i.e. chimpanzees, gorillas, orang-utans and gibbons) have been found to
carry the virus (Deinhardt, 1976; Eichberg and Kalter, 1980). Most of this screening was
carried out to ensure that animals were not already infected with HBV as they were to be
used, amongst other things, in infection susceptibility experiments. These experiments also
showed that only the great or lesser apes were susceptible to infection in the laboratory
environment, although there were some early reports of vervet monkeys and rhesus monkeys
becoming infected (Deinhardt, 1976). These results have not been reproduced, partly because
it has become less and less acceptable to carry out these types of experiments.
As early as the late 1960's and early 1970's, scientists were realising that it was unsustainable
to use chimpanzees in HBV research due to the threat of extinction. The only other primate
that seemed susceptible to infection was the gibbon, another family of species that is
unsustainable to use, as it is also under threat of extinction. More recently, baboons (Papio
spp.) and macaques (Macaca spp.) have been evaluated as possible primate models for HBV
research. Baboon studies from 1996 (Michaels et al., 1996) concluded that baboons were in
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fact resistant to HBV infection, whereas a study from 2000 (Kedda et al., 2000) showed that
chacma baboons (Papio ursinus orientalis) were susceptible to HBV infection and developed
a chronic carrier state. Further experiments with chacma baboons have confirmed these
findings (Baptista et ah, 2003). Infectivity studies using macaques also indicate the possible
use of this primate species in HBV research (Gheit et al., 2002). This would be advantageous,
as this type of small primate is relatively easy to breed and keep in captivity.
It was always assumed that any HBV infected primates had picked up their HBV infections
from humans involved in the chain of handling before they were tested. Primates captured in
the wild were often given injections of pooled human sera, as a protection against human
diseases, prior to their transport to research facilities around the world. It is possible that this
practice was in fact responsible for some of the infections detected in the primates. The tests
of the time did not look at the genetic sequence of the virus, but only looked for serological
positivity. It is therefore possible that at least some of the infections detected were due to
natural infections, with virus variants closely enough related to the human HBV viruses to be
cross-reactive in serological tests. It is now known that the primate HBV variants share the
same serological determinants as the human genotypes and are closely related to them. A
more detailed description of each of the primate HBV variants detected to date is found
below.
5.1.2 History ofHBV infection in chimpanzees and gorillas
The first major report of hepatitis in chimpanzees came out in 1978, after an outbreak at
London Zoo (Zuckerman et al., 1978). At the time it was thought that the infection was of
human origin, but later when the entire genome of the isolate from one of the chimpanzees
involved in the outbreak was sequenced in 1988 (Vaudin et al., 1988), it became clear that this
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virus was closely related to, but distinct from human HBV. Since this first isolate was
published several more isolates have been reported. In 2000 three papers were published in a
short period of time that described more isolates (Hu et ah, 2000; MacDonald et ah, 2000;
Takahashi et ah, 2000), and it became clear that chimpanzee HBV was a distinct genotype of
HBV specific for this species. In 2001 a further two papers were published that concentrated
on chimpanzee HBV, and they showed that HBV infection is indigenous to the ape species,
with the possible existence of sub-species specific sub-genotypes within the ape HBV clades
(Hu et ah, 2001; Takahashi et ah, 2001).
One paper in 2000 (Grethe et ah, 2000) also reported a chimpanzee isolate, although this
isolate was most closely related to gibbon HBV (see sections 5.1.6 and 5.3.2), and the first
isolate from a western lowland gorilla {Gorilla gorilla gorilla). The gorilla isolate was very
closely related to chimpanzee HBV. A recently published study of HBV prevalence in non-
human primates in Gabon and the Congo (Makuwa et ah, 2003) reported a high frequency of
infection in western lowland gorillas, but unfortunately no sequence data was published. This
sequence data will be very important in the future for determining whether there is a separate
gorilla genotype ofHBV, or whether gorillas are infected with a variant of chimpanzee HBV.
The papers from 2000 and 2001 were beginning to speculate on the virus-host relationships of
HBV and the possible origins and evolutionary history of the virus. Hu (2001) suggested that
there were subspecies types of HBV within the chimpanzee HBV clade, and used
mitochondrial data to back up his claims. In 2002 there was a report published where
researchers had isolated an HBV strain from Pan troglodytes schweinfurthii, which meant that
HBV was present in all the four subspecies of the common chimpanzee (Vartanian et al.,
2002). This isolate branches off separately in the phylogenetic tree, supporting the existence
of subspecies-specific HBV strains as suggested by Hu (Hu et al., 2001). To elucidate further
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the exact relationships between chimpanzee HBV and the subspecies it would be helpful if
isolates were genetically characterised in the bonobo {Pan paniscus), eastern lowland gorilla
(G. g. graueri), and the mountain gorilla (G. g. berengei).
In this study I have screened samples from common chimpanzees for the presence ofHBV to
further elucidate the chimpanzee HBV clade.
5.1.3 History ofHBV infection in gibbons
Although seropositivity of gibbons for HBV was reported in the early years of HBV research
it was not until 1996 that HBV DNA was isolated from a gibbon and the complete genome
was sequenced (Norder et al., 1996). There had been an earlier report of a PreS gene sequence
from a gibbon (Mimms et al., 1993), but gibbon HBV was not fully characterised until 1996.
After the publication of this sequence it became clear that this was another species-specific
HBV variant. A large number of gibbon sequences have now been published (Aiba et al.,
2003; Grethe et al., 2000; Lanford et al., 2000; Mimms et al., 1993; Noppornpanth et al.,
2003; Norder et al., 1996), and as is the case for chimpanzee HBV, it has become clear that
there is a separate and distinct gibbon HBV genotype.
In this study I have screened samples from a variety of gibbon species for the presence of
HBV DNA, and have investigated the possible presence of subtypes within the gibbon clade.
5.1.4 History ofHBV infection in orang-utans
The complete genome of an orang-utan HBV isolate (accession number NC_002168, orang¬
utan Somad) was first reported in 1999 (Warren et al., 1999), and orang-utan HBV has since
been characterised further (Verschoor et al., 2001). Orang-utan HBV is closely related to
gibbon HBV, but appears to be separate from it, in contrast to the gorilla/chimpanzee HBV
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relationship. Large numbers of orang-utans have been screened for HBV as part of
rehabilitation and release schemes, and there appears to be a high frequency of infection, both
active and past (Warren et ah, 1998). However, only a limited number of isolates have been
sequenced and published.
In this study I screened orang-utan samples for the presence of HBV DNA in an attempt to
increase the amount of sequence data available for this species and evaluate the orang-utan
HBV clade.
5.1.5 HBV in other primates
Apart from the reports of HBV in vervet monkeys (Deinhardt, 1976) there have been few
reports ofHBV infection in other primate species. There has been only one report of a single
Cercopithecus aethiops monkey showing signs of infection (Heckel et al., 2001), and the
detection of hepadnavirus-like particles in two ruffed lemurs (Varecia variegata variegata)
(Worley and Stalis, 2002), but no sequences have been published. No Old World primates
apart from the great and lesser apes have been shown to harbour HBV infection with naturally
occurring species-specific virus variants, neither in older studies (Deinhardt, 1976; Eichberg
and Kalter, 1980; Michaels et ah, 1996) nor in more recent ones (Makuwa et ah, 2003).
New World monkeys have also been screened for the presence of HBV, and to date there is
only one report of one species being positive- the woolly monkey (Lagothrix lagotricha)
(Lanford et ah, 1998). This will be discussed further later. In this study I screened a large
number of serum/plasma samples from Old World monkeys in an attempt to isolate an HBV-
like virus.
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As part of the study HBV screening data for primates already published was compiled to
investigate the overall frequencies of infection in primates.
5.1.6 Cross-species transmission ofHBV
As mentioned earlier, it is possible to infect apes with human HBV variants, and this used to
be thought to be the explanation for the presence ofHBV infection in captured primates. The
detection of human genotype E in a chimpanzee (accession number AB032431) is most likely
explained by this type of scenario. The detection of a gibbon-like HBV variant in a
chimpanzee (Grethe et ah, 2000) on the other hand suggests the possibility ofHBV crossing
the species barrier among non-human primates in the other direction, from primate to human.
Since we now know that there exist in nature a number of nonhuman primate HBV variants,
the possibility arises of cross-species transmission from the natural hosts to humans.
This scenario seems especially likely in parts of Africa, where bush meat is gaining in
popularity again and is posing a threat to the world's primate populations. It is also a concern
that must be considered in the medical field, where xenotransplantation using primate organs
is being investigated as a possible solution for the organ shortages experienced worldwide. It
has already been shown that infections can cross the species barrier through this type of
procedure (Michaels et al., 1996).
Baboon livers have been used in xenotransplantations, as these primates have been considered
resistant to HBV infection (Lanford et ah, 1995). As it has now been shown that at least one
species of baboon, the chacma baboon (Baptista et ah, 2003; Kedda et ah, 2000), can be
infected with HBV the suitability of baboons for this type of medical procedure is doubtful,
although screening for HBV in donor animals would eliminate the risk. As mentioned above
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(see section 5.1.5), the ability of these primates to support human HBV replication may
indicate the existence of a natural baboon HBV variant. In one sample taken from a baboon
liver xenograft given to an HBV patient HBV DNA was detected in one assay (Lanford et al.,
1995). The most likely source of this DNA is extrahepatic HBV DNA of patient origin
entering the liver via the cardiovascular system, but the possibility remains that it may be of
primate donor origin. Transmission of infectious baboon cytomegalovirus through
xenotransplantation has been documented (Michaels et al., 2001), so zoonotic transmission
from baboon to human is a real possibility.
There has been one report of possible gorilla to human transmission of HBV in a Zoo
(Linnemann, Jr. et al., 1984), although this was not backed up by any sequence data from
either the gorilla or the keeper involved. Large scale screening of primate handlers working
with gibbons has also failed to produce any evidence for primate to human transmission
(Noppornpanth et al., 2003). Nevertheless, cross-species transmission and subsequent
evolution within new hosts has been proposed as a possible scenario for the origin of human
HBV infections in modern populations (as discussed in more detail in chapter one, section
1.5.2).
In this study I combined human and primate HBV sequence data in a search for evidence of
past cross-species transmission events, in an attempt to shed more light on the evolutionary
origin and history of the hepatitis B viruses infecting primates today.
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5.2 Materials and methods
5.2.1 Primate serum and plasma samples
A total of 137 primate serum samples were available for screening. 71 were samples from
drills (Mandrillus leucophaeus) residing at a rescue centre in Nigeria, 48 ofwhich were wild-
born and 23 captive-born, all previously tested HBsAg negative. 24 samples were obtained
from the following species; 8 drills, 2 mandrills (Mandrillus sphinx), 4 cherry-capped
mangabeys (Cercopithecus torquatus) and 7 chimpanzees (Pan troglodytes spp.), kept at the
Limbe wildlife centre in Cameroon, all of which were wild-born. The drills, mandrills and
mangabeys were all HBsAg negative, 2 chimpanzees were HBsAg positive, 3 were negative
and 2 were unknown. One sample from a known HBsAg positive chimpanzee from a rescue
centre in Nigeria and 3 samples from mona monkeys (Cercopithecus mono), 2 samples from
putty-nosed monkeys (C. nictitans), and 3 samples from red-eared monkeys (C. erythrotis) all
known to be HBsAg negative were also available. HBsAg positivity normally indicates a
carrier of HBV, although it is known that in humans chronic carriers can loose their HBsAg
expression and still show the presence ofHBV DNA. Therefore all animals previously tested
for HBsAg and found to be negative were also screened for the presence ofHBV DNA.
20 samples from various gibbon species (Hylobates spp., Nomascus spp.), 4 of which were
known to be HBsAg positive and 16 negative, and 14 Bornean orang-utan (Pongo pygmaeus
pygmaeus) samples, all HBsAg negative were sent from the Pintung rescue centre in Taiwan.
These animals were all wild-born, and the veterinarian Dr John Lewis took samples on site.
Samples were stored at 4°C prior to shipping to the UK according to CITES regulations, and
then stored at -25°C prior to analysis. One male and one female lar gibbon (Hylobates lar)
both captive born and from the Welsh Mountain Zoo were also included. These samples were
provided by Dr Andrew Greenwood. They were HBsAg tested at the City Hospital,
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Edinburgh, and the female was found to be positive whereas the male was negative. Samples
were extracted and screened for the presence of HBV DNA as described in chapter 2 sections
1, 2, and 3.
5.2.2 Screening, sequencing and phylogenetics
Serum or plasma samples from the primates were extracted as described in chapter 2. The
DNA was then screened for the presence ofHBV DNA using two separate nested PCR assays
as described earlier in chapter 2. Positive samples were subjected to further PCR
amplification to obtain overlapping fragments representing the entire genome of the HBV
isolate. Primers used for this sequencing are described in chapter 2. Complete sequences were
then aligned with all previously published primate HBV isolates as well as representative
sequences from all the human genotypes of HBV. These sequences were then subjected to
phylogenetic analysis, using both the neighbour-joining method in MEGA2 and the maximum
likelihood method (carried out by Edward Holmes in Oxford).
5.2.3 Screening of Old World monkey samples with highly conserved primers
To investigate whether Old World monkey species may be carrying a highly divergent HBV
variant that is undetectable using current serological and molecular screening strategies a new
PCR was developed. A region of the HBV genome which is highly conserved between all the
human, primate and rodent HBV variants was identified. A new set of primers was selected to
amplify this region of the HBV genome. Primers 21, 22, 23, and 24 (see chapter 2 for primer
sequences) were chosen. An alignment showing the segment of the S gene region and the
primer sites can be found below (Figure 5-2). These sets of primers were shown in control
experiments to be equal in sensitivity when compared with the two other sets of primers used
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in screening. PCR buffers and thermal cycling conditions were as described earlier in chapter
2 section 2.
p^^^^^^^HHconserved prime s eerie primers T 2... :7." "J
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Figure 5-1. Gel image showing a comparison of the S gene PCR (chapter 2) and the conserved
PCR. Lane 1 in each case is undiluted human HBV DNA positive control DNA, lane 2 is a
1/100 dilution of the control DNA and lane 3 is a 1/1000 dilution of the control DNA. Each
set of primers was tested in duplicate. Both sets of primers failed to amplify a 1/10000
dilution of control DNA. Lane L is a molecular size marker, with the brightest band having a
size of 500bp. The fragment amplified by the S gene primers is 200bp long and the fragment
amplified by the conserved primers is 300 bp long.
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Figure 5-2. Sequence alignment showing the conserved primers within the S gene region used
to screen Old World monkeys for the presence of HBV DNA. A simplified genome map
shows the position of the PCR fragment that is amplified within the genome (black line).
164
5.2.4 Mitochondrial 12S region PCR and sequencing ofprimate samples
Since no species information was available for the chimpanzees and some of the gibbon
samples it was decided to try to determine the species using mitochondrial data to enable
more precise comparison ofHBV and species phylogenies. Without this type of information it
is difficult to make any hypotheses regarding the origins and evolutionary history of HBV in
primates and the relationships between the viruses and their hosts. A search was done on
GenBank for mitochondrial sequence data. Different regions of the mitochondrion were
chosen and phylogenetic analysis carried out to evaluate the potential use of the regions for
the purpose of determining species. The 12S region was chosen, as the phylogenetic tree
obtained using this data showed a close congruence to the evolutionary tree of primates as
accepted today (Catriona MacFarlane, PhD thesis).
Primers 12S-S (5'-CCATAAACAMAYAGGYTTGGTCC-3'; positions 641 to 664) and 12S-
AS (5' -CAGGGTTTGCTGAAGATGGCGGTATATA-3'; positions 1270 to 1298) were
designed using the sequence data from GenBank (Catriona MacFarlane, PhD thesis). These
sequences were then used in the phylogenetic analysis of the 12S sequences. Accession
numbers can be found in this tree (Figure 5-5).
A single round PCR was set up using 2 pi of extracted sample DNA in a total reaction volume
of 50 pi. The PCR buffer was made up as described earlier for the screening of the samples
for the presence ofHBV. The PCR was carried out using the following conditions; 40 cycles
of 94°C for 60 sec, 55°C for 60 sec and 72°C for 60 sec, followed by a final extension step at
72°C for 7 minutes and a holding step at 20°C for 10 minutes. 15pl of product was loaded
onto a 2% agarose gel (stained with ethidium bromide) and electrophoresed for 40 minutes at
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150V. A 100 bp marker was run alongside the products to check the fragment size. PCR
fragments were then visualised under UV light and a picture was taken.
Fragments were then sequenced using primer 12S-S and the BigDye automated sequencing
protocol as described earlier. Sequencing data was then imported into the SIMMONIC
sequence analysis program and aligned to the GenBank sequences used to design the primers.
Phylogenetic trees were then constructed using MEGA2 as described earlier. An attempt was
then made to identify the species of the primate samples for which this information was
unavailable.
5.2.5 Association Index analysis
Association Index (AI) analysis was carried out as described earlier in chapter 3. This analysis
was done in the first instance to investigate in which parts of the HBV genome the human and
primate genotypes segregate into the groups seen in phylogenetic analyses (see Fig. 3-1). The
analysis was carried out across the genome using 250bp sizes fragment windows, and moving
along the genome in 100 bp overlapping steps. The results were then plotted into a barchart
using Microsoft Excel. AI analysis was also carried out to investigate groupings seen within
the primate clades using the same method as used for investigating geographical sub-
groupings within human HBV genotypes (see chapter 3 section 2.4). Chimpanzee isolates,
gibbon isolates and orang-utan isolates were tagged separately in the analysis. Genotype F
and the woolly monkey HBV sequence were omitted from the analysis due to the lesser
relatedness of these to the remaining genotypes.
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5.2.6 Recombination analysis
To investigate the existence of recombinant HBV genomes within the primate genotypes in
the search for evidence of cross-species transmission events two methods were used. The AI
method can be used to look for recombination in HBV genomes as described in chapter 4. 600
bp windows moving along the genome in 20 bp steps were used in the first instance, and then
500bp windows with lOObp overlapping steps were used after this was shown to provide the
same results (see chapter 4, page 119). SimPlot analysis was then carried out using the same
sequence groups, window and step sizes (Lole et al., 1999).
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5.3 Results
5.3.1 Frequency ofHBV viraemia in primates
The frequency ofHBV viraemia in primates was calculated both for samples screened in this
study, and for previously published results in combination with the results of this study.
5.3.1.1 Frequency of viraemia seen in study samples
A total of 7 out of 136 primates tested positive for HBV DNA, all of which were within the
ape group. No old World monkey species tested positive with the two HBV screening PCR's
described in chapter 2. When these samples were re-screened using highly conserved primers
for part of the S gene region able to pick up rodent HBV variants as well as all the known
human and primate HBV variants, no positive samples were found either (Table 5-1). Two
chimpanzees were found to be positive for HBV DNA by PreS and S gene PCR.
Chimpanzee 1, Louisa, was HBsAg tested in 1997 and found to be negative. Louisa is of the
Pan troglodytes troglodytes subspecies of chimpanzee (this was shown by amplification and
phylogenetic analysis of mitochondrial DNA, see section 5.2.5), and was captured and then
confiscated in south-western Cameroon. Prior to confiscation she was kept by local people.
She is kept with other chimpanzees at the Limbe wildlife centre in Cameroon. Since
confiscation she has had no contact with primates of other species, but the exact details of
how she was kept prior to confiscation are unavailable.
The second chimpanzee is Osang who belongs to the vellerosus subspecies of chimpanzee
(see section 5.2.5). He was donated to a conservation project in the south-eastern part of
Nigeria on the 16th of January 1996. He was HBsAg tested on arrival and was found to be
positive. Osang was also kept by local people prior to his arrival at the project. He is kept with
other chimpanzees at the centre.
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Five gibbons were found to be HBV DNA positive by PCR. Of these 4 were wild-caught and
one was captive born. The captive born animal is a female named Tamang (Hylobates lar),
and as mentioned before she was HBsAg tested at the City Hospital in Edinburgh and found
to be positive. She was born in 1989 at Cricket St Thomas and moved to the Welsh Mountain
Zoo in 1995. She was born to a captive born father (Paignton Zoo) with known wild-caught
parents from Malaysia and Thailand, and a captive born mother (Stuttgart Zoo) with unknown
parental origins. At the welsh Zoo she is kept with a male, Jake who was born at the Zoo and
is both HBsAg and HBV DNA negative.
The remaining 4 positive gibbons consist of Crazy Woman (H. agilis) confiscated in Taiwan
06-09-1993, TB Black (species not identified) confiscated in Taiwan 17-05-1996, Happy
(Nomascus gabriellae) confiscated in Taiwan 08-10-1996, and Wendy (A. gabriellae)
confiscated in Taiwan 27-05-1999. Their histories prior to confiscation are unknown, as are
their origins. Their origins can be estimated from their species denotation. They have been
kept on their own since confiscation. All four were tested and found to be HBsAg positive.
The species of the chimpanzees was determined by mitochondrial sequencing, whereas the
sanctuary provided most species names for the gibbons. Mitochondrial sequencing was
carried out on gibbon samples as well to provide species denotations for those animals for
which this information was unavailable.
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5.3.1.2 Frequency of viraemia seen in all primates
Looking first at the results for the ape species, all three species groups of great ape, as well as
the lesser ape gibbon have prevalences over 15%, with an overall prevalence of infection of
18.7% (Table 5-2). This figure compares to that found in human populations in endemic
areas.
Moving on to look at the Old World monkeys, a large number of different species have been
screened. So far none have been found to contain a HBV-like virus using current serological
and molecular screening techniques. Even when using highly conserved primers in a new
PCR strategy, no HBV-like virus is detected in these species of primate (Table 5-3). Apart
from the captive woolly monkey, no New World primate species have been found to harbour
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5.3.2 Phylogenetic analysis of primate HBV isolates
Following complete genome sequencing of the 7 HBV positive primate samples phylogenetic
analysis was carried out (Figure 5-3). All previously published primate isolates were included
in the analysis (n = 25), as well as 10 representative sequences from each of the human
genotypes A-H as described earlier (accession numbers for all sequences used in this analysis
can be found in chapter 2). The complete genome analysis splits the resulting tree into three
sections; South America (both primate and human), all other human genotypes, and all the
remaining primate genotypes (see Fig. 5-3).
Complete genome analysis shows that the primate isolates from this study fall into the
previously described primate clades (Fig. 5-3). The gibbon/orang-utan clade is made up of
four main branches. The first of these is made up of the two orang-utan isolates and two of the
gibbon isolates from this study (Crazy Woman and TB Black). One of these is an agilis
gibbon (Crazy Woman), and the other is of unknown species (TB Black). This unknown
gibbon species most likely belongs to the Hylobates subgenus (see section 5.3.3) using
mitochondrial data, although it was not possible to determine the exact species using this
method. One lar gibbon (Tamang) from this study can be found on a branch with other
isolates from lar gibbons and the chimpanzee isolate mentioned earlier (accession number
HBV131575, see section 5.1.6), and a gabriellae gibbon (Wendy) can be found on another
branch which has mainly concolor gibbons within it. Another gabriellae gibbon (Happy) is an
outlier. The final branch contains isolates from pileatus gibbons.
Within the chimpanzee clade one divergent isolate can be seen; AB046525 belonging to the
troglodytes subspecies (Fig. 5-3). The other isolates are separated onto two main branches,
with the exception of AB032431 which groups within human genotype E. One branch
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contains isolates of the verus subspecies, and the other isolates from the vellerosus,
troglodytes and schweinfurthii subspecies, as well as the single gorilla isolate. Vellerosus
isolates, including Osang from this study, branch off first within this clade, followed by the
schweinfurthii isolate, the gorilla isolate and then the troglodytes isolates including Louisa
from this study. There again appears to be separation of isolates depending on the host species
of primate. This species separation of HBV variants resembles the evolutionary relationship
between the species (Fig. 5- 7b), but does not mirror it exactly. This is partly due to the inlier
position of the gorilla isolate. HBV from the vellerosus subspecies is also more closely related
to the troglodytes/scweinfurthii clade than to that made up of verus isolates.
One isolate from a chimpanzee originally reported to be of the verus subspecies (Chimp 2
from MacDonald et al., 2000) is found in the troglodytes cluster. Serum from this chimpanzee
was available for testing, so mitochondrial PCR and sequencing was carried out. This showed
that this chimpanzee was most likely of the troglodytes species and not a verus as first
reported. This information has subsequently been verified by the sanctuary where the
chimpanzee is now being kept. In this analysis, apart from the isolates grouping according to
which species they were derived from, there is also an East/West split within the African
primates based on the habitat ranges. The geographical distributions of gorillas and
chimpanzees are described further in section 5.3.4.
The main human clade splits into two as well, one containing genotypes A, B, and C, the
other containing genotypes D, E, and G. The overall branching order within the complete
genome tree resembles quite closely the evolutionary tree of the primates (Fig. 5-7a), with
gibbon and orang-utan branching off first, followed by chimpanzee and gorilla, and then
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human genotypes A-E and G, with the New World woolly monkey isolate forming the
outgroup. Only the outlier position ofhuman genotypes F and H does not fit.
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Figure 5-3. Phylogenetic analysis of complete genomes ofHBV isolated from study primates.
This analysis splits the tree into three sections; 1- all human genotypes except F and H, 2- all
primate genotypes, and 3- all South American genotypes, human and primate.
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A number of further isolates for primates are available in the S gene region of the HBV
genome only, so phylogenetic analysis of this region was also carried out. Again for the
chimpanzee clade there is distinct separation ofHBV variants according to which species was
the host species (Fig. 5-4). The gorilla isolate is now an outgroup to the rest of the isolates,
and the schweinfurthii isolate is most closely related to the troglodytes cluster. The branching
order of the chimpanzee S gene phylogenetic tree mirrors the tree based on mitochondrial
DNA data (Fig. 5-7b) very closely. The geographical separation of the chimpanzee species
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gure 5-4. S gene phylogenetic analysis of chimpanzee HBV isolates, and the geographical
stribution of species within Africa. Species specific clusters can be seen. These are
lpported by an AI analysis value of 0.0074 (Table 5-5). These clusters also segregate
wording to the geographical origin of the species (AI 0.0010, Table 5 5)
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Within the gibbon clade there also again appears to be separation according to species (Fig. 5-
5), although again this does not reflect the phylogenetic relationship between the species, as
isolates from the Nomascus subgenus can be found on a branch separating two clades with
species-specific isolates from the Hylobates subgenus. One isolate is highly divergent in this
region (Happy from this study). One interesting finding from this analysis that also would not
be predicted from the evolutionary tree of gibbons is the very close relationship between the
orang-utan isolates and gibbon isolates from species with habitat ranges that overlap with the
orang-utans. Two isolates from this study are included in this group. There are also two
groups within the orang-utan cluster, as described earlier (Warren et al., 2001). One isolate
from a concolor gibbon (HBV131573) fails to group within the main concolor cluster.




































Figure 5-5. S gene phylogenetic analysis of gibbon and orang-utan HBV isolates, and the
geographical distribution of these species within Southeast Asia. Some species specific
clusters are seen, and these are supported by an AI value of 0.1774 (Table 5-5). Geographical
segregation of species and HBV variants is more strongly supported (AI 0.03 9, )
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5.3.3 Mitochondrial PCR and sequencing ofprimate samples
Mitochondrial 12S region PCR and sequencing was carried out in an attempt to determine the
subspecies of primate samples for which this information was unavailable (Fig. 5-6). For the
chimpanzees it was possible to differentiate between troglodytes, verus and vellerosus
subspecies using sequence data from this region. Troglodytes is the central African subspecies
of chimpanzee. Most of the animals screened in this study originated in Cameroon, and as
expected most were of the troglodytes subspecies. One of the positive chimpanzees from this
study was found to be of the vellerosus subspecies (Osang, originating in Nigeria), and the
other was of the troglodytes subspecies (Louisa, a chimpanzee from Cameroon, labelled as
L21 in the mitochondrial DNA phylogenetic tree). This analysis also showed that chimp 2
(LI 8) (MacDonald et al., 2000) was in fact not of the verus subspecies as claimed in the
publication, but of the troglodytes subspecies. This has since been confirmed by the
sanctuary. Chimp 4 from that same study was confirmed to be a verus chimpanzee by the
sanctuary where it is kept.
For the gibbons it was not possible to determine the exact species using this particular
mitochondrial region, with only the lar species forming a monophyletic group, but the
subgenus could be determined. The species were known for 4 of the positive gibbons from
this study (Tamang, labelled as GFMIT012; Crazy Woman, labelled as G1MIT012; Wendy,
labelled as G17MIT01; and Happy, labelled as G8MIT012), and the fifth was determined to
be of the hylobates subgenus (TB Black, labelled 6MIT012). A phylogenetic tree showing the
species for all chimpanzee, gibbon and orang-utan samples and a selection of samples
representing other species is shown in figure 5-4. This tree was not used to determine the
species phylogenies used in the analysis of the relationship between the HBV variants and
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their hosts. Previously published data with suggested gibbon phylogenies were used for that
purpose.
It is not surprising that it was not possible to determine the exact species of the gibbons using
this particular region of the mitochondria, as there is currently major controversy regarding
the species phylogenies within the gibbon species group. Different genomic and
mitochondrial regions have been investigated as potential species phylogeny determinants, but
so far there is no agreement about which way is the best (Roos and Geissmann, 2001). A lot
of species determination is still done in the field using morphology, fur colour and song
pattern, as well as habitat. The gibbon species are all found in distinct habitats, with small
overlapping regions in some cases. There is some interbreeding between species in the wild,
but this phenomenon is much more common in captivity. Hybrids in the wild do not seem to
















Figure 5-6. Phylogenetic analysis of mitochondrial 12S sequences obtained from study
samples. Samples downloaded from GenBank are highlighted in the yellow boxes. Two
human controls were also sequenced as part of the study. These are NEGMITOl (serum
negative for HBV) and POSMITOl (serum positive for HBV). They were included as an
internal contamination check, as they were also used as the positive and negative controls for
HBV PCR screening.
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5.3.4 Geographical distribution ofprimates in Africa and Asia and HBV variants
As can be seen in the map in figure 5-5, African primates have geographically separated
habitats. The only species with overlapping habitats are found within the central and eastern
parts of Africa. The gorilla exists as three subspecies. Gorilla gorilla gorilla is also known as
the western lowland gorilla, and this habitat is also shared with the troglodytes subspecies of
chimpanzee. In the East there is also an overlap of habitat, this time between the
schweinfurthii subspecies of chimpanzee and the two eastern species of gorilla; G. g. graueri
(the eastern lowland gorilla) and G. g. berengei (the mountain gorilla). If we relate this to the
species phylogeny of the African apes (Fig. 5-7b) we see that the East/West split of habitats is
reflected in the genetic differences within both gorilla and chimpanzee subspecies
populations. If we then relate this to the HBV trees from section 5.3.2 we see that the
geographic distribution of the primates explains the HBV variant separation very well, even
though the species phylogeny also fits the data.
The gibbon species are much more overlapping in their habitats, which can be seen from the
map in figure 5-6. Not all species are shown on this map, only the ones from which HBV has
been isolated have been selected. The species distribution of the subgenera is described
below. Species where HBV has not been isolated are also described, to give a better picture of
the distribution and interactions of these primates in the wild. Gibbons are divided into four
subgenera; nomascus, hylobates, bunopithecus and symphalangus. These are determined by
differences in the numbers of chromosomes.
Subgenus nomascus is made up of three species; concolor, leucogenys and gabriellae.
Concolor gibbons can be found in an area from south-eastern China to north-western Laos
and northern Vietnam, as well as Hainan. Leucogenys can be found in southern Yunnan and
throughout Central Laos and Central Vietnam. Gabriellae can be found in southern Laos,
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through eastern Cambodia and southern and central Vietnam. Subgenus hylobates is made up
of six species; lar, pileatus, agilis, moloch, muelleri, and klossii. Lar gibbons can be found in
southern Yunnan through eastern and southern Burma, Thailand, eastern and southern
mainland Malaysia and northern Sumatra. Pilaetus gibbons can be found in southeastern
Thailand, south-western Laos and Cambodia. Agilis gibbons can be found in southern
peninsular Thailand, north-western mainland Malaysia, southern Sumatra and south-western
Borneo. Moloch gibbons are found only on Java and muelleri gibbons in all regions ofBorneo
except the southwest. Klossii gibbons can be found on a number of the Mentawai Islands off
western Sumatra. Subgenus bunopithecus is made up of only one species, the hoolock gibbon,
which can be found in areas of eastern Bangladesh, Burma and the border region of Yunnan.
Subgenus symphalangus is made up of the syndactylus species, or siamang, which is found in
mainland Malaysia and Sumatra. Orang-utans exist as two separate species, Pongo pygmaeus
pygmaeus which can be found on Borneo, and P. p. albelii which is found on Sumatra.
If we relate this information to the species phylogeny of the Asian primates (Fig. 5-8) we see
that the geographical distribution of the species reflects the genetic differences. A rough line
can be drawn placing hylobates species to the west and nomascus species to the east. If we
then relate this to the trees from section 5.3.2, we again see that there is a better correlation
between the geographical distributions of the species (though not necessarily the subgenus)
and the HBV variants carried, than between the species phylogeny and HBV variant.
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Figure 5-7. Phylogenetic trees showing the ancestral relationships between the major primate
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Figure 5-7b is an adapted composite of mitochondrial DNA data published by Gao et al







Figure 5-8. Phylogenetic tree showing the ancestral relationships between the gibbon species.
This tree is adapted from a maximum likelihood tree based on mitochondrial control region
DNA sequence data published by Roos & Geissmann (2001). This tree is rooted with a human
sequence although the orang-utan is the next closest relative, as can be seen in figure 5-7a.
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5.3.5 Association Index analysis of primate HBV genomes
AI analysis was used to investigate the groupings observed within the chimpanzee and
gibbon/orang-utan clades respectively (Table 5-5).
As this analysis shows, there is strong support for both geographical and species determined
HBV variant distribution within the chimpanzee/gorilla clade. This is seen both for complete
genomes and the S gene region. The geographical determinant has a stronger support than the
species determinant. The difference between the two is largest when analysing the complete
genome. Within the gibbon/orang-utan clade the geographical separation of HBV types is
most strongly supported, again particularly when looking at the complete genome.
Complete genome S gene
Chimpanzee clade Gibbon clade Chimpanzee clade Gibbon clade
Species 0.1006 0.3248 0.0074 0.1774
Geography 0.0166 0.0043 0.0010 0.0349
Table 5-5. AI results for the geographical and species separation of HBV variants infecting
the different species of primates. Species denotes AI analysis of groups of sequences defined
by the species from which they were isolated, whereas geography denotes the arrangement of
sequences into groups depending on the geographical origin of the host-species. The
geographical ranges were defined as East and West for the chimpanzee clade analysis and
North and South for the gibbon clade analysis.
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5.3.6 Recombination analysis
Primate samples were investigated for the presence of recombinant sequences using two
methods, AI bootscanning and SimPlot bootscanning. Control sequences for gibbon, orang¬
utan, gorilla and chimpanzee HBV were tested in the first instance to provide profiles for
comparison. Samples from this study and divergent variants published by other groups were
then analysed. At first gibbon and orang-utan were tested as separate groups, but after
analysis of the orang-utan isolate gave a puzzling result with low association to both gibbon
and orang-utan HBV (Figure 5-9B), they were also tested as one group (Figure 5-10). As can
be seen from the control analysis using the AI method, combining the gibbon and orang-utan
isolates into one group does not affect the control analysis of the gibbon isolate, whereas the
result for the orang-utan is improved. This suggests that these two groups of isolates are very
closely related, like two members of the same genotype.
The SimPlot results for the gibbon isolate shows a greater degree of relatedness to the
combined group than to the separate gibbon group. The SimPlot results for the orang-utan
isolate is the opposite. It was decided to use the combined group in all further analyses. In the
gibbon and orang-utan analyses a combined gorilla and chimpanzee group is used, after data
showed these groups to be closely related also (see appendix E). Only the analysis of one lar
gibbon from this study (Tamang) is shown here (Fig. 5-11). The remainder of the analyses can
be found in appendix E.
The gorilla isolate showed a high degree of association with the chimpanzee isolates, except
for part of the S gene region (bases 1-1000). A chimpanzee control sequence was also tested
using both a combined gorilla and chimpanzee group and gorilla and chimpanzee separate.
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There is no significant difference between the two analyses using either the AI method or
SimPlot, so it was decided to use the combined group for all further analysis.
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Figure 5-9. AI and SimPlot analysis of gibbon (A) and orang-utan (B) control sequences,
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Figure 5-10. AI and SimPlot analysis of gibbon (A) and orang-utan (B) control sequences,
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In the AI analysis the isolates from chimpanzees Osang and Louisa both show a strong
association with the chimpanzee/gorilla group, with profiles resembling that of the control
HPBVCG. SimPlot shows this as well, but does also show a larger amount of variation within
the S gene region for both isolates, although more so for the Louisa isolate. Neither isolate
shows any evidence ofpossible recombination.
The isolate from gibbon Tamang shows a great resemblance in analysis profile with the
control sequence HBU46935, both in the AI and SimPlot analyses, and shows no signs of
recombination. There are no areas of the genome that appear divergent from previous data.
The SimPlot analysis does identify a region within the core gene with a higher degree of
variation. This region coincides with the region of the HBV genome where the support for the
human/primate split is weaker.
The isolate from gibbon Wendy again shows a high degree of agreement between the two
analyses. SimPlot analysis identifies an increase in sequence variation within the S gene, but
this cannot be seen in the AI analysis. No evidence to suggest recombination is seen.
The isolate from gibbon TB Black shows much more divergence from the control group,
especially in the S gene and core gene. These areas are identified in both analyses. There is a
lot of discrepancy between the results of the two analyses, with AI showing the isolate as
divergent and SimPlot as a recombinant with human genotype C in the S gene and
chimpanzee HBV in the core gene.
The isolate from gibbon Crazy Woman also shows a degree of divergence in the core gene
that is identified in both analyses. The remainder of the genome shows a high degree of
relatedness to other gibbon/orang-utan isolates in the AI analysis. SimPlot identifies a second
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area of divergence in the S gene. Although divergent, this isolate is not shown to be a
recombinant in the SimPlot analysis or the AI analysis.
The isolate from gibbon Happy again shows a higher degree of divergence, especially in the S
gene. SimPlot again identifies a second area of divergence, again in the core gene, that is not
seen in the AI analysis, but does not show the isolate as a recombinant either.
Isolate AB032431 is a chimpanzee isolate that groups with human genotype E (see Fig. 5-3).
Both AI and SimPlot analysis show the sequence to be very closely related to genotype E over
the entire genome, with no signs of recombination with HBV of any other genotype.
Isolate HBV131575 is a chimpanzee isolate that groups with the gibbon isolates. AI and
SimPlot analysis both show a high degree of relatedness to the other gibbon/orang-utan
isolates. SimPlot does however identify one region of increased divergence in the core gene
not shown by the AI data. Neither analysis suggests a recombination event.
Isolate AB046525 is a chimpanzee isolate from a troglodytes subspecies animal. It was
reported as having a divergent core gene (Takahashi et al., 2001). This divergence is clearly
shown in both AI and SimPlot analysis. AI analysis does not suggest recombination with any
of the known genotypes, although there is a small region where the closest relationship is with
gibbon HBV. SimPlot also fails to show a distinct recombination event, although there is one
small region most closely related to the woolly monkey isolate and another with genotype G.
None of these regions show strong enough association to suggest recombination in either the
AI or the SimPlot analysis.
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5.4 Discussion and conclusions
When the results of this study are added to a number of previous studies that report screening
data for primates it becomes clear that HBV infection is prevalent in a very restricted range of
primate species. The frequency of infection in chimpanzees and gibbons found in this study
are high, at 22.7 and 25% respectively. Other studies have found similarly high frequencies in
chimpanzees, gorillas, gibbons and orang-utans (Grethe et al., 2000; Lanford et al., 2000;
Makuwa et al., 2003; Noppornpanth et al., 2003; Warren et al., 1998; Warren et al., 1999).
When data from multiple studies are combined an overall frequency of active infection of
18.7% for all ape species is obtained, and those for the individual species are all over 15%.
Human populations in endemic areas have active infection rates that compare to these figures.
The fact that HBV appears to be endemic in other ape species apart from humans is not the
only parallel that can be drawn between these infections.
Transmission patterns may also be the same. In humans vertical transmission is the main
mode of transmission in Asia, whereas in Africa horizontal transmission predominates.
Evidence for both these modes of transmission has been reported for gibbons (Grethe et al.,
2000; Lanford et al., 2000; Noppornpanth et al., 2003). No such data have been published for
chimpanzees or gorillas, as most frequently the animals sampled have not been kept in large
groups/family groups, but rather represent orphaned and confiscated unrelated animals.
However, since such similarities exist between human and gibbon HBV transmission, one
may speculate that a similar situation will occur in African apes as well.
This study failed to identify the presence of a HBV-like virus in any of the Old World
monkey species screened. A recent study showed identical results following screening of a
large number of animals representing 9 different species (Makuwa et al., 2003). To date HBV
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negative screening results have been published for 15 different species. This evidence
suggests that these species do not carry HBV. One cannot, however, definitely conclude the
absence of HBV in these monkeys. There are a large number of monkey species in the Old
World, and the 15 tested represent only a fraction of these. One explanation for the lack of
HBV in Old World monkeys so far is that we simply haven't found the carrier species yet.
Another explanation for this lack of HBV detection could be that these species actually do
carry HBV, only the genomes are so divergent they cannot be detected using current
serological and molecular screening techniques, possibly even more divergent than the woolly
monkey isolate (Lanford et ah, 1998). To investigate this possibility a new PCR assay was
developed, using primers specific for the S gene region of the viral genome and conserved
enough to enable detection of HBV from the rodent species. This alternative screening
strategy failed to identify any HBV positive animals among the Old World monkeys in this
study. This strengthens the evidence that suggests that apes are the only carriers of HBV.
Further screening ofmore different species is necessary before any further conclusions can be
made regarding the presence or absence ofHBV in Old World monkeys. The fact that rodents
and birds carry HBV-like viruses suggests the existence of a monkey virus.
HBV infection in New World primates is another issue that requires resolution. To date 10
woolly monkeys, all captives, are the only examples of HBV infection in primates other than
apes (Lanford et ah, 1998). Only four species have so far been screened for HBV, so the same
argument that applies to Old World monkeys has to be applied. There may be new genotypes
of HBV still to be discovered, with unknown primate carriers. Also, all positive animals are
captives, so there is no evidence to support the existence of woolly monkey HBV in the wild.
It is a possibility that the infection could have arisen in captivity through cross-species
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transmission from another unidentified primate species. Woolly monkeys do seem to suffer
liver disease and mortality due to this infection, although the frequency of this is not known,
as many deaths due to liver disease were assigned as HBV deaths without performing any
tests (Lanford et al., 1998).
Phylogenetically the isolates from non-human primates fall into species-specific genotypes as
described by previous studies (Grethe et al., 2000; Hu et al., 2001; Takahashi et al., 2001;
Verschoor et al., 2001). There also appear to exist sub-types within these genotypes,
determined partly by the sub-species of primate which is the carrier. This is supported by
mitochondrial data both from this study and others (Hu et al., 2001). The close relationship
between the gorilla isolate and those from chimpanzees is confirmed. An analogous
relationship emerges in Southeast Asia, where gibbon and orang-utan isolates cluster together,
which contradicts the previous claims that orang-utans are infected with a specific genotype
ofHBV (Verschoor et al., 2001; Warren et al., 1999). There appears to be some separation of
isolates according to the species of origin, although this does not mirror the phylogenetic
relationship of the species (Fig. 5-8). If a North/South split is made according to the
geographical range of the habitats of the species this corresponds well with the branches
within this complete genome tree. More information about the geography of gibbons and
orang-utans is found in section 5.3.4.
There is a lack of diversity between the orang-utan isolates, and this coupled with the fact that
this study failed to detect HBV in 14 orang-utans suggests that HBV may not be so
widespread in this species. This is highly indicative of a more recent origin and cross-species
transmission, as in both Africa and Asia there are regions of habitat overlap between species
infected with HBV. Chimpanzees and gorillas share habitat ranges in Africa, and gibbon
species and orang-utans share habitats in Southeast Asia..
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As has been suggested recently (Fares and Holmes, 2002) humans may be the vector
responsible for this spread. No other primate moves over the distances that humans are able
to, although this has dramatically increased in the last few hundred years or so. Humans are
still however, the most widespread primate in the world as well as the most prevalent, and
they do come into contact with other primate species regularly. Using the estimates rate of
sequence change of 2.1 x 10"5 nucleotide changes/site/year, the divergence of the HBV
variants infecting the different subspecies of chimpanzee can be dated at 1600 to 2300 years
ago, which agrees with the 6000 years ago divergence date for the hominid HBV viruses
suggested by Fares (2002).
Although HBV appears to exist as sub-species variants within the different primate HBV
genotypes, the HBV phylogeny and the host phylogeny do not always agree. The relationship
between the African apes and the HBV isolates that they carry is closer than that seen in Asia,
both when analysing complete genomes and S gene sequences. In Asia there appears to be a
greater concordance between the actual geographical origin of the host species and the HBV
variant rather than the species. This geographical separation is seen also in Africa. To
investigate the sub-clades seen in chimpanzee and gibbon HBV the Association Index
analysis was employed. For the African apes both species separation and geographical
separation are strongly supported, whereas in Asia the geographical separation is most
strongly supported. This existence of geographical variants is another parallel between
human and non-human primate HBV, but is also a parallel that can be drawn with avian and
mammalian HBV (Pult et al., 2001b; Testut et ah, 1996). The importance of such
geographical variants still needs to be investigated.
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Recombination between HBV isolates from different genotypes is seen in human HBV
infection, but not in the other primate HBV genotypes. This may be due to the fact that
humans from different geographical areas, and humans in general, come in contact with other
carriers more frequently than other species of primates do. Due to human expansion
throughout Asia and Africa the habitats for the other apes have been decimated, and where
once there were large regions of overlap between habitats there are now ever decreasing such
regions. Humans are known to be able to become superinfected with more than one genotype
of HBV. This has not been seen in any of the HBV infected primates detected to date. If
primates are able to become superinfected, there is the possibility that recombinants could
arise. The fact that we have not seen any recombinant sequences may also be due to the rarity
of this event. Recombinants are rare in human populations, and far fewer primates have been
HBV tested than humans. The fact that chimpanzees, gorillas, gibbons and orang-utans are all
on the endangered species list also means the likelihood of contact between different species,
even though there is some habitat overlap, is also decreasing. More extensive sampling of
primates for HBV research may turn up recombinant genomes.
Cross-species transmission certainly does appear to be possible. The infectivity of human
HBV in other species of primate has been well documented. In this study we have confirmed
one case of human genotype E infection in a chimpanzee (Takahashi et ah, 2000) as a non-
recombinant virus of human origin. The absence of human genotypes in infected primates
screened in this study and others support this. If humans and primates shared genotypes, or
did so in the past, one would expect to find evidence for this in sequences isolated from these
primates. Cross-species transmission between other species of primate also appears possible,
as the gibbon-like HBV isolate from a chimpanzee (Grethe et ah, 2000) shows. This animal
was kept with gibbons in a Zoo, and the recombination analysis shows that this isolate is only
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of gibbon origin, with no chimpanzee HBV segments. From this same study (Grethe et ah,
2000) an isolate from a concolor gibbon was among those published. In the phylogenetic
analysis carried out as part of this project this isolate (HBV131573) did not group with
isolates from other concolor gibbons. This animal was also a captive animal, and may have
caught HBV from another gibbon species whilst in captivity. The close relationship between
gorilla and chimpanzee isolates, and gibbon and orang-utan isolates also suggests cross-
species transmission. The existence of a highly divergent chimpanzee isolate (AB046525)
(Takahashi et ah, 2001) with a core gene that is not closely related to any HBV genotypes
isolated to date is also highly suggestive of cross-species transmission, although this could
also be due to the existence of another chimpanzee genotype, AB046525 being the first
example of this. This isolate hints at the possible existence in nature of highly divergent HBV
isolates, in as yet unidentified primate hosts. No HBV-like viruses have so far been reported
from Old World rodents, and therefore these species must also be considered as a possible
source of this infection.
Recent cross-species transmissions between species is one possible explanation for the
distribution of the HBV variants of the non-human primates. Another possible explanation is
that the genotypes seen today arose during the evolution of the primate species. The rate of
sequence change estimated for HBV does not agree with this. The chimpanzee subspecies
started diverging around 1.5 million years ago (Morin et al., 1994), yet the HBV variants
infecting them can be calculated to have diverged between 1600 and 2200 years ago.
However, the constraints that exist for the evolution of the HBV genome (Mizokami et al.,
1997) may prevent the fixation of many mutations into the genome. However, when non-
coding regions of the HBV genome are used to calculate divergence low rates are found, and
a more recent divergence date of 6000 years for hominoid HBV is obtained (Fares and
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Holmes, 2002). The close relationship between the gibbon and orang-utan HBV isolates, and
a potentially analogous relationship between chimpanzee and gorilla HBV, also do not fit into
this model. Another trait difficult to explain is the number of different genotypes that infect
humans, although genotypes A-E and G have a monophyletic origin, the position of F and H
is not accounted for. If a population age for modem humans is taken to be 150 000 years
(Stringer, 2002) and the divergence of chimpanzees as 6 million years ago there is a
discrepancy between the level of diversity seen for the HBV isolates. There is less diversity
within the chimpanzee clade than within the human HBV group, even though there has been
much more time to evolve. The sizes of chimpanzee populations are vastly smaller than those
seen for humans, placing a constraint on the number of different isolates that are able to
circulate within these populations. This in turn will lead to a decreased immune pressure on
the HBV genome to evolve.
To get a truer picture of the HBV carrier rate in wild populations of primates new strategies
for sampling must be developed. Non-invasive sampling of faecal matter and hair from nest
sites are the best way to sample a large number of individuals without disruption. This type of
sampling has proved effective for SIV researchers (Santiago et al., 2003a; Santiago et ah,
2003b). Recently a novel assay for HBV DNA in faecal samples was developed (Makuwa et
ah, 2003), but only one positive sample was identified out of 36 tested. As a high rate of
active infection was detected using plasma samples this may not be a sensitive enough assay.
More sequence data is needed from gorillas and orang-utans to further evaluate the
relationship between HBV carried by these species and HBV carried by their neighbouring
species. The screening of further species for the presence ofHBV, such as bonobos and the
two eastern species of gorilla, as well as more monkey species would also be very helpful in
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the search for the origin ofHBV. The development ofmore sensitive non-invasive assays like
that described above are needed to facilitate this research.
A recent origin of HBV in the different primates with frequent cross-species transmission





6.1 Frequency of viraemia and epidemiology
HBV infection appears to be endemic in both human and non-human primate populations.
Rates of infection of 15% or more can be found in human populations, and current primate
data suggests this level of infection in the ape species as well. The level of diversity seen
within the chimpanzee and gibbon HBV genotypes is also indicative of endemicity. The
distribution of genotypes in human populations was as expected with genotypes A and E in
Africa and C and D in Papua New Guinea. The ape isolates found in this study also fell
within the expected genotypes for each species. The apparent restriction of HBV to apes is
surprising, considering the existence of HBV viruses in rodents and birds. Recombination
analysis and conventional phylogenetic analysis failed to identify any evidence for the
presence of primate-like viruses in humans or human viruses in any of the primates.
Subgroups exist within the non-human primate genotypes, and when looking at chimpanzee
HBV for example, these groups can be compared to the different genotypes that exist for
human HBV.
The transmission networks responsible for maintaining HBV infection within a host
population can be either horizontal or vertical, and both these types have been demonstrated
for gibbons in captivity (Noppornpanth et al., 2003). In Asia the predominant route of
infection is from mother-to-child, whereas in Africa horizontal, or contact, transmission plays
a larger part. Until this type of epidemiological data is published for chimpanzees we can only
assume that transmission follows the same routes as has been demonstrated for gibbons and
humans. The development of sensitive non-invasive screening methods is needed to obtain
this type of data. Similar studies on gibbons in the wild would also provide valuable
information. This type of sampling will be able to provide a better picture of the actual rates
of infection in the wild populations of primates, and will be able to identify any new viruses
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carried by ape species from which none have been reported to date, such as bonobos and the
East African gorilla species. As humans continue to expand their villages, towns and cities
further, the habitats of other primates are disappearing. The collection of epidemiological data
for infections occurring naturally in these primates is very important. As human and primate
habitats get closer the chance of encounters increases. Cross-species transmission of primate
viruses to humans have been documented, and as bushmeat is gaining in popularity in Africa
the risks to human health have to be evaluated (Brooks et al., 2002; Lerche et al., 2001;
Peeters et al., 2002).
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6.2 Geographical distribution of genotypes
A further parallel between human and non-human primate HBV is the existence of
geographically defined clusters of related isolates. In chimpanzees and gorillas these
also correspond very well with the actual species or subspecies that is infected. The
groups seen within the primate genotypes can be compared to the different human
genotypes. Human genotypes A to E and G form a single monophyletic group within
the phylogenetic tree, and the distribution of the genotypes is geographically defined.
The outlying position of the genotype F clade is difficult to explain. There is also
geographical distribution of variants within human genotypes A, C, and D, and
evidence has recently been published suggesting a similar scenario for genotype F in
Central and South America (Devesa et al., 2004). The geographically defined
subgroups may play a role in differences in infectivity and pathogenicity of HBV
variants in different populations. Molecular characterization of these variants will be
important in future investigations ofHBV pathogenicity and treatment.
These geographical variants are also analogous to the variants seen in the non-human
primate genotypes. The geographical origin appears to be more important than
species in determining which HBV variant is found infecting populations. The fact
that the human genotypes show geographical distribution supports this. The
geographical variants within the human genotypes suggest that transmission
networks are localised. Differences in host factors may help explain why this occurs.
The geographical distribution of the HBV genotypes infecting humans and other apes
holds clues as to the origins of these viruses. This will be discussed later.
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The AI analysis carried out in these investigations will provide a helpful tool for
researchers looking to compare differences between patient groups. Certain types of
isolates may be more commonly associated with acute infection, whereas other types
may be more associated with a chronic carrier state, e antigen expressors may have
different types than those infected individuals that do not express e antigen. When
carrying out these analyses one must remember that the genotype of the virus variant
may not be directly responsible for the phenotype seen in the infected individual,
host factors play an important role and must be considered. AI analysis can be
applied to multivariate data sets to compare both host and viral genotypes with the
infection phenotype.
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6.3 Recombination within HBV genomes
A recombinant HBV genome is one which contains distinct genetic elements with
the characteristics of different and distinct genotypes. For recombination to occur,
several criteria have to be met. Multiple genotypes must exist, superinfection with
more than one genotype within the same individual must be possible and occurring,
and a mechanism for recombination must exist. For HBV recombination may take
place during replication of the viral genome, by template swapping.
Recombination between HBV genomes from different genotypes does occur, within
the human genotypes. Little evidence has been published to date to suggest this
occurs also for non-human primate genotypes. This may simply be due to the relative
lack of available sequence data for this HBV group in comparison to human HBV.
One chimpanzee isolate does appear to be recombinant (Takahashi et al., 2001), but
the genotype responsible for donating that part the core gene remains to be identified.
For human HBV recombination occurs most often between genotypes A and D, and
B and C. Considering the geographical distributions of these genotypes these
combinations are not unexpected. The human genotypes split into three main groups
when analysed phylogenetically (Fig. 5-3). One containing the South American
genotypes F and H, one containing genotypes D, E, and G, and one containing A, B,
and C. The close relationship seen between genotype F and H is also seen between
genotypes B and C, and between D and E. This suggests three ancestral human HBV
viruses. The recombination seen between B and C has been proposed as a recent
event (Fares and Holmes, 2002), but considering the phylogenetic relationship
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between these two genotypes it may also be a remnant of a common ancestor. This
could also explain the A and D recombinants.
Recombinants exist that, like the chimpanzee isolate described above, contain
sequence elements that do not belong to any of the known genotypes (Hannoun et al.,
2000b) although initial analyses identified these segments as genotype A. This
suggests that recombinant sequences exist that have not been correctly identified,
which may confuse the genotyping of isolates and lead to false identification of
recombinants. The close relationship seen between chimpanzee and gorilla HBV, and
gibbon and orang-utan HBV suggests recombination may have played a role in the
evolution of these genotypes, in combination with cross-species transmission. HBV
may have initially existed as totally distinct species-specific variants, but through
cross-species transmission and recombination these have evolved into a larger, less
species-specific genotype infecting the African apes. When genotype G was first
reported it was thought to be a recombinant genotype (Stuyver et al., 2000). This all
suggests that recombination may be playing a large and complex role in the evolution
of HBV by creating further variability among circulating virus populations. Further
research needs to be carried out to clarify the mechanisms involved in recombination
and the impact this has on the pathology ofHBV infection.
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6.4 Origins and evolution ofHBV within primates, human and non-human
Each of the primate genotypes has a single origin, and a similar observation can be
made for human genotypes A-E and G, whereas genotypes F and H have a separate
origin to all other FIBV variants. The relationship between F and H is similar to that
between B and C, and D and E. If the "Out of Africa" hypothesis (Magnius and
Norder, 1995; Norder et al., 1994) is applied to this data F and H would represent the
oldest HBV variants. If these genotypes existed at the time ofmigration out ofAfrica
and were spread as far as the New World, the geographical isolation of that region
until around 400 years ago could explain why they are so divergent. The more
continuous movement of humans through Europe, Africa and Asia, due to the
continuous landmass making access to different areas easier, would give more
opportunity for diversification into further genotypes. Founder effects following
migration of populations to new geographically separated areas would lead to a
smaller number of variants circulating among susceptible individuals. This would
mean that they would evolve independently of other virus populations in other areas.
Cross-species transmission and recombination between viral genomes could then
have given rise to new genotypes. This seems to fit the hypothesis, but it fails to
explain why gibbon and chimpanzee HBV variants are more closely related to each
other than they are to the human genotypes that can be found in the same
geographical areas.
If the "New World origin" hypothesis (Bollyky et al., 1997) is applied to the data it
does not fit. The amount of diversity within each genotype is too great to have been
generated in such a short time-span, and the geographical distribution of the
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genotypes, and subtypes within the genotypes, is very difficult to explain if this was
the case. Genotypes F and H are restricted in their distribution to mainly native
populations in Central and South America. Genotypes F and H have not been
reported in any other countries, and this study failed to identify any in the countries
surveyed. Other genotypes can be found in the Americas, but F and H are prevalent,
especially in native populations (Devesa et al., 2004; Pineiro y Leone et ah, 2003).
No data published to date supports this hypothesis for the origin ofHBV.
Cross-species transmission does appear to have played a part in the emergence of the
primate genotypes in Africa and Southeast Asia, but there is no evidence to date to
suggest cross-species transmission between humans and other primate species. There
is, however, no evidence to support the hypothesis of co-speciation/co-evolution as
proposed previously (MacDonald et ah, 2000). The relationship between the ape
genotypes is closer than the relationship between genotypes from the same
geographical areas, i.e. between genotypes B and C and gibbon HBV in Asia, and
genotype E and chimpanzee HBV in Africa. If the position of genotypes F and H
were not as outliers, but as part of the monophyletic group that contains all the other
human genotypes, coevolution would be a possibility, as gibbon HBV appears to
have diverged before chimpanzee HBV, and the human genotypes were the last to
diverge. This agrees with the speciation of the primates. Genotypes F and H do
remain outliers however, making this scenario unlikely.
The data from this study has provided evidence for the correlation between the
geographical origin and sequence divergence. In non-human primates this seems to
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cut across the species-barriers, with African apes sharing a common genotype and in
Asia overlapping habitat ranges between gibbons and orang-utans result in the
clustering ofHBV isolates. A scenario is proposed for the relatively recent spread of
HBV among the African and Southeast Asian primates, with cross-species
transmission between animals in overlapping habitats. This accounts much better for
the geographical association, rather than species association, of HBV genotypes in
these primates than previous co-speciation hypotheses (MacDonald et al., 2000;
Magnius and Norder, 1995; Norder et ah, 1994). This agrees most closely with the
recent origin proposed by Fares (Fares and Holmes, 2002), and the role of humans in
the dissemination ofHBV throughout the world needs to be more fully evaluated.
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6.5 Conclusions
Several different hypotheses have been proposed for the origin ofHBV, but reconstructing the
evolutionary history of human and non-human primate HBV has proven difficult. The
evolution of the viral genome is subjected to constraints on the level of nucleotide change that
can occur without a detrimental effect on virus replication, recombination between different
genotypes is occurring, and the genotypes show geographical distribution which in humans
also is associated with differences in pathology. This study, like previous studies, has
demonstrated the existence of HBV variants which group interspersed with the human
genotypes. No ape isolates have been identified that are as divergent as the human genotypes
F and H or the woolly monkey isolate. One chimpanzee isolate which has a highly divergent
core sequence (Takahashi et ah, 2001) hints at the existence of such divergent variants, but
the species that is its host remains to be identified. Further work is necessary to identify the
original species distribution of these divergent variants, and identifying them will help resolve
the evolutionary history, origin, and past epidemiology of HBV in primates, including
humans. There is also no evidence of cross-species transmission ofHBV between humans and
other primate species in their natural habitats. These findings deepen the mystery of HBV
origins and evolution in humans, and provide a context for ongoing studies ofHBV biological
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Accession Numbers Used for




HBVADW, HVHEPB, S50225, E00010, HUMPRECX, HPBADWZCG, HBVA317,
HBVXCPS, HBVGEN2, HEB344115, AF297625, AF297624, AF297623, AF297622,
AF297621, AF090842, AF090838, AF090839, AF090840, AF090841, AF143298,
AF143299, AF143302, AF143304, AF143307, AY034878, U87742, U87740, U87741,
U87743, U87744, U87745, U87747, U87748, HEB309371, HBVPRESS
GENOTYPE B
AB014366, HPBA1HKK2, HPBA2HYS2, HPBA3HMS2, D50521, D50522, AF79684,
AY033072, AY033073, HBV131133, AF121251, AF121249, AF121247, AF282918,
AF461360, AF461362
GENOTYPE C
HPBETNC, HBV18858, HHVBC, HPBADRC, HPBCG, HPBE8A, HPBH2B, HPBB4HST1,
HPBB5HK01, HPBC5HK02, HPBC6T588, HPBA11A, HPBADRA, HPBADR1CG,
S75184, HBVADR, HBVADR4, HEHBVAYR, HBVADRM, HBVPREX, HHVCCHA,
AF461358, AF233236, NC_001707, AF473543, AF461043, AF458665, AF458664,
AY066028, AF384372, AY057947, AF411408-AF411412, AF182805, AF330110,
AF223961, AY040627, AF384371, AF363961-AF363963, AB048704, AB049610,
AB049609, AB050018, HBV18856, D28880, AF461359, AF461361, AF461363, AB033553,
AB042282-AB042285, AB048705, AF208868, AF208869, HPBC4HST2, HPBCGADR,




HBVGEN1, HPBAYW, HPBHBVAA, U95551, XXHEPAV, HBVAYWMCG, HBVAYWC,
HBVORFS, HBVPRES12, HBVP2CSX, HBVP3CSX, HBVAYWGEN, AF151735,
AF121239-AF121242, HBV132335, HEB344116, HEB344117, AB048701-AB048703,
AB033558, AB033559, AF065110, AF065112, AF065117-AF065119, AF208870,
AF208872, AF208874, AF208877, AF209396, AF209398, AF209401, AF280817,
AF391286, HHVBDS, HHVBD, AF360972-AF360978, AB090269, AB090270
GENOTYPE E
HHVBBAS, HHVBE4, AF323617-AF323636, AF208817, HEB297868, HPBVAR,
HPBSAGA, AB091255-AB09126, AB033272-AB033275, AB166564
GENOTYPE F
HBVADW4A, HHVBF, HHVBFFOU, AB036905-AB036920, AF223962, AF223965,
AB037944-AB037946, AF043561, AF043573, AF043577, AF043578, HHVBFS, AF288623-
AF288628, HBU91803, HBU91805, HBU91806, HBU91807, HBU91808, HBU91811,
HBU91821, HBU91822, HBU91825, HBU91829, HBU91831
GENOTYPE G
AF160501, AF405706, AB064310-AB064313, AB056513-AB056516
GENOTYPE H
AY090457, AY090460, AY090454, HBU91819, HBU91827
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Figure B-l. Recombination analysis of HBV isolate HBVADWE () using the AI (top) and
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Figure B-2. Recombination analysis of HBV isolate AF297620 () using the AI (top) and
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Figure B-3. Recombination analysis of HBV isolate AF241407 () using the AI (top) and














Figure B-4. Recombination analysis of HBV isolate AF241409 () using the AI (top) and
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Figure B-5. Recombination analysis of HBV isolate HBVDNA () using the AI (top) and
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Figure B-6. Recombination analysis of HBV isolate AB031265 () using the AI (top) and
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Figure B-7. Recombination analysis of HBV isolate AY057948 () using the AI (top) and














































































































































































































Figure C-l. Phylogenetic analysis of HBV isolate HBVAYWE, reported to be an A/D




































































































































Figure C-2. Phylogenetic analysis of HBV isolate AF297620, reported to be an A/D












































































































Figure C-3. Phylogenetic analysis of HBV isolate AF241409, reported to be an A/C
recombinant. Analysis supports recombinant result fro AI and SimPlot analysis, and shows



























































Figure C-4. Phylogenetic analysis of HBV isolate HBVDNA, reported to be an A/D
recombinant. Genotype A is highlighted in the green box, genotype D in the blue box, and the


















































































































































































Figure C-5. Phylogenetic analysis of HBV isolate AB031265, reported to be a B/C
recombinant. Genotype B is highlighted in the grey box, genotype C in the yellow box, and


































































































































Figure C-6. Phylogenetic analysis of HBV isolate AY057948, reported to be a C/D
recombinant. Genotype C is highlighted in the yellow box, genotype D in the blue box, and




















































































Figure C-7. Phylogenetic analysis of HBV isolate AF241407, reported to be an A/C
recombinant. Genotype A is highlighted in the green box, genotype C in the yellow box,
genotype G in the pink box and the isolate in the red box. Phylogenetic analysis supports the
AI and SimPlot findings that this is not an A/C recombinant, but may be a recombinant with





Results for the Two Methods Used
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Figure D-l. Recombination analysis ofHBV isolate HBVP6PCXX (Bowyer, 2000) using the
AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a
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Figure D-2. Recombination analysis of HBV isolate AF297619 (Owiredu et al., 2001) using
the Al (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant, SimPlot -
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Figure D-3. Recombination analysis of HBV isolate AF121245 (Hannoun et al., 2000) using
the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant, SimPlot -
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Figure D-4. Recombination analysis of HBV isolate AB100695 (Tran et al., 2003) using the
AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a
divergent core region, SimPlot - recombinant in the core region.
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Figure D-5. Recombination analysis ofHBV isolate AF100308 (Fares & Holmes, 2002) using
the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant, SimPlot -
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Figure D-6. Recombination analysis ofHBV isolate AF100309 (Fares & Holmes, 2002) using
the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant, SimPlot -
recombinant in the core region.
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Figure D-7. Recombination analysis ofHBV isolate HPBADW2 (Bowyer, 2000) using the AI
(top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant, SimPlot -
recombinant in the core region.
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Figure D-8. Recombination analysis of HBV isolate HPBADW3 (Norder et al., 2003) using
the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant divergent
across the entire genome, SimPlot - recombinant in the core region with a divergent fragment
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Figure D-9. Recombination analysis ofHBV isolate HPBADWZ (Bowyer, 2000) using the AI
(top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant divergent across
the entire genome, particularly the region spanning the S gene and Pol overlap, SimPlot -
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Figure D-10. Recombination analysis ofHBV isolate HBVP4CSX (Bowyer, 2000) using the
AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a
divergent P/X region, SimPlot - recombinant in the core region.
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Figure D-ll. Recombination analysis of HBV isolate HBVCWGITY (Bowyer, 2000) using
the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant, SimPlot -
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Figure D-12. Recombination analysis of HBV isolate AB073821 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a
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Figure D-13. Recombination analysis of HBV isolate AB073822 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-14. Recombination analysis of HBV isolate AB073823 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a
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Figure D-15. Recombination analysis of HBV isolate AB073824 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-16. Recombination analysis of HBV isolate AB073826 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-17. Recombination analysis of HBV isolate AF073827 (Sugauchi et la., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AT - non-recombinant,
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Figure D-18. Recombination analysis of HBV isolate AB073828 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
SimPlot - recombinant in the core region.
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Figure D-19. Recombination analysis of HBV isolate AB073829 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-20. Recombination analysis of HBV isolate AB073830 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a
divergent core region, SimPlot - recombinant in the core region.
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Figure D-21. Recombination analysis of HBV isolate AB073831 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
SimPlot - recombinant in the core region.
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Figure D-22. Recombination analysis of HBV isolate AB073833 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-23. Recombination analysis of HBV isolate AB073834 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-24. Recombination analysis of HBV isolate AB073835 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant
divergent across the entire genome, SimPlot - recombinant in the core region.
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Figure D-25. Recombination analysis of HBV isolate AB073836 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
SimPlot - recombinant in the core region.
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Figure D-26. Recombination analysis of HBV isolate AB073837 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-27. Recombination analysis of HBV isolate AB073839 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant with a
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Figure D-28. Recombination analysis of HBV isolate AB073840 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
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Figure D-29. Recombination analysis of HBV isolate AB073841 (Sugauchi et al., 2002b)
using the AI (top) and SimPlot (bottom) methods. Interpretation: AI - non-recombinant,
SimPlot - recombinant in the core region.
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Appendix E
AI and SimPIot Analysis of Primate
isolates
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Figure E-l. AI and SimPlot analysis of the gorilla sequence, using the combined
gibbon/orang-utan group.
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Figure E-2. AI and SimPlot analysis of a chimpanzee control sequence using separate groups
for chimpanzee and gorilla (A) and the combined chimpanzee and gorilla group (B).
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Figure E-5. AI and SimPlot analysis of the complete genome sequence ofHBV isolated from
gibbon Wendy.
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Figure E-6. AI and SimPlot analysis of the complete genome sequence ofHBV isolated from
gibbon TB Black.
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Figure E-9. AI and SimPlot analysis of the complete genome sequence ofHBV isolated from
a chimpanzee, accession number AB032431.
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Figure E-10. AI and SimPlot analysis of the complete genome sequence ofHBV isolated from
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Figure E-l 1. AI and SimPlot analysis of the complete genome sequence ofHBV isolated from
a chimpanzee, accession number AB046525.
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Abstract
Infection with hepatitis B virus (HBV) has been detected in human populations thoughout the world, as well as in a number of ape species
(Pan troglodytes, Gorilla gorilla, gibbons [Nomascus and Hylobates species] and Pongo pygmaeus). To investigate the distribution of
naturally occurring HBV infection in these species and other African Old World monkey species (Cercopithecidae), we screened 137 plasma
samples from mainly wild caught animals by polymerase chain reaction (PCR) using several of highly conserved primers from the HB
surface (HBs) gene, and for HBs antigen (HBsAg) by EL1SA. None of the 93 Cercopithecidae screened (6 species) showed PCR or serology
evidence for HBV infection; in contrast 2 from 8 chimpanzees and 5 from 22 gibbons were PCR-positive with each set of primers.
Complete genome sequences from each of the positive apes were obtained and compared with all previously published complete and
surface gene sequences. This extended phylogenetic analysis indicated that HBV variants from orangutans were interspersed by with HBV
variants from southerly distributed gibbon species (H. agilis and H. moloch) occupying overlapping or adjacent habitat ranges with
orangutans; in contrast, HBV variants from gibbon species in mainland Asia were phylogenetically distinct. A geographical rather than
(sub)species association of HBV would account for the distribution of HBV variants in different subspecies of chimpanzees in Africa, and
explain the inlier position of the previously described lowland gorilla sequence in the chimpanzee clade. These new findings have a number
of implication for understanding the origins and epidemiology of HBV infection in non-human primates.
© 2003 Elsevier Inc. All rights reserved.
Introduction
Infection with hepatitis B virus (HBV) is a major global
health problem, and is estimated to account for approxi¬
mately one million deaths from chronic liver disease and
hepatocellular carcinoma each year (Thomas and Jacyna,
1993). High frequencies of active infection, ranging from
8-15% are found in South and East Asia, sub-Saharan
Africa and amongst indigenous peoples in Central and
South America (Andre, 2000). In Asia this endemic pattern
of HBV infection is primarily maintained through mother-
to-child perinatal transmission and establishment of a highly
infectious carrier state that transmits infection to the next
* Corresponding author. Fax: +44-131-650-6511.
E-mail address: Peter.Simmonds@ed.ac.uk (P. Simmonds).
generation. In contrast, horizontal transmission is the pre¬
dominant mechanism in Africa.
Although HBV (classified as a member of the Hepad-
naviridae) contains a DNA genome, replication occurs
through an RNA intermediate sequence analogous to the
genomic RNA sequence of retroviruses. The copying of
DNA from sequences from genomic DNA templates, and
from the intermediate RNA transcript, is carried out by a
virally encoded polymerase protein. The lack of proof¬
reading during viral transcription introduces a high fre¬
quency of mutations into the copied sequences (Hannoun
et al., 2000). Indeed, HBV populations are characterized
by a moderate degree of genetic diversity, with a total of
8 currently classified genotypes infecting human popula¬
tions worldwide, differing from each other by nucleotide
sequence distances of approximately 10-13%. Geno¬
types A, D and possibly G have global distributions,
0042-6822/03/$ - see front matter © 2003 Elsevier Inc. All rights reserved,
doi: 10.1016/S0042-6822(03)00430-6
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genotypes B and C are found predominantly in East and
South East Asia, genotype E in West Africa, and geno¬
types F and H amongst various population groups, in¬
cluding indigenous peoples, in Central and South Amer¬
ica (Norder et al., 1994; Arauz-Ruiz et al., 1997; Arauz-
Ruiz et al., 2002).
Recently, we (MacDonald et al., 2000) and others
(Takahashi et al., 2000; Hu et al., 2000; Vartanian et al.,
2002; Hu et al., 2001) have documented the existence of
HBV infection in chimpanzees in the wild, findings
which add to other descriptions of frequent infection of
gibbons and orangutans in South East Asia (Warren et al.,
1999; Grethe et al., 2000; Verschoor et al., 2001; Nop-
pornpanth et al., 2003). Nucleotide sequencing of HBV
recovered from these ape species revealed the existence
of new genotypes of HBV generally specific to each
species, although with some exceptions, such as the de¬
tection of a human genotype E variant in a captive chim¬
panzee (Takahashi et al., 2000), the close relatedness of
HBV recovered from a lowland gorilla to chimpanzee
sequences (Grethe et al., 2000), and the detection of a
gibbon-like HBV sequence in a captive chimpanzee (Gre¬
the et al., 2000).
Apart from humans and non-human primates, far more
divergent HBV-like viruses have been detected in New
World rodents such as the woodchuck (Marmota monax),
and squirrel species (Spermophilus beecheyi, S. parryii),
and a range of bird species (ducks, geese, and grey
heron). The evolutionary history of HBV in these various
host species has been the subject of great debate over the
past 5 years, principally fueled by the difficulty in rec¬
onciling the frequently interspersed genotype distribu¬
tions of human and non-human primate sequences that
seems to fit neither hypothesis for very recent or very
ancient origins for HBV (Magnius and Norder, 1995;
Norder et al., 1994; MacDonald et al., 2000) [reviewed in
(Simmonds, 2001)]. In the current study, we have at¬
tempted to discover more about the distribution of HBV
infection in apes and Old World monkey species (Cer-
copithecidae) using a large archive of stored serum and
plasma samples from a wide range of different African
and South East Asian primate species. Combining the
new data obtained in this study with recently published
sequences from gibbons, orangutans and chimpanzees
(Vaudin et al., 1988; MacDonald et al., 2000; Takahashi
et al., 2000; Hu et al., 2000; Hu et al., 2001; Warren et
al., 1999; Grethe et al., 2000; Verschoor et al., 2001;
Noppornpanth et al., 2003; Takahashi et al., 2001;
Vartanian et al., 2002), we have been able to carry out
comprehensive genetic comparisons of the expanded
dataset of primate and human-derived HBV variants that
indicates that geographical separation in primates ex¬
plains genotype distributions of HBV better than species
associations.
Results
Detection ofHBV infection in non-human primates
To determine the frequency of active HBV infection in
Apes and Old World primate species, we screened available
plasma or serum samples collected from a range of species
by PCR using previously described primers from the pre-S
and S region (SI, S2). All samples had been screened for
HBsAg by commercially available ELISAs. The pre-S and
S primers were conserved between human genotypes A-G,
the more divergent F and H genotypes, and all published
HBV sequences recovered from non-human primates in¬
cluding the HBV variant obtained from New World woolly
monkey species (Fig. 1A and B).
Results from the two sets of primers were concordant
with each other and with the results of HBsAg screening
with the exception of 1 HBsAg positive chimpanzee that
was DNA negative. The frequency of detection of active
HBV infection depended on the host species. Within the
apes, we detected 2 HBV-positive samples from the 8 chim¬
panzees screened, 5 from the 22 gibbons species, and none
from 14 orangutans (total prevalence of active infection in
apes: 7/44 [15.9%]). In contrast, none of the 93 samples
available from a total of 6 Old World Monkey species were
positive in either PCR assay, nor confirmed positive for
HBsAg. The observed restriction of HBV injection to apes
and the frequency of active infection found in this study was
consistent with previous surveys of HBV infection in pri¬
mates (Table 1; see Discussion). Further evidence for a lack
of HBV infection in these samples of Old World monkey
species was provided by the lack of detectable antibodies to
the HBV core protein (anti-HBc), used diagnostically as an
indication of past resolved infection in samples negative for
HBsAg.
Previous studies have demonstrated that non-human pri¬
mates are generally infected with species-specific genotypes
of HBV (Vaudin et al., 1988; MacDonald et al., 2000;
Takahashi et al., 2000; Hu et al., 2000; Hu et al., 2001;
Warren et al., 1999; Grethe et al., 2000; Verschoor et al.,
2001; Noppornpanth et al., 2003; Takahashi et al., 2001;
Vartanian et al., 2002). Therefore, one explanation for the
apparent absence of HBV infection in Old World monkey
species is that the putative variants of HBV perhaps present
in these more evolutionarily distant species may be too
divergent to be detectable by conventional HBV primers
and hence too different antigenically to be detectable by
conventional HBsAg or anti-HBc screening. To investigate
this possibility, we developed a new set of primers (S3)
from a highly conserved region of the surface gene that
matched not only all human and non-human primate HBV
variants, but also the sequences of each of the HBV-like
viruses recovered from rodents (ground and arctic squirrels,
woodchuck; Fig. 1C). The new primers showed equivalent
sensitivity for human and primate HBV sequences as the SI
and S2 primers for human and primate genotypes of HBV
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Primer SI Primer S3
CATCA GGAYTCCTAG GACCCCT CGTGTTACAG GCGGKGTKTT TCTTGT
163 223





Primer S6 Primer S5
CTACACAGA CGCCGCAAAA TAGTA GG AGAMGTAGGA CGACGATACG GAG
371 432
CGCT GGATGTGTCT GCGGCGTTTT ATCATATTCC TCTTCATCCT GCTGCTATGC CTCATCTT















C) S3 (Highly conserved region)
Primer 21
primer GACTT CTCTCARTTT TCYAGGGG
257 289
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TCAG TCCGTTTCTC TTGGCTCAGT TTACTAGTGC
Fig. 1. Sequence conservation of HBV and HBV-like virus sequences from primates and rodents in regions of the genome targeted by SI, S2 and S3 primer
sets used for PCR. Primer sequences were compared with consensus sequences from the human HBV genotypes A-H (H-A to H-H), consensus sequences
from chimpanzee, gibbon, orangutan (CH, GN, OT), and the woolly monkey sequence (WM). The lower panel for each alignment contains HBV-like virus
sequences from North American rodent species, ground squirrel (GS), arctic ground squirrel (AGS) and woodchuck (WC, OHVCGC). For each alignment,
differences from the consensus genotype A sequence was shown; primer sequences included degenerate bases (represented by the codes: M: A/C; Y: C/T;
R: A/G; K: G/T) in variable regions. Alignment numberings refer to a minimal alignment of human and primate derived HBV sequences listed in the Methods
section.
(data not shown). However, screening of this sample of Old
World primate species failed to detect any additional cases
of HBV infection (Table 1).
Species and sub-species identification of HBV-infected
apes
Of the two chimpanzees positive for HBV DNA, one
(Osang) originated from Central Africa and its subspecies
identification as P. troglodytes vellerosus was determined
by mitochondrial sequencing. The other infected chimpan¬
zee (Louisa) originated from Cameroon and belonged to the
troglodytes subspecies. The infected gibbons belonged to
species H. lar (Tamang), H. agilis (Crazy Woman), N.
concolor (Happy) and N. gabriellae (Wendy). This species
information was provided by the Welsh Mountain Zoo and
the rescue centre respectively. It was not possible to obtain
a species assignment for the final HBV-infected gibbon
analyzed in the study (TB Black), although it was possible
to identify it as belonging to the Hylobates genus and most
likely belonging to the agilis or moloch subspecies as Mi¬
tochondrial 12S region sequences for these species were
interspersed when compared phylogenetically (data not
shown).
Sequence comparison of HBV sequences from non-human
primates
Sequence relationships between the 7 (from 44) ape
samples positive for HBV DNA by PCR with previously
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Table 1
Frequencies of detection of HBV DNA sequences, HBsAg and anti-HBc in current and previous studies of primates
Species PCR* Total Active* anti-HBc Reference
S1/S2 S3 PCR* HBsAg lnfection (%)
APES
Gorilla gorilla spp. — — 7/18 2/15 7/18(39%) — (Grethe et al., 2000; Zuckerman et al., 1978;
Linnermann, Jr. et al., 1984; Thornton et al., 2001;
Worley and Stalis, 2002)
Pan troglodytes spp. 2/8 — 28/38 38/496 54/517(10.5%) 2/6 This study, (Takahashi et al., 2000;
MacDonald et al., 2000; Hu et al., 2000;
Takahashi et al., 2001; Hu et al., 2001;
Grethe et al., 2000; Zuekerman et al., 1978)
(Vaudin et al., 1988) (Deinhardt, 1976;
Ogata et al., 1993; Eichberg and Kalter, 1980)
Hylobates spp. 5/22 — 53/177 35/191 55/213 (25.8%) 48/130 This study, (Grethe et al., 2000; Norder et al., 1996;
Lanford et al., 2000; Vaudin et al., 1988;
Deinhardt, 1976; Thornton et al., 2001;
Noppornpanth et al., 2003)
Pongo pygniaeus spp. 0/14 — 32/104 58/141 58/297 (19.5%) 1/14 This study, (Warren et al., 1999; Davis et al., 2000;
Vaudin et al., 1988; Deinhardt, 1976)
Total Apes 7/45 — 120/337 133/843 174/1045 (16.7%) 51/150
OLD WORLD MONKEYS
Papio spp. — — 0/4 0/168 0 0/103 (Deinhardt, 1976; Michaels et al., 1996;
Eichberg and Kalter, 1980)
Cercopithecus aetiops — — — 0/19 0 — (Eichberg and Kalter, 1980)
Cercopithecus torquatus 0/4 0/4 0/4 0/4 0 0/4 This study
Cebus albifrons — — — 0/10 0 — (Eichberg and Kalter, 1980)
C. mona 0/3 0/3 0/3 0/3 0 0/3 This study
C. nictitans 0/2 0/2 0/2 0/2 0 0/2 This study
C. erythrotis 0/3 0/3 0/3 0/3 0 0/3 This study
Mandrillus leucophaeus 0/78 0/78 0/78 0/78 0 0/78 This study
M. sphinx 0/2 0/2 0/2 0/2 0 0/2 This study
Total OWM 0/102 0/102 0/96 0/289 0 0/195
NEW WORLD MONKEYS
Lagothrix lagotricha — — 10/35 7/31 10/33 — (Lanford et al., 1998)
Saimiri sciureus — — — 0/20 0 — (Eichberg and Kalter, 1980)
Callithrix jacchus — — — 0/6 0 — (Eichberg and Kalter, 1980)
Saguinus oedipus — — — 0/12 0 — (Eichberg and Kalter, 1980)
Total NWM — — 10/58 7/69 10/33 (30%) —
* PCR results from pre-S and S gene primers (SI, S2), and from highly conserved primers (S3; Fig. 1C) from this study.
* Combined PCR results from current survey and from previous studies (cited in last column).
* Combined results for PCR-positivity and detection of HBsAg indicating active HBV infection.
described variants of HBV from human and non-human
primates were investigated by determination of their com¬
plete genome sequences and phylogenetic analysis. HBV
variants included in the analysis comprised all previously
published full length HBV sequences from non-human pri¬
mates and 10 representative sequences from each of the
human genotypes A-H. The maximum likelihood tree of
these data provided bootstrap support for each human ge¬
notype and primate-associated species, with the exception
of gibbon and orangutan sequences (Fig. 2). However, other
than the close relationships between genotypes D and E, and
F and H, there was little support for any other inter-clade
relationship. A separate comparison of S gene sequences
was also carried out to enable several further partial
genomic sequences from primates to be included in the
analysis (Fig. 3; see below).
Chimpanzee sequences
Both complete genome and surface gene sequences from
the two HBV-infected chimpanzees (Louisa, Osang)
grouped consistently with other previously published se¬
quences (Fig. 2 and 3A). This together with the handling
and testing history is consistent with infection in the wild.
Within the divergent clade of chimpanzee sequences, indi¬
vidual sequences fell into a variety of groups, with a strong
association with subspecies and/or geographical origin (Fig.
4A). For example, clusters were observed corresponding to
verus subspecies from West Africa (whole genome se¬
quences AB032433, HPBVCG, AB032432, AB032433,
AF222323 and Chimp 4), troglodytes from Central Africa
(AF222322, Chimp 2 and Louisa), vellerous from Central-
West Africa (Osang, AF305327), and a separate clade for
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□ Gorilla gorilla gorilla
O P. I. schweinfurthii
A P. t. vellerosus
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Fig. 2. Maximum likelihood phylogenetic tree for 99 complete HBV genomes (3342 bp) representing human genotypes A to H and all ape HBV sequences
with the single woolly monkey HBV sequence as an outgroup. Neighbor-Joining bootstrap values (>75%) for major groupings are indicated on the relevant
nodes. All horizontal branch lengths are drawn to scale.
the single Schweinfurthii (East African) HBV variant
(AF498266). The only sequence that failed to group within
its sub-species group was AB046525 obtained from a cen¬
tral African troglodytes species; this may be because it
contains an unusual core gene sequence thought to have
originated through recombination with a highly divergent
and hitherto undiscovered entirely separate genotype of
HBV (Takahashi et al., 2001) (see below). Similar grouping
of sequences into subspecies- or geographically-associated
clades was found on analysis of partial S gene sequences.
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Fig. 3. Maximum likelihood phylogenetic trees of partial S gene sequences (689 bp) from (A) chimpanzees and (B) gibbons and orangutans. The chimpanzee
tree is rooted using a single gibbon sequence (Tamang) and the gibbon/orangutan tree is rooted using a chimpanzee sequence (Osang). Neighbor-Joining
bootstrap values (>75%) for major groupings are indicated on the relevant nodes. All horizontal branch lengths are drawn to scale.
Finally, the single available sequence from the gorilla
(HBV131567) fell into its own unique clade within the chim¬
panzee genotype, an unexpected position if it is assumed that
HBV variants are species (and sub-species)-specific, but not
inconsistent with the alternative hypothesis for a geographical
basis for the observed sequence groups. As indicated (Fig. 4A),
western lowland gorillas share their geographical range with
the troglodytes subspecies of chimpanzee in Central Africa.
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Interestingly, the gorilla-derived sequence groups most closely
with HBV sequences from this subspecies on comparison of
complete genome sequences (Fig. 2), although this similarity
does not lead to a bootstrap supported G. gorilla/P.t.trogl-
odytes clade, nor is this similarity apparent upon sequence
comparison of the surface gene fragment (Fig. 3A).
Gibbon sequences
Complete genome sequences from 5 gibbons were ob¬
tained and compared with the 12 previously published HBV
sequences from gibbon species and with those from two
orangutans, and the single chimpanzee sequence (Fig. 2). As
with the chimpanzee sequences, there was evidence for
marked clustering ofHBV sequences according to their host
species, although the total sequence divergence within the
clade was greater than found amongst the chimpanzee sub¬
species, and much greater than within human genotypes.
There was also greater lineage differentiation within the
gibbon sequence group, including well defined sequence
clusters of sequences from H. lar, nomascus species (N.
concolor, leucogenys and gabriellae) and from H. pileatus
and a series of divergent single sequences, including those
from Happy, TBBlack and CrazyWoman obtained in the
current study. Lack of strict species-specificity of HBV
variants was demonstrated in the S gene fragment by
the highly divergent sequences obtained from H. moloch
and agilis (CrazyWoman, AF213010, AF213008 and
AF213009), the relation of an HBV variant from N. con-
color (HBV 131573) with these sequences and its failure to
group with the main clade of concolor sequences (Fig. 3).
Other anomalies include the outlier positions of the H.
pileatus variant (AF477488) and the highly divergent se¬
quence we obtained from Happy (N. gabriellae).
If a broader division of gibbon species into the hylobates
(moloch, agilis, pileatus and lar species) and nomascus
(concolor, leucogenys and gabriellae species) genera is
made, there is still no association between host and HBV
phylogeny. However, the greatest discordance between
HBV grouping and species of origin is demonstrated by the
phylogenetic position of the HBV sequences obtained from
orangutans. The two complete genome sequences
(NC_002168 and AF193864), and the further 5 partial S
gene sequences (HBVY17559-HBVY17565) grouped
closely together, but they consistently fell within the gibbon
clade, in an analogous manner to the position of the lowland
gorilla sequence within chimpanzee sequences (see above).
A better correlation was observed between geographical
origin and/or host range of the HBV-infected species with
the phylogenetic clustering ofHBV variants recovered from
them. The gibbon and orangutan sequences can be divided
into three main groups, the first of which contains orangutan
HBV variants and those infecting two of the hylobates
species, which inhabit the Southern region of SE Asia, and
overlap in range with orangutans. The second group con¬
tains sequences from northerly distributed nomascus species
of gibbons and H. lar, distributed predominantly in Central
Thailand and Laos. HBV variants infecting H. pileatus, a
gibbon species inhabiting Cambodia and Central Thailand
made up the third clade of sequences.
The main inconsistency with the phylogeny of gibbon-
derived HBV sequences is the anomalous position of the
chimpanzee-derived HBV variant, HBV131575. This se¬
quence groups with a number of HBV variants infecting H.
lar, including HBV131571 from the same study (Grethe et
al., 2000). This is the only case where an HBV variant
infecting a non-Asian primate groups with gibbon and or¬
angutan sequences, and further information is required on
whether a cross-species transmission of HBV could have
occurred in captivity.
Discussion
Host range and epidemiology ofHBV in primates
Our PCR-based and serological survey of a wide range
of Old World primate species provided further evidence for
a substantial restriction of HBV infection to apes (Table 1),
and is consistent with previous observations for the absence
of detectable HBV infection in Old World monkey species
(Deinhardt, 1976; Michaels et al., 1996; Eichberg and
Kalter, 1980). Combining data from this and previous sur¬
veys, HBV infection appears to be common in all species of
apes, with combined rates of PCR-positivity and/or HBsAg
carriage of 16.7% (Table 1). This rate of active infection is
remarkably similarly to that of human populations in areas
of endemic infection, such as Central Africa and South East
Asia.
Further parallels between the epidemiology of HBV in¬
fection in human and non-human primates is provided by
the evidence for efficient mother-to-child transmission of
HBV in captive primate species (Noppornpanth et al., 2003;
Lanford et al., 2000). In humans, such perinatally acquired
infections generally lead to lifelong HBV high infectivity
carriage associated with partial immunotolerance and the
production of the HBV "e" antigen (HBeAg). Persistent
infection of females perpetuates the infection cycle to each
succeeding generation. Observations of frequent vertical
transmission in captive gibbons (Noppornpanth et al., 2003)
supports the hypothesis that this may also be an important
mechanism for the maintenance of HBV infection in gib¬
bons and potentially other ape species in the wild.
One explanation for the failure to detect HBV infection
in Old World monkey species is that they were infected with
HBV variants so divergent in sequence from previously
described HBV variants infecting humans and other pri¬
mates that they would be refractory to amplification with
conventional primers, and be serologically non-cross-reac-
tive with reagents used in HBsAg and anti-HBc assays.
Such viruses would therefore have to be more divergent
than the outlier HBV variant found in a captive woolly
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monkey (Lanford et al., 1998). To address this issue we
re-screened the Old World monkey species by PCR using
primers that matched even the highly divergent HBV-like
viruses infecting North American rodents. Our failure to
detect a single additional case of HBV infection in the 93
African monkey samples available provided further evi¬
dence for an absence of infection of hepadnaviruses in these
species of the Cercopithecidae, although it is possible that
this picture may change with more extensive sampling in a
greater range of species (see below).
Why HBV infection in the wild should be generally
restricted to apes remains unclear at this stage. Given this
highly selective distribution of HBV infection in Old World
species, the existence of HBV infection in woolly monkeys
(a New World primate species) becomes more difficult to
account for. A total of 10 infected animals have been re¬
ported be HBV-infected in a US zoo, although a previous
serological survey of three other New World primate spe¬
cies (owl monkey, tamarind, and squirrel monkey) have
failed to detect evidence of active of past HBV infection in
this group [Table 1; (Eichberg and Kalter, 1980)]. Clearly
further surveys would be required to determine whether
HBV infection is present in wild caught monkeys in South
America.
HBV origins
Reconstructing an evolutionary history ofHBV using the
data set of sequences of HBV variants infecting humans and
other primates has proven to be both complex and difficult
to reconcile with theories of either recent or remote times of
origin (Bollyky et al., 1997; Magnius and Norder, 1995;
Norder et al., 1994; MacDonald et al., 2000; Simmonds,
2001). The new sequence information obtained in this pa¬
per, and the combined analysis with the much larger dataset
of HBV sequences now available from other studies, has
provided strong evidence for a correlation between geo¬
graphic origin of infection and sequence divergence that
cuts across species barriers of non-human primates. Thus,
HBV sequences from Central Africa group together, irre¬
spective of their origin in chimpanzees or gorillas. A similar
picture is observed in South Eastern Asian primates where
gibbon and orangutan HBV sequences cluster together and
their host species have overlapping geographic ranges.
Understanding the epidemiology of HBV infection in
non-human primates is additionally complicated by the dif¬
ficulty in constructing a time-scale for the divergence of the
current distribution of variants found in non-human species.
However, short-term rates of HBV sequence change have
been determined for HBV infecting humans, with evidence
for a higher rate of sequence change in individuals who
mount an effective immune response to infection. Based on
the HBeAg/anti-HBe status, mean frequencies of fixation of
nucleotide substitution range from 2.1 to 25 X 10~5 nucle¬
otide change per site per year (Hannoun et al., 2000). As
HBeAg carriage (associated with a slower rate of sequence
change) is typically associated with early acquisition of
HBV infection from vertical transmission, a mode of trans¬
mission that maintains HBV infection in human populations
and potentially in primates (Noppornpanth et al., 2003), the
sequence divergence of HBV variants infecting different
subspecies of chimpanzee can be conservatively estimated
as ranging at most from 1600 to 2200 years (mean sequence
divergence 7%; rate of sequences change 2.1 X 10~5 nu¬
cleotide change per site per year). A similar time-scale for
HBV evolution was inferred using non- overlapping regions
of the HBV genome (Fares and Holmes, 2002).
The calculated time-scale of HBV evolution implied by
measurement of rates of sequence change over short inter¬
vals indicates that the current wide distribution of HBV
infection in apes must have arisen through several cross-
species or subspecies transmissions in the relatively recent
past. For example, HBV transmission following limited
population contact between different ape species in South
Eastern Asia (including between orangutans and gibbons),
and between subspecies of chimpanzee and with gorillas
with Africa may have provided the necessary conditions for
both the introduction and subsequent differentiation ofHBV
genetic clusters into otherwise separate host populations.
In contrast to the co-speciation hypotheses discussed
below, the recent emergence hypothesis for HBV infection
in primates resolves many of the unexpected phylogenetic
groupings evident from the comparison of the much larger
datasets of ape-derived HBV sequences (Fig. 3). Despite the
previous claim for the existence for an orangutan-specific
genotype of HBV (Warren et al., 1999; Verschoor et al.,
2001), the availability of a larger number of gibbon se¬
quences, including those obtained in the current study,
clearly places orangutan-derived variants deep into the gib¬
bon clade of HBV sequences. Indeed, they show the closest
genetic relationship with HBV variants infecting hylobates
species with geographically close or overlapping habitat
ranges. In contrast, HBV variants infecting H. lar and the
nomascus gibbons from mainland Asia generally group sep¬
arately.
The lack of sequence diversity of HBV sequences be¬
tween separate infected orangutans further suggests that the
introduction of HBV into this species may have been rela¬
tively recent. Indeed, the absence of HBV infection in our
sample of 14 wild caught orangutans from Borneo suggests
that HBV infection may not be so widely distributed geo¬
graphically in this species as it evidently is in gibbons, and
more consistent with recent introduction. Recent cross-spe¬
cies transmission events may also account for the close
relationship between the single available gorilla-derived
HBV variants with HBV infecting the troglodytes subspe¬
cies of chimpanzee whose ranges overlap in Central Africa
(Fig. 2 and 3A), although more sequence information of
HBV infecting other gorillas in the wild is required to
substantiate this further possible example of cross-species
transmission in the wild.
An alternative explanation of the distribution of non-
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human HBV genotypes in Africa and South East Asia pro¬
poses that the distinct genotypes of HBV in different pri¬
mate species arose during the evolution of different ape
species over the past 20 million years. However, the implied
very low rate of nucleotide substitution of HBV over these
extended periods of host diversification is incompatible with
extrapolations of the previously calculated rate of HBV
sequence change over short observation periods. For exam¬
ple, while we estimate that the sequence divergence ofHBV
infecting different subspecies of chimpanzees arose
«1600-2200 years ago, the times of host species diver¬
gence range from 0.8 million years for the divergence be¬
tween subspecies of chimpanzees from Central Africa (trog¬
lodytes, vellerosus and schweinfurthii subspecies) and an
estimated 1.5 million years between these subspecies and
P.t. verus from West Africa (Morin et al., 1994). Similarly,
extrapolating from the above rates of sequence change, the
radiation of gibbon- and orangutan-associated HBV variants
can be timed as no more than 3500 years, a time-scale
difficult to equate with the species and/or geographic dif¬
ferentiation of HBV variants in the wide range of primates
infected with HBV.
In defence of the co-speciation hypothesis, it could be
argued that constraints on sequence change, such as the
unusual and extensive use of overlapping reading fames for
protein coding in the HBV genome, as well as the role of
RNA structures in transcription and translation (Mizokami
et al., 1997) may prevent the simple and relatively uncon¬
strained fixation of neutral mutations. For example, the
absence of true synonymous sites in over 65% of the ge¬
nome through the use overlapping reading frames, and the
existence of cis-acting RNA structures required for HBV
transcription and translation may lead to a rapid saturation
of sequence substitutions and homoplasy in the (relatively
few) phenotypically unconstrained sites, although low rates
of divergence were also observed in non-overlapping re¬
gions of the HBV genome (Fares and Holmes, 2002). The
loss of the variable, phylogenetically informative sites
through homoplasy would therefore explain the instability
of any sequence grouping of HBV variants below the level
of (human) genotype or of non-human primate genetic
groupings. More importantly, extensive homoplasy would
prevent the extrapolation of the short term rate of sequence
change of HBV (over 10 years) to the longer periods un¬
derlying the differentiation ofHBV into separate genotypes.
However, no permutation of the co-speciation hypothesis
can explain the inlier position of orangutan-derived HBV
variants within the clade containing gibbon sequences (Fig.
2 and 3B), or the anomalous position of the lowland gorilla
HBV sequence in the chimpanzee HBV phylogeny. Even
more seriously, it fails to account for the substantial se¬
quence diversity of HBV variants infecting humans. While
it might be possible to compress human genotypes A to E
and G into a single group that reproduces the diversity of
HBV sequences found in gibbons (and orangutans), this
approach cannot account for the outlier position of geno¬
types F and H. Nor can the diversity of HBV variants
infecting humans, with a maximum population age of
150,000 years (Stringer, 2002), be reconciled with the much
more restricted sequence diversity of HBV variants infect¬
ing the several subspecies of chimpanzee which diverged
over a time-scale 10 times greater, or different species of
gibbon that diverged even longer ago.
Secondly, the hypothetical restrictions on sequence di¬
vergence can not explain how HBV-like viruses infecting
rodents and birds have become so divergent from human
and primate HBV variants over maximum chronological
times of 100 to 300 million years. Even against the yardstick
of these much longer periods for sequence diversification,
greater sequence divergence and an outlier position for
gibbon-derived HBV sequences would be expected to be
resolvable over the 15 million years of ape diversification.
In summary, the proposed scenario for the relatively
recent spread of HBV among African and South East Asian
primates and cross-species transmission between animals in
adjacent or overlapping ranges accounts much better for the
geographical rather than the species association of HBV
genotypes in non-human primates than previous co-specia¬
tion theories (Magnius and Norder, 1995; Norder et al.,
1994; MacDonald et al., 2000). However, while the trans¬
mission networks of HBV in Africa and South East Asia are
clearly separate, one difficult remaining question is how
HBV could have spread between the African, Asian and
potentially South American continents in the previous few
thousand years. Resolving this question will require a better
understanding of the relationship between human and non-
human primate HBV variants, and the potential role of
humans in disseminating HBV infection over these much
larger geographical distances in the more remote past.
HBV divergence
Current and previous studies of HBV genotype distribu¬
tions in apes have demonstrated the existence of HBV
variants with relatively limited sequence diversity, mani¬
fested in particular by the grouping of these variants inter¬
spersed with the human genotypes A-E and G (Fig. 2).
There is no evidence so far for HBV variants in apes as
divergent as the human genotypes F and H, nor the HBV
variant obtained from a captive woolly monkey.
However, the core gene sequence of the HBV variant,
AB046525, recovered from a P.t. troglodytes subspecies in
Central Africa (Takahashi et al., 2001) is highly divergent
from equivalent regions in other HBV variants obtained
from chimpanzees, other apes or humans, and indeed is as
divergent from viruses in these latter species as the woolly
monkey sequence (Lanford et al., 1998). Strangely the rest
of the genome of AB046525 groups with HBV variants
recovered from the troglodytes subspecies of chimpanzees
(eg., in the S gene; Fig. 3B). As previously suggested, this
virus is likely to be a recombinant between a troglodytes-
associated HBV variant and another highly divergent HBV
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variant of unknown origin. Combined with the woolly mon¬
key variant (again of obscure origin), these findings hint
towards the existence of much more divergent HBV vari¬
ants in nature that are refractory to current primate surveil¬
lance methods. Further work to discover the original species
distribution of such variants will provide considerable in¬
sights into the ultimate origins and evolution of HBV in
primates, and may help to resolve the many conflicting
theories for the origin and past epidemiology of HBV in¬
fection in human populations.
Materials and methods
Primate samples
A total of 137 primate serum and plasma samples were
available for screening. From Africa, samples from 71 drills
(Mandrillus leucophaeus) were available from a rescue cen¬
tre in Nigeria; in the study population, 48 were wild-born
and 23 captive-born; all samples were negative for HBV
surface antigen (HBsAg). A total of 14 samples were avail¬
able from 8 drills, 2 mandrills (Mandrillus sphinx), 4
cherry-capped mangabeys (Cercopithecus torquatus) kept
at the Limbe Wildlife Center in Cameroon, all of which
were wild-born. From the same centre, a total of 7 samples
from chimpanzees were also available, of which 2 were
HBsAg positive, 3 were negative and 2 were unknown.
Finally, one sample from a known HBsAg positive chim¬
panzee and 3 HBsAg-negative samples from mona monkeys
(■Cercopithecus mona), 2 samples from putty-nosed mon¬
keys (C. nictitans) and 3 samples from red-eared monkeys
(C. erythrotis) were provided for the study from a rescue
centre in Nigeria.
From South East Asia, 20 gibbon samples from various
wild-born gibbon species (Hylobates spp.\ 4 HBsAg posi¬
tive and 16 negative), and 14 samples from wild-born
Bornean orangutan (Pongo pygmaeus pygmaeus; all HBsAg
negative), were provided by the Pingtung Rescue Center in
Taiwan. One male and one female lar gibbon (H. lar) from
the Welsh Mountain Zoo were also included. They were
HBsAg tested at the City Hospital, Edinburgh and the fe¬
male was found to be positive whereas the male was neg¬
ative.
All samples were stored at 4°C prior to shipping to the
UK according to CITES regulations, and then stored at
—25°C prior to analysis.
Source of infection in HBV-positive primates
Louisa (P. troglodytes, subspecies troglodytes) was con¬
fiscated in Southwest Cameroon from local people, after
which she was housed in the Limbe Wildlife Centre. Since
confiscation she has had no contact with any other primate
species. The exact details of how she was kept prior to
confiscation are unknown. The second chimpanzee was
Osang (P. troglodytes, subspecies vellerosus), and was do¬
nated to a conservation project in South-Eastern Nigeria in
1996, at which time he was positive for HBsAg. Osang was
also kept by local people after he was captured, and was
subsequently kept with other chimpanzees at the conserva¬
tion centre.
Of the 5 HBV-infected gibbons, 4 were wild-caught and
one was captive-born. The captive-born was a female, Ta-
mang (Hylobates lar) from a captive-born father (Paignton
Zoo) with known wild-caught parents from Malaysia and
Thailand, and a captive-born mother (Stuttgart Zoo) with
unknown parental origins. At the Welsh Zoo she is kept
with a male, Jake (H. lar) who was born at the Zoo, who
was both HBsAg and HBV PCR negative. The remaining 4
positive gibbons consist of Crazy Woman (H. agilis) con¬
fiscated in Taiwan in 1993, TB Black (species not identi¬
fied) confiscated in Taiwan in 1996, Happy (H. concolor
gabriellae) confiscated in Taiwan in 1996, and Wendy (H.
concolor gabriellae) confiscated in Taiwan in 1999. Their
histories prior to confiscation are unknown, as are their
origins. For the latter 4, all were HBsAg positive on first
testing after confiscation. Tamang likely acquired infection
from her mother peri- or post-natally. The subgenus and
species identifications of the HBV-infected gibbons were
provided by the sanctuary.
PCR screening and sequencing of HBV DNA
HBV sequences were amplified by PCR as previously
described (MacDonald et al., 2000) from 100 p\ volumes of
serum or plasma using pre-S (SI) and S (S2) gene primers
(Fig. 1A and B). Nucleotide sequencing was carried out
directly on second round amplification products using either
the Sequenase version 2.0 kit (United States Biologicals), or
ABI PRISM d-rhodamine or Big Dye kits (Applied Biosys-
tems). Positive primate samples were sequenced using over¬
lapping primers covering the entire genome as described
previously (MacDonald et al., 2000) using primers S5, S3,
4, 22, 25, 26, 30, 33, 42 and the new primers 44 (5'-
GTCCTTGWTGGGRTTGAAGTCCCAATC-3'; positions
2959 to 2985), 45 (GGTCACMWTAYTCYTGGGAA-
CAAGA; positions 2824 to 2848), 46 (ACCAWTTTATG-
CYRCAGCCTCCTA; positions 1778 to 1801) and 47
(GGACGTCCTTTGTKTACGTCCC; positions 1415 to
1442).
For investigation of infection with possibly more diver¬
gent HBV-like viruses in Old World primates, a further
PCR assay was developed using highly conserved primers
(set S3) in the surface gene that matched the following
additional sequences recovered from HBV-like viruses re¬
covered from North American rodent species: K02715
(ground squirrel), NC004107 and M19183 (woodchuck)
and U29144 (arctic ground squirrel). Samples were ampli¬
fied using the assay and cycling conditions as for the S1 and
S2 gene primers. Nucleotide sequences obtained in this
study have been submitted to GenBank and have been
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assigned the following accession numbers: Ay330911 to
Ay330917
Sequencing of the 12S mitochondrial region ofprimate
samples
Primate samples were also amplified and sequenced us¬
ing primers specific for the 12S region of the mitochondria
to confirm the species and distinguish between subspecies
and individual animals to allow comparisons of the primate
and HBV phylogenies. 2 pi nucleic acid was added to PCR
mix as described before and amplified using a single round
PCR reaction. Primers 12S-S (5' -CCATAAACAMAYAG-
GYTTGGTCC-3'; positions 641 to 664) and 12S-AS
(CAGGGTTTGCTGAAGATGGCGGTATATA; positions
1270 to 1298) were used. PCR conditions were 40 cycles of
94°C for 60 sec, 55°C for 60 sec and 72°C for 60 sec,
followed by a final extension at 72°C for 6 min. Amplified
DNA was directly sequenced using the ABI PRISM Big
Dye kit (Applied Biosystems).
Mitochondrial sequencing was used to determine the
sub-species of the 2 HBV-infected chimpanzees, from
which the following assignments were made: Osang: P.
troglodytes vellerosus, Louisa: P. troglodytes troglodytes.
Mitochondrial sequencing was unable to determine the spe¬
cies for gibbon TB Black because sequences for subspecies
agilis and moloch were interspersed, and published se¬
quences for gibbons were mainly determined in a different
region of the mitochondrial genome. Mitochondrial se¬
quencing was also performed on samples from the previ¬
ously described HBV-infected chimpanzees from whom
complete genome sequences were published [Chimp 2,
Chimp 4; (MacDonald et al., 2000) ]. Although both were
originally classified as being verus subspecies on the basis
of morphology, mitochondrial sequencing indicated that
Chimp 2 was the troglodytes subspecies; this designation
has subsequently been confirmed by the sanctuary.
Sequence analysis
Sequence data obtained using the ABI PRISM kits was
viewed using the CHROMAS sequence viewer and di¬
rectly imported into the SIMMONICS sequence align¬
ment program and edited. HBV sequences were aligned
with up to 10 representative sequences of each human
genotype: Genotype A—HUMPRECX, AF090839,
AF297624, E00010, HVHEPB, HEB344115, AF090838,
U87742, AF297625, AF297619; Genotype B—AY033073,
HPBA3HMS2, D50522, HPBADW3, HPBADWZ,
AF282918, HBV131133, HPBADW2, AF121249,
AF121243; Genotype C—AF233236, HHVBC, AB049610,
AF411412, HPBADRA, AF330110, AF461359, HP-
BADRC, AF4 1 1408, AF363964; Genotype
D—HEB344116, AB033559, AF280817, AF121240,
U95551, HBVAYWC, HBVAYWGEN, HBVGEN1, HB-
VORFS, HBVP6PCXX; Genotype E—HHVBE4, HHVB-
BAS; Genotype F—HBVADW4A, HHVBFFOU,
AF223965, AF223962, HHVBF, AB036910, AB036908,
AB036916, AB036905, AB036913; Genotype
G—AB056515, AF405706, AB056516, AB064312,
AB064310, AB064311, AB056514, AF160501, AB056513,
AB064313 and Genotype H—AY090454, AY090457,
AY090460. Sequences were also compared with every
available complete genome sequence obtained from pri¬
mates: Chimpanzee—AB032431, HBV131575, AF242585,
AF222322, AF498266, AB046525, AF305327, AF222323,
AF242586, AB032432, HPBVCG, AB032433; Gorilla—
HBV 13 1567; Gibbon—AY077736, AY077735,
HBV131568, HBV131574, HBV131571, HBV131569,
HBU46935, HBV131572, AB037927, AB037928; Orangu¬
tan—AF193864, NC_002168 and woolly monkey—
AF046996.
Sequence comparisons in the S-gene included the following
additional further partial sequences from primates: Chimpan¬
zees—AF305328, AF222318, AF222321, AF222312,
AF222319, AF222313, AF222314, AF305326, AF222316,
AF222320, AF305329, AF222317, AF305330; Gibbons—
AF213009, AF213008, AF21210, AF274495, AF274496,
AF274499, AF477482, AF477483, AF477484, AF477485,
AF477486, AF477487, AF477488, AF477489, AF477490,
AF477491, AF477492, AF477493, AF477494; Orangu¬
tans—HBVY17565, HBVY17562, HBVY17559, HBVY-
17564, HBVY17561.
Phylogenetic trees for these data sets were estimated
using a maximum likelihood (ML) method. To undertake as
robust an analysis as possible, we employed the most com¬
plex GTR+I+r model of nucleotide substitution available;
this allowed each type of nucleotide change to occur at a
different rate (the general time-reversible substitution
model, GTR), a proportion of nucleotide sites to be invari¬
ant (I) and a gamma (y) distribution of among-site rate
variation with the a shape parameter (with 4 categories)
estimated from the empirical data. The maximum likelihood
base composition was also estimated from the data. All
parameter values are available from the authors on request.
An heuristic search procedure was used to find the ML tree
using successive rounds of TBR branch-swapping, optimis¬
ing the ML substitution parameters at each stage. To deter¬
mine the support for key nodes on the tree we conducted a
bootstrap resampling analysis using 1000 replicate neigh¬
bor-joining trees constructed under the substitution model
as defined above. All these analyses were performed using
the PAUP* package (Swofford, 1998). In all cases the
single woolly monkey sequence (AF046996) was used as an
outgroup to root the phylogenetic trees.
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